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Background: The Sodium Glucose Co-Transporter-2 (SLGT2) Inhibitors are the newest class 
of antihyperglycemic medications available on the market. These agents have gained quick 
popularity due to demonstrated cardiovascular benefits among patients with pre-existing 
cardiovascular disease. While we have estimates for the probabilities of benefits and harms 
for SGLT2 inhibitors, the overall balance of risk and benefits that reflects the values of 
patients is unknown.      
Objectives and Methods:  
1. To conduct a systematic review and meta-analysis of the current state of knowledge 
surrounding post-market safety concerns of the SGLT2 inhibitors, including acute 
kidney injury (AKI), diabetic ketoacidosis (DKA), urinary tract infection (UTI), bone 
fracture and amputation, in patients with type 2 diabetes.  
2. To estimate the strength of preferences, relative importance, and trade-offs that 
Canadians with type 2 diabetes make between characteristics of glucose-lowering 
medications using a discrete choice experiment (DCE). 
3. To bring together Canadian patient preferences for attributes of diabetes therapies 
with probabilities of efficacy and safety retrieved from the literature, to compare 
the SGLT2 inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists, using 
quantitative benefit-risk assessment (BRA) following the incremental net benefit 
(INB) framework. 
 iii 
Results: The analysis of the adverse outcomes of the SGLT2 inhibitors, suggested no 
significant increase in the risk of AKI, DKA, UTI (exception: high dose dapagliflozin) or bone 
fractures. Amputation was poorly reported, however CANVAS trials do show an increased 
risk. The DCE showed that all eight examined attributes for diabetes medications, including 
cost, risk of macrovascular and microvascular events, risk of minor side effects, severe 
hypoglycemia, serious long term consequences, and life expectancy were each shown to 
significantly influence choice. Life expectancy and cost were more important to patients.  
Finally, the BRA demonstrated that there was a minimal difference in INB between the 
SGLT2 inhibitors and the GLP1 receptor agonists, but favored the SGLT2 inhibitors (INB = 
0.2) and results were consistent in sensitivity analysis.  
Conclusion: This program of research used emerging methods, including a network meta-
analysis, a DCE, and preference-weighted BRA to examine the balance between risks and 
benefits of the SGLT2 inhibitors and GLP1 agonists. These studies resulted in a final INB that 
favored SGLT2 inhibitors, though magnitude was small. More importantly, this research 
identifies several challenges and limitations, including gaps in methodological guidance that 
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1. Introduction and Overview 
1.1 Type 2 Diabetes  
 Type 2 diabetes is a chronic disease that results from the body’s inability use the 
insulin that it produces, or insulin resistance. Insulin is a hormone that is produced in 
response to glucose in the bloodstream and it regulates the amount glucose that remains 
in the blood by signaling to body cells to take in glucose to use as energy or store as fat. 
When cells are resistant to the actions of insulin, high levels of glucose remain in the blood 
and can lead to damage of the organs, nerves or blood vessels.1     
The prevalence of type 2 diabetes in Canada, as of 2015, was about 3.4 million 
individuals or 9.3% of the population. However the prevalence is estimated to grow by 44% 
to 5 million Canadians or 12.1% of the population by the year 2025. These high rates of 
diabetes puts a tremendous strain on the health care system as this population experiences 
higher incidences of several co-morbidities including, but not limited to, cardiovascular 
disease, kidney disease, retinopathy,  nerve damage, infections and amputations. 
Additionally, patient with diabetes typically experience a greater number of hospital stays 
and premature death.2  
The increasing prevalence of type 2 diabetes is a result of a number of factors 
including the strong positive correlation with obesity and cardiovascular conditions like 
hypertension and hypercholesterolemia, all of which are related to poor diet and lifestyle 
choices. Other risk factors include: family history (first degree relative), history of 
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gestational diabetes or prediabetes, diagnosis of polycystic ovary syndrome, psychiatric 
conditions or obstructive sleep apnea, and a history of glucocorticoid mediation use.3     
 
1.1.1 Management of Type 2 Diabetes 
 The management of type 2 diabetes has changes dramatically over the last century. 
Until the 1920s, when insulin was discovered, there was no known treatment for the 
condition. Insulin remained the only therapy until the 1950 when some oral antidiabetic 
agents were introduced to the Canadian market, first generation sulfonylureas like 
tolbutamide and biguanides like metformin. It was not until the 1980s when a few more 
products came to market making it easier to achieve blood glucose levels closer to the non-
diabetic range.4 Still despite several advancements, Canadian Clinical Practice Guidelines 
changed very little over the decades. Metformin has long been recommended as the first 
line therapy, and then a switch or add-on therapy was necessary and of the other available 
agents were considered acceptable alternatives. However, since 2016, we are seeing a shift 
in the recommendations for second line therapy as a result of tremendous advancements 
in therapy options.5 Since 2008 three new classes of medications, the glucagon-like peptide-
1 (GLP-1) Receptor Agonists, the dipeptidyl peptidase-4 (DPP-4) Inhibitors, and the sodium 
glucose co-transporter 2 (SGLT2) Inhibitors, which include 12 unique molecules, have 
become available. Figure 1-1 is a table of second line therapies and comes from the Diabetes 
Canada 2018 Clinical Practice Guidelines.  
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Figure 1-1 Diabetes Canada 2018 Clinical Practice Guidelines - Second-line Therapies 
 
Reprinted from Publication Canadian Journal of Diabetes, Vol 42 /Supplement 1, Diabetes Canada Clinical 
Practice Guidelines Expert Committee, Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, et al., 
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Can J Diabetes., Pages No. S93, Copyright 
(2018), with permission from Elsevier. 
 4 
 In 2007, during post-market surveillance, it was noted that commonly used 
antidiabetic agent, rosiglitazone, was associated with an increased risk of myocardial 
infarction and death.6–8 This prompted a tightening in regulatory monitoring of diabetes 
agents, given the already high prevalence of cardiovascular co-morbidity in this population. 
As of 2008, the US FDA has required manufacturers demonstrate cardiovascular safety 
through randomized controlled trials prior to market approval for any new diabetes agents. 
Not only have the GLP-1 receptor agonists, the DPP-4 inhibitors, and the SGLT2 inhibitors 
all shown cardiovascular safety, but there are studies with the SGLT2 inhibitors and GLP-1 
agonists that demonstrate cardiovascular benefit among individuals with existing 
cardiovascular disease.9–13 These associated benefits have results in changes to the 
Canadian, 5 American14 and European15 Diabetes Guidelines which that now elevate certain 
SGLT2 inhibitors and GLP1 agonists to preferred second line status in individuals with 
existing cardiovascular disease.   
 
1.1.1.1 Sodium Glucose Co-Transporter-2 Inhibitors 
 The SGLT2 inhibitors are the newest class of diabetes therapies to hit the Canadian 
market, with the approval of canagliflozin in 2014.16 There are currently four SGLT2 
inhibitors available in Canada including dapagliflozin, canagliflozin, empagliflozin and 
ertugliflozin, and a fifth agent, ipragliflozin that has been approved for use in Europe and 
Asia. The novel mechanism for this class of agents is that it causes glucose to leave the body 
through the urine. Typically, in a healthy individual no glucose is excreted through the urine 
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as it is reabsorbed from the glomerular filtrate by two SGLT proteins (SGLT1 and SGLT2), 
both of which act independently of insulin. The SGLT2 protein is responsible for the 90% of 
the reabsorption and this occurs at the first section of the proximal tubule, while only 10% 
is removed through the action of SGLT1 further down the tubule. For this reason, the drugs 
are designed to target the SGLT2 protein over SGLT1.17   
 In 2015, the first cardiovascular trial among the SGLT2 inhibitors was published. The 
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG) trial, 
demonstrated a significant benefit in the empagliflozin group over placebo for the 
composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction 
and nonfatal stroke (MACE) in individuals with preexisting cardiovascular disease.9 These 
results were replicated in 2017 with the Canagliflozin Cardiovascular Assessment Study 
(CANVAS) showing a significant benefit with the SGLT2 inhibitor over placebo in the 
composite MACE outcome.12 The Dapagliflozin and Cardiovascular Outcomes in Type 2 
Diabetes (DECLARE-TIMI) study published in 2019 did not show a reduction in MACE, 
however did show significant cardiovascular death and hospitalization for heart failure.13 
The SGLT2 inhibitors are the first class of agents to demonstrate cardiovascular benefit and 
as a result were promoted to the preferred second line agent among individuals who have 
existing cardiovascular comorbidities in the Diabetes Canada guidelines pharmacotherapy 
update in 2016.18  
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1.2 Systematic Reviews and Meta-Analyses  
 Systematic reviews and meta-analyses have become the gold standard approach to 
summarizing the totality of evidence on a particular topic in health care. A systematic review 
takes a structured approach to retrieve all the of available data on a topic and involves the 
following key steps:19 
1. Defining the study question, including the population, intervention, comparator, 
outcome and study design (PICOS); 
2. Establishing appropriate inclusion and exclusion criteria for the review; 
3. Designing and executing a comprehensive search strategy; 
4. Duplicate screening of search results using inclusion criteria; 
5. Duplicate data abstraction of all the key data elements; 
6. Critical appraisal of each of the included data sources; and 
7. Summarizing the results.  
The systematic approach allows for reproducibility of the findings and enables easy 
updates to the review. Perhaps the most critical step in this approach is the critical or quality 
appraisal. As summary of poorly conducted studies does not result in a high quality review. 
The critical appraisal allows for the contextualization of the findings according to the quality 




A meta-analysis can follow a systematic review when the identified studies from the 
systematic review are similar enough to be combined statistically. This approach was first 
described by Gene Glass in 1976,20 however earlier examples of pooling data from multiple 
sources date back to early 1900’s. This process first involves calculating summary statistics 
and measures of uncertainty from each of the included trials, then averaging the summary 
statistic, weighted by the inverse of the variance. Combining treatment effects from 
multiple studies improves reliability and statistical power.19  
There is one key assumption that needs to be met to be able to conduct a meta-
analysis, which is between study homogeneity. The included trials need to be similar 
enough to be pooled and interpreted together. That is, is the baseline population similar?; 
is the indication the same?; and, are the interventions and comparisons the same? This 
assumption can be assessed by comparing individual studies to answer these questions, and 
can also be tested statistically using the I-squared test. Typically, acceptable levels of 
heterogeneity are considered to be an I2 value 50% or 50%. Levels greater than this, 
explanation and justification would need to be provided for pooling those trials.19    
There are two basic models for analyzing the results of the meta-analysis depending 
on the degree of heterogeneity detected. Where little to no heterogeneity is detected, a 
fixed effect model can be used (equation 1). This model only accounts for within study 
variability in the error term, represented by 𝜎𝑖
2.  The second model is the random effects 
model, which takes into account both the within and between study heterogeneity, 
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represented by 𝜏2(equation 2). Using the random effects model will tend produce effect 
estimates with wider confidence intervals to account for this added variability.19  
 
Fixed Effect Model:  𝑌𝑖 =  Θ + 𝑒𝑖     Where 𝑒𝑖~𝑁(Θ, 𝜎𝑖
2)      (1) 
Random Effects Model:   𝑌𝑖 =  Θ𝑖 +  𝑒𝑖      Where 𝑒𝑖~𝑁(Θ, 𝜎𝑖
2) and Θ𝑖~𝑁(Θ, 𝜏
2)  (2) 
 
1.2.2 Network Meta-Analyses 
 In the last decade, methods used for conducting meta-analyses have matured 
dramatically addressing many potential issues and barriers. One such advance has been the 
network meta-analysis (NMA), which was introduced by Salanti et al. in 2008.21 This 
approach allows for the inclusion of indirect evidence alongside direct evidence. Figure 1-2 
shows the relationships in meta and network meta-analyses. Each intervention can be 
represented as a node (e.g. A, B, etc.), and solid lines represent where two interventions 
have been compared in a head-to-head trial. In a pairwise meta-analysis there would be 
two or more studies that compare the same two interventions in similar populations (top 
right). One problem when examining new interventions is that they are often compared to 
placebo and not necessarily to the existing gold standard. Practically, we want to know 
which available interventions performs better, but this is challenging with little or very few 
direct comparisons. The NMA takes into account all the indirect evidence to overcome this 
barrier. That is, they can quantitatively make comparisons between two interventions via a 
third common comparator (e.g. placebo or other). In Figure 1-2 the dotted lines represent 
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the indirect comparisons that can be drawn from the available evidence. The diagram in the 
bottom right depicts an example where both direct and indirect evidence are pooled 
together to compare two alternatives.22 It is not always the case that no direct evidence 
exists, but sometimes it is limited and direct evidence can be used to strengthen the existing 
direct evidence. 
   
Figure 1-2. Pairwise versus network meta-analysis 
 
Reproduced under the Creative Commons Attribution License from: Roever L, Biondi-Zoccai G, Roever L, Biondi-
Zoccai G. Network Meta-analysis to Synthesize Evidence for Decision Making in Cardiovascular Research. Arq 
Bras Cardiol. 2016 Apr;106(4):333–7. 
  
Network meta-analyses can be done using either a frequentist or Bayesian statistical 
approach, however the Bayesian method tends to be more commonly used due to its ability 
to integrate posterior distributions into the framework. When the Bayesian framework is 
used the results provide point estimates along with credible intervals, rather than 
confidence intervals used in frequentist approaches. 
To be able to successfully conduct a NMA there are two assumptions that need to 
be considered in addition to the homogeneity assumption. The first is transitivity, which 
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concerns the validity of making indirect comparisons. This cannot be tested statistically, but 
rather individually examining the characteristics of each trial. The final assumption is 
consistency. This refers to the agreement/disagreement between the direct and indirect 
evidence of the same comparison where both direct and indirect evidence exists. This 
assumption can be tested statistically using one or more of the several proposed 
approaches, such as node-splitting, back calculation and global Q statistic.23 
Despite being a major advance in meta-analysis methodologies, there are several 
drawbacks to using this approach. Probably the most important is the tendency to place too 
much trust on the results of network meta-analyses. Results can add context and strengthen 
the power in pairwise comparisons, and even draw comparisons where no direct evidence 
exists, however it must be understood that meeting the three assumptions successfully is 
challenging, and maybe even impossible. Pure indirect comparison estimate should be 
looked at as hypothesis generating only.24  
 
1.3 Benefit-Risk Assessment 
 Benefit-Risk Assessment (BRA) is a process that is taken to evaluate if the intended 
benefits of a drug or medical device outweighs the potential harms. BRA’s are often done 
at the time of regulatory approval as well as post market when new benefits and harms are 
identified in post market surveillance exercises. Though systematic reviews and meta-
analyses are ideal starting points for identifying and quantifying benefits and harms, they 
are not tools that can address several important considerations when assessing the true 
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relevance of those benefits and risks. Aside from the risk of occurrence, other aspects to 
assess are the severity of the particular outcome, the expected time to onset, and the 
duration of the outcome.       
 Several regulatory agencies including the US Food and Drug Administration (FDA)25 
and the European Medicines Agency (EMA),26 as well as the Pharmaceutical Research and 
Manufacturers of America (PhRMA)27 have developed frameworks to encourage systematic 
approaches to BRA throughout the product lifecycle.28 Taking a proactive approach to BRA 
increases the likelihood that drugs and devices that bare unacceptable risk are removed 
from the market in a timely fashion (e.g. rofecoxib,29 troglitazone30 and cisapride31), leading 
to better patient safety and improved health outcomes. The FDA’s framework,25 similar to 
the EMA framework, encourages a global assessment of the condition, possible therapies, 
the benefits and risks of those therapies and any uncertainties around the estimates for 
these factors. Then a value judgement or qualitative assessment is needed to bring that 
assessment together into a recommendation.  
 Typically, a complete structured BRA is only necessary when the decisions they are 
informing are complex. Where the evidence leads to obvious choices, this systematic 
process is not needed. Given the dramatic change in the landscape of available medications 
to treat type 2 diabetes, decisions regarding second-line therapies is complex with many 
benefits and risks that can play a role in decisions. Additionally, given that three new classes 
of medications have come to the market in the last decade alone, many of the newer 
products, despite early indications of unintended benefits, still have a great deal of 
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uncertainty around the true rates of benefits and risks. For this reason, formal BRA 
assessment is important.  
 
1.3.1 Quantitative Approaches to Benefit-Risk Analysis 
In addition to the frameworks outlined above, there are many measures that 
clinicians and researchers use to help quantify risks and benefits and the balance between 
the two. Figure 1-3 is a summary of the many proposed measures, from a review conducted 
by the ISPOR Risk-Benefit Working Group.28 The Unified Framework for Classification of 
Methods for Benefit-Risk Assessment, proposed by Najafzadeh et al. (2015), further 
explores these measures categorizing them into three main sub-groups: 1) measures that 
are not weighted; 2) measures that are weighted by patient preferences, and 3) measures 
that are weighted with preferences of decision makers.32 This framework also demonstrates 
that all of these metrics can be captured using a common formula (equation 3), and 
measure the incremental net benefit. 
 
𝐼𝑁𝐵 =  ∑ 𝑣𝑖𝑇𝑖∆𝑝𝑖
𝐼
𝑖=1 −  𝜇 ∑ 𝑣𝑗𝑇𝑗∆𝑞𝑗
𝐽
𝑗=1              (3) 
 
The INB quantifies the difference between the sum of the benefits from the sum of 
the harms between two interventions. In this equation the pi represents the change in 
probability of beneficial outcome i, and qj is the change in probability of a harmful 
outcome j, each weighted by the average time (T) that an individual is impacted by that 
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outcome and patient preference (v). The  then represents the importance a decision 
maker places on harms over benefits. A =1 means importance is equal and a >1 indicates 
a higher importance on avoidance of harms. When mapping metrics like number needed to 
treat or number needed to harm (NNT/NNH), which are unweighted, the values for v and T 
would be set to equal one, and the INB would simply be a difference between the sum of 




Figure 1-3. Summary of Quantitative Measures of Benefit and Risk 
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Reprinted from Value in Health, Vol 13 /Number 5, A Review of Quantitative Risk-Benefit Methodologies for 
Assessing Drug Safety and Efficacy-Report of the ISPOR Risk-Benefit Management Working Group.Guo J, 
Pandey S, Doyle J, Bian B, Lis Y, Raisch D. Pages No. 660, Copyright (2010), with permission from Elsevier. 
 
1.4 Patient Preferences in Risk-Benefit Analysis 
 One approach that is gaining popularity for capturing patient preferences in the BRA 
process, is choice modelling.  This is a research area that focuses on modelling decision 
process and looking at the characteristics that influence those decisions. Choice modelling 
has long been used in the areas of marketing, economics and transportation as a method 
of measuring human decisions on activities and consumption. Effectively and accurately 
measuring human demand and needs and preferences for products and services allows for 
appropriately matching supply and setting market prices.33 This approach has only more 
recently been used in health-care, as we aim to focus our delivery of healthcare in a more 
patient-centered manner.34    
 Choice modelling can either examine revealed preferences, which is to examine 
choices that individuals actually make in the real world (through sales data, administrative 
data, etc.), or stated preferences, which is to examine choice people make when presented 
with a hypothetical scenario. Both modelling approached provide insight in different 
settings.35 Revealed preferences are important for examining existing choice alternatives, 
for example the choice between visiting a family physician or the emergency room for 
various issues. Stated preference, on the other hand, is valuable in assessing preferences 
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for choices that may not currently be available, or perhaps in decisions where individuals 
have not traditionally had much say (e.g. choice of drug therapy).    
 
1.4.1 Discrete Choice Experiments 
 Discrete choice experiments (DCE) are one stated preference approach commonly 
used to quantitatively capture patient preferences for health care decisions.34 It is grounded 
in multi-attribute utility theory which states that when people make choices between 
alternatives they take into consideration the qualities of those alternatives and then they 
make trade-offs on the performance of those qualities. 
 For example, if you making a choice between two pain relievers you may consider 
the effectiveness (likelihood of response), the time to effect, the risk of harm and the cost. 
Figure 1-4 is an example of a typical choice task that might be presented in a DCE. It give 
two alternatives and describes those alternatives based on the attributes considered 
important in making the choice. In this example, Alternative 1 performs better than 
Alternative 2 on likelihood of response and risk of stomach upset, however underperforms 
on time to effect and cost. Responders would make trade-offs, and select the one that best 
suits their needs. With repeated choice tasks, using new hypothetical alternatives described 
by the same attributes, it becomes possible to quantify the preference weights that 
respondents placed on each attribute, on average.    
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Figure 1-4. Sample Discrete Choice Experiment Choice Task 
Scenario: It is 10 am and you have a busy work day ahead. Suddenly you have a really bad headache come 
on and you need to choose between two available therapies. Based on the qualities of the alternatives which 
therapy would you chose? 
 
 
1.4.1.1 Design Considerations 
There are several design elements to consider when building a survey to capture 
preference weights. The first step is to define the choice that you are attempting to measure 
and then selecting attributes and levels that are relevant to that choice. The attributes are 
the characteristics, like those described in the example above. Though there are potentially 
many attributes that could influence choice, especially in choices of drug therapy due to the 
many potential benefits and harms, you need to identify those that are most important in 
driving decisions. There are no gold standard approach to completing this step, but the most 
common approach is to review previously published studies, consult experts in their field 
and maybe conduct focus groups with the target population.36  
The next decision is to determine if the alternatives will be labelled or not. In Figure 
1-4, the choices are unlabeled and identified as “Alternative A” and “Alternative B”. 
Alternatively you could use a label which conveys some meaning beyond the order in which 
they are presented, for example “Old Drug” and “New Drug”. When labelled choice tasks 
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are used, you need to ensure all options are presented, while for unlabeled choice tasks, a 
subset can be used.37  
Practically speaking, you need to ensure the survey does not over burden the 
respondents and that choices are easy to understand. This can be achieved by managing 
the number of attributes used and the number of choice tasks included, as well as keeping 
descriptions simple and even using pictures to support understanding of difficult concepts 
(e.g. risk). It is recommended to keep attributes to the minimum amount necessary, but not 
to exceed eight.38 The more attributes that need to be considered, the more likely it is that 
responders will only look at their two or three most important and not even make trade-
offs with the remainder.39  
When it comes to experimental design a couple of things are taken into 
consideration. First is the design (a data matrix) which indicates which levels for each 
attribute will be presented in each choice task. A full factorial design is one in which all 
possible combination of attribute levels are presented in a survey. For a survey will six 
attributes, each with three levels, this would equate to 729 (3x3x3x3x3x3) choice tasks per 
survey participant. This is clearly not feasible and therefore attempts are made to design 
efficient surveys that only include a manageable number of choice tasks, or a fractional 
factorial design.40 The design matrix is typically done with the assistance of a computer 
software program, with the intent of maximizing efficiency. This is achieved by ensuring all 
levels are presented the same number of times throughout the survey. The optimal design 
was historically thought to be an orthogonal design, which is where every pair of levels 
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occurs equally across all pairs of attributes. This view now as widely held anymore as it they 
are difficult to design and orthogonality is easily lost.40 Orthogonality can be lost when 
attribute levels are not evenly spaced, when there is missing survey data, and when certain 
types of data coding are used. Instead we see an aim towards near-orthogonal designs (e.g. 
Bayesian efficient, D-efficient, S-efficient).40  
 The second design consideration is the number of choice tasks needed to be able 
to accurately estimate preference weights. This in part is determined by the design matrix 
discussed above, but is also a function of the utility function you are trying to estimate. 
Consider the list of attributes and levels presented in Table 1-1 that corresponds to the 
choice task in Figure 1-4.  
 
Table 1-1. Sample of Discrete Choice Experiment Attribute and Levels 
Attribute Level 
Likelihood of Response 90% of people will respond 
80% of people will respond 
70% of people will respond 
Time to Effect 10 minutes 
30 minutes 
60 minutes 
Cost $1 per treatment 
$5 per treatment 
$10 per treatment 
Risk of Stomach Upset 1% will experience 
10% will experience 





Each of the attributes are described using continuous variables and in a regression equation, 
the weight for each attribute could be captured in a single beta estimate per attribute, as 
in equation 4, where 𝑉𝑛 = Utility;  𝑎𝑠𝑐 = alternative specific constant; 𝛽  = coefficient; and 
𝑋𝑛 = attributes. 
 
𝑉𝑛 = 𝑎𝑠𝑐 + ( 𝛽𝑟𝑒𝑠𝑝 ∗ 𝑋𝑟𝑒𝑠𝑝) + (𝛽𝑡𝑖𝑚𝑒 ∗ 𝑋𝑡𝑖𝑚𝑒)+( 𝛽𝑐𝑜𝑠𝑡 ∗ 𝑋𝑐𝑜𝑠𝑡)+(𝛽𝑠𝑡𝑜𝑚𝑎𝑐ℎ ∗ 𝑋𝑠𝑡𝑜𝑚𝑎𝑐ℎ)    (4) 
 
Consider however, if we added the attribute “route of administration” with the levels 
“oral”, “patch” and “injection”. These are not continuous and therefore in the utility 
function you would need a beta estimate for each level.40 To estimate the minimum number 
of choice tasks you need, you first need to know the number of parameters you need to 
estimate (beta estimates) and the number of alternatives you will include in each choice 
task (Equation 5). More practically speaking however, as a researcher you want to maximize 
the number of tasks without over-burdening the respondent.   
 
Minimum number of choice tasks = (number of parameters) / (number of levels -1)         (5) 
 
 Finally, before the survey is launched, assessments for data quality should be 
considered. DCE surveys can be challenging for respondents to grasp, especially if the 
attributes are complicated to understand (e.g. risk). Building in quality checks helps to 
mitigate poor quality data. One approach could be to include one or two dominant choice 
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tasks. These are choice tasks where there are no trade-offs to be made and the correct 
answer is obvious. One alternative would be better than the other on every attribute. When 
someone gets a dominant choice task wrong, it is a signal that they do not understand the 
survey or they are not reading and providing reflective responses.41 Given that in a two 
alternative tasks there is a 50/50 chance that someone will select the correct answer by 
chance, it would be best to include two dominant choice tasks. Care needs to be made when 
using this approach to test data quality. The choice should be one that has a true dominant 
answer. Sometimes this is not feasible with some choices where people may legitimately 
have opposing preferences. Other way to assess data quality would be to set threshold for 
the time it would take to complete the survey to eliminate speeders, or to include one 
choice set twice to evaluate consistency (test-retest).41  
 
1.4.1.2 Analysis 
 Several regression models can be used with DCE data. The very basic model being 
the multinomial logit (MNL) model. The MNL model has three key assumptions. The first is 
that the beta coefficients are fixed across respondents; the second is the Independence of 
Irrelevant Alternatives (IIA); and finally the Independence of Identically Distributed (IID) 
error components.37 The IIA assumption is often referred to as the “red bus/blue bus 
problem” as this analogy provides a clear explanation of this restriction. If you consider a 
city with two modes of transportation, taking a red bus or walking, and 50% of people tend 
to select each option, therefore the odds of selecting either of these would be 1.0. If a third 
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option is add, a blue bus, then the IIA assumption implies the odds ratio would still be 1.0 
between the red bus and walking (e.g. if 40% selected red bus, 40% selected walking and 
20% selected the new blue bus, the odds ratio between the red bus and walking would still 
be 1.0 as an equal percent of people chose each option). The reality however is that most 
people who chose to walk, would still chose to walk even if a blue bus is added and the 
those who select the red bus would now split between the two buses (e.g. 25% red bus, 
25% blue bus, and 50% walk).  The IID assumption refers to the fact that any unobserved 
utility (error) is distributed independently and across alternatives and respondents. Despite 
these restricted limitations, the MNL model is quite widely used due to its ease in 
computation and interpretation.42 
 Other models include the nested logit, mixed logit and latent class models. The 
nested logit model, unlike the MNL, assumes that there is some correlation between a sub-
set of alternatives in the model. For example there could be a relationship between the 
odds of selection of the blue bus or the red bus, as discussed previously. This means there 
is a partial relaxation of the IIA assumption. Mixed logit models allow for random 
parameters (accounts for preference heterogeneity) and variation in the variance condition 
associated with the random component (accounts for scale heterogeneity). Finally, latent 
class, allows for exploring heterogeneity through the estimation of coefficients for sub-
classes of the population (e.g. males vs. female; those with cardiovascular disease vs. those 
without).37   
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1.5 Rationale and Objectives 
 There has been major shifts in the manner in which we approach second line therapy 
for type 2 diabetes, largely due to the demonstration of cardiovascular benefits in users of 
the SGLT2 inhibitors and the GLP1 receptor agonists with established cardiovascular 
disease.10–13,43 These are the first classes of anti-hyperglycemic agents to demonstrate this 
benefit and have therefore been highlighted as preferred agents in patients with 
cardiovascular disease who have failed treatment with metformin in clinical practice 
guidelines.5 As with all medications, the SGLT2 inhibitors and the GLP1 receptor agonists 
also come with risk of harms, some of which may still remain unmeasured given how little 
time either class has been available on the market.   
It is unclear if either the SGLT2 inhibitors or the GLP1 receptor agonists performs 
better overall. To address this gap in our knowledge around these new classes of 
medications, we have conducted a series of studies to support a detailed comparison 
evaluating the balance of risks and benefits of these agents. The first two studies were 
focused on the unanticipated adverse effects of the SGLT2 inhibitors as identified by 
regulatory agencies. These were narrowly focused studies as there already existed an 
abundance of systematic reviews and meta-analyses on these agents, but one focused on 
these unanticipated outcomes was not available. The third study focused on gathering 
preference weights for attributes of diabetes medications, and the fourth study was a 
quantitative risk benefit assessment comparing SGLT2 inhibitors to GLP1 receptor agonists.    
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The specific objectives of this research were:  
1. To conduct a systematic review and meta-analysis of the current state of knowledge 
surrounding key post-market safety concerns of the SGLT2 inhibitors compared to 
active and non-active comparators in patients with type 2 diabetes.  
2. To conduct a systematic review and network meta-analysis of the dose-response 
relationship between SGLT2 inhibitors and UTI in individuals with type 2 diabetes 
compared to other diabetes therapies or placebo.  
3. To estimate the strength of preferences, relative importance, and trade-offs that 
Canadians with type 2 diabetes make between characteristics of glucose-lowering 
medications. 
4. To bring together Canadian patient preferences for attributes of diabetes therapies 
as well as probabilities of efficacy and safety retrieved from the literature 
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3. Comparative safety of the sodium glucose co-transporter 2 
(SGLT2) inhibitors: A systematic review and meta-analysis1 
 
3.1 Background 
The sodium glucose co-transporter 2 (SGLT2) inhibitors are a novel drug class 
available for the management of type 2 diabetes. Clinical guidelines recommend the SGLT2 
inhibitors as one of numerous potential pharmacologic approaches for second-line therapy 
following metformin failure or intolerance.1,2 Some clinical guidelines recommend the 
SGLT2 inhibitor, empagliflozin, or the Glucagon-like peptide-1 (GLP1) receptor agonist, 
liraglutide, as preferred second-line therapies in patients with cardiovascular disease who 
have failed to achieve glycemic control while on monotherapy.1 This paradigm shift in the 
management of type 2 diabetes is largely supported by evidence from recent landmark 
clinical trials.3–5 In 2015 the EMPA-REG trial showed that the SGLT2 inhibitor, empagliflozin, 
significantly reduced the risk for composite endpoint of cardiovascular death, myocardial 
infarction, or stroke by 14% and all-cause mortality by 32%, in a population with existing 
cardiovascular disease after approximately 3 years of follow up.5 The LEADER and SUSTAIN-
6 trials have also demonstrated similar benefits with liraglutide and semaglutide.3,4 
Considering the relative potential harms and benefits, clinicians and policy makers 
must continue to integrate new pharmacotherapeutic evidence to optimize health 
                                                     
1 A version of this manuscript has been published. Citation: Jennifer R. Donnan, Catherine Grandy, Eugene 
Chibrikov, Carlo A. Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel 
Curnew, Hai Nguyen, John-Michael Gamble. Comparative safety of the sodium glucose co-transporter 2 
(SGLT2) inhibitors: A systematic review and meta-analysis. BMJ Open. Diabetes and Endocrinology. 2019. 
Vol. 9 no. 1. E022577. It has been reproduced according to the Creative Commons Licence.  
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outcomes. Although the EMPA-REG trial showed that the SGLT2 inhibitor, empagliflozin, 
significantly reduces the risk of cardiovascular morbidity and mortality, regulatory agencies 
including the Food and Drug Administration (FDA), the European Medicines Agency (EMA) 
and Health Canada have issued safety warnings for several adverse events. These include 
acute kidney injury (AKI), diabetic ketoacidosis (DKA), urinary tract infections (UTI), bone 
fractures and lower limb amputations, based primarily on case report data.6–14        
With respect to AKI, there is conflicting information coming forward from clinical 
trials and case reports. Despite early indication of a protective effect from SGLT2 
inhibitors,15 the FDA published in a safety communication in June 2016 that 101 cases of 
AKI were reported among users of canagliflozin and dapagliflozin.10 To date, no meta-
analysis of AKI has been published. In May 2015 the FDA published a safety update 
indicating an increased risk of UTI and DKA. Among patients taking SGLT2 inhibitors, they 
identified 19 cases of life-threatening infections that originated as a UTI, and 73 cases of 
DKA. However, to date clinical trial evidence does not support these potential risks. Four 
published meta-analyses of randomized control trials (RCT) and found no increased risk of 
UTIs, except within a sub-group of dapagliflozin,15–18 and one study found an increased risk 
with empagliflozin 25mg users.18 One meta-analysis on the risk of DKA currently exists, and 
shows no increased risk.19 In January 2016, the FDA issued an expanded warning regarding 
a potential increased risk for fracture with canagliflozin.12 Two published meta-analyses20,21 
of SGLT2 inhibitors did not find an increased risk, nor did a pooled analysis of eight 
canagliflozin trials.22 Finally, in May 2017, the FDA supported earlier speculation of 
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increased risk of low limb amputation9 with evidence gathered from re-analysis the CANVAS 
and CANVAS-R trials, demonstrating a two-fold increased risk.23 No meta-analysis of RCTs 
currently exists with respect to amputation. 
In light of recent guideline changes that promote earlier integration of the SGLT2 
inhibitors into therapy, clinicians and policy makers need to continue examining the 
potential risks to their patients. Our objective is to address the current knowledge gap 
surrounding the post-market safety of the SGLT2 inhibitors compared to active and non-
active comparators in patients with type 2 diabetes. We have conducted a systematic 
review and meta-analysis of RCTs to estimate the risk of AKI, DKA, UTI, bone fracture and 
lower limb amputation.  
 
3.2  Methods and Analysis 
3.2.1 Study Design 
This study has been designed in accordance with the PRISMA statement on 
systematic reviews and meta-analysis (PRISMA Checklist in Section 1 of Appendix A).24 This 
protocol has been registered (CRD42016038715) with PROSPERO (International Prospective 
Register of Systematic Reviews).25,26  
 
3.2.2 Search Strategy 
A comprehensive search strategy was developed with an experienced health science 
librarian. The search strategy for published studies was developed in the PubMed database, 
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and comprised of keywords and MEDLINE controlled vocabulary or Medical Subject 
Headings (MeSH). A methodological search filter was applied to identify RCTs27 and the 
search was limited to English language publications. This search strategy served as a 
template for additional search strategies tailored to other databases, including the 
Cochrane Library, EMBASE and International Pharmaceutical Abstracts. In addition, the 
reference lists of topical review articles, editorials, and included studies were hand-
searched to identify other potentially relevant studies. A list of search terms is provided in 
Section 2 of Appendix A.  
The search for unpublished studies and materials included ProQuest Dissertations & 
Theses Global (ProQuest), and clinical trial registries (ClinicalTrials.gov). Inclusion of 
unpublished data from the FDA has been shown to substantially impact the effect estimates 
of meta-analyses of drug trials.28  
 
3.2.3 Eligibility Criteria  
We included RCTs with a study population consisting of patients 18 years of age and 
older with a diagnosis of type 2 diabetes. Studies were required to have a formal definition 
of type 2 diabetes based on established diagnostic criteria during the time of the study. No 
restriction was applied with respect to history of diabetes medication use.  One of the RCT 
study groups was required to be one of the following SGLT2 inhibitors: canagliflozin, 
dapagliflozin, empagliflozin, ipragliflozin or any other investigational or approved SGLT2 
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inhibitor during study period. Eligible comparators included metformin, second-generation 
sulfonylureas (glyburide, gliclazide, glimepiride, glipizide –first generation sulfonylureas 
excluded as they are currently not used in clinical practice), basal insulins (NPH, lente, 
glargine, detemir, degludec), dipeptidyl peptidase-4 Inhibitors (DPP-4I) (alogliptin, 
linagliptin, saxagliptin, sitagliptin), GLP-1 agonists (dulaglutide, exenatide, liraglutide), 
thiazolidinediones (TZDs) (pioglitazone, rosiglitazone), alpha-glucosidase Inhibitors 
(acarbose) or placebo/no treatment. All premixed or acute care insulin protocols were 
excluded due to inconsistencies in dosing of the short-acting insulins. Any investigational 
agents other than SGLT-2 inhibitors were excluded.  
The outcomes of this study include the serious safety events as highlighted through 
the federal regulatory drug safety communications.6–14  These include: AKI, DKA, UTI, bone 
fractures, and lower limb amputations.  
Studies were eligible regardless of duration of follow-up, or publication date; 
however, non-English citations were excluded. Language restriction does not appear to bias 
estimates of therapeutic interventions.29,30   
 
3.2.4 Study Selection and Data Extraction 
We used DistillerSR, a systematic review software,31 for screening and data 
extraction.  Studies went through a two-level screening process. First, titles and abstracts 
were reviewed using the inclusion and exclusion criteria. Any studies that meet those 
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criteria, or where a clear decision could not be made, moved to second level screening. At 
level two screening, full text articles were retrieved and the same criteria applied. Duplicate 
screening was carried out using the “liberal accelerated” method at both level one and level 
two, which was first applied by Khangura.32 This method involves having a second reviewer 
only evaluate studies that were deemed not relevant by the lead reviewer. This reduces the 
overall number of papers that require duplicate screening without increasing the risk of 
having appropriate studies inadvertently excluded.  
Information extracted included study characteristics (country, definitions of 
exposure(s) and controls), patient characteristics (sex, age, duration of diabetes) and 
outcome data (a complete list of extracted variables is available in Section 3 of Appendix A). 
Where the data conflicted between the published paper and other sources (e.g. 
ClinicalTrials.gov), the data from the published paper were used. Data were only 
supplemented from other sources when gaps in information existed. In cases where more 
than one publication reported data on the same study, preference was taken to studies that 
reported numbers of events (versus only relative risk or hazard ratio) and the most recent 
were used for data extraction. The exception to this rule was when there was a change to 
the intervention or comparator groups (e.g. drug, dose, etc.) for study extensions, then data 
from the original publication were used. Any disagreements were resolved through 
discussion and consensus. Where necessary, a third reviewer was consulted. All DistillerSR 
screening and extraction forms were created a priori and piloted using a small sample of 
eligible studies.  
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3.2.5 Risk of Bias Assessment 
Each included study was critically appraised using the Cochrane Collaboration 
domain-based tool for assessing the risk of bias for RCTs.33,34  This tool captures six main 
sources of bias, including: randomization sequence, allocation concealment, blinding of 
participant and researcher, blinded outcome assessment, incomplete outcome data and 
selective reporting. A seventh category captures any other potential sources of bias. Bias 
was assessed at the study level. Low risk of bias was defined as an assessment on the risk 
of bias tool that included no more than two categories with “unclear risk”. Studies were 
defined as high risk if they had: three or more categories of “unclear risk”; one or more 
categories of “medium risk”; or one or more categories of “high risk”. Publication bias was 
examined using funnel plots. 
3.2.6 Data Synthesis 
We conducted a series of pair-wise random effects meta-analyses to estimate the 
pooled treatment effect using relative risks, using the restricted maximum likelihood 
method.35 The primary analysis was split into two comparisons, with the first between 
SGLT2 inhibitors and placebo, and the second SGLT2 inhibitors and any active comparator. 
Between-study variance was estimated using the restricted maximum likelihood method. If 
there were zero events reported, a default value of 0.5 was added to all groups within that 
study. Statistical heterogeneity was evaluated using the I2 statistic, with significant 
heterogeneity defined as an I2 > 50%.36 To explore treatment effect heterogeneity, we 
conducted numerous subgroup analyses according to individual SGLT2 inhibitors, risk of 
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bias, and concurrent use of other diabetes medications. Concurrent/prior use was defined 
as any previous use of anti-diabetic agents that were used prior to enrollment or added as 
background therapy after enrollment. If patients could be therapy-naïve or have used other 
medications to meet enrollment criteria, then they were categorized as concurrent/prior 
use. Treatment-naïve was defined as patients that: have never had an anti-diabetic 
medication in the past, have not been on any other anti-diabetic medication in weeks 
leading up to enrolment, or, were able to go through a washout prior to enrolment. We also 
conduced sensitivity analyses to explore the impact of methodologic decisions within our 
analysis. First, we pooled studies that had at least one reported event. Second, we repeated 
our analyses using fixed-effects models. All analysis was conducted using R statistical 
software (version 3.4.1).  
 
3.3 Results 
3.3.1 Included Studies 
A total of 2418 unique titles and abstracts were screened. Of these, 650 proceeded 
to full text screening. A total of 144 citations met our inclusion criteria, however 34 were 
excluded at the data extraction phase due to duplication of data, from the publication of 
extension studies or post-hoc analyses (Figure 3-1). A final total of 109 publications were 
included, representing 112 randomized populations.  
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Intervention(s) Comparator(s) Outcomes 
Reported 
NCT01059825 
Amin, 2015 37 












Amin, 2015 38 
International 4 194 Uncontrolled on 2 
agents 
Ertugliflozin  
1mg, 5mg, 25mg 
Placebo UTI 
NCT02157298 
Araki, 2016 39 





Placebo UTI, Bone 
Fracture (BF) 
NCT01368081 
Araki, 2015 40 








Bailey, 2013 41 
International 102 546 Prior metformin Dapagliflozin  
2.5mg, 5mg, 10mg 
Placebo UTI, Acute Kidney 
Injury (AKI), BF 
None 
Bailey, 2012 42 
International 24 282 Treatment Naive Dapagliflozin  
1mg, 2.5mg, 5mg 








Placebo UTI, DKA, BF 
NCT01106651 
Bode, 2015 44 
International 104 716 Prior Naive mono 
or combo therapy 
Canagliflozin  
100mg, 300mg 




European 102 182 Prior metformin Dapagliflozin  
10mg 
Placebo UTI, BF 
NCT01031680 
Cefalu, 2015 46 




Placebo UTI, AKI, BF 
NCT01505426 
Lu, 2016 47 
Korea and 
Taiwan 
24 171 Prior metformin Ipragliflozin  
50mg 




International 52 686 Prior metformin Empagliflozin  
10mg, 25mg 





























International 24 485 Treatment Naive Dapagliflozin  

















Frias, 2016 53 
International 28 695 Prior metformin Dapagliflozin  
10mg 





















Heise, 2013 56 





Heise, 2013 57 
Germany 9 days 48 Prior Naive mono 






Henry, 2012 58 
International 24 603 Treatment Naive Dapagliflozin  
5mg 
Placebo UTI, BF 
NCT00643851 
Henry, 2012 58 







Henry, 2012 58 
International 24 641 Treatment Naive Dapagliflozin  
10mg 
Placebo UTI, BF 
NCT00859898 
Henry, 2012 58 






Ikeda; 2015 59 
International 12 398 Naive or 
metformin 
Tofogliflozin  
2.5mg, 5mg, 10mg, 
20mg, 40mg 





















































Placebo UTI, BF 
NCT01381900 
Ji, 2015 66 
International 18 678 Prior Metformin 
and maybe SU 
Canagliflozin  
100mg, 300mg 
Placebo UTI, BF 
NCT01095653 
Ji, 2014 67 
Asia 24 393 Treatment Naive Dapagliflozin  
5mg, 10mg 




Japan 2 30 Treatment Naive 
or monotherapy 
Ipragliflozin  









No comparator UTI, BF 
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NCT00972244 
Kaku, 2013 70 
Japan 12 279 Treatment Naive 
or 1 or 2 agents at 
low dose 
Dapagliflozin  
1mg, 2.5mg, 5mg, 
10mg 
Placebo UTI, BF 
None 
Kaku, 2014 71 




Placebo UTI, BF 
None 
Kaku, 2014 72 
Japan 24 235 Treatment Naive 
or washout 
Tofogliflozin  
10mg, 20mg, 40mg 










Japan 26 131 Treatment Naive 

















Japan 52 165 Treatment Naive 






Kohan, 2014 77 
International 104 252 Not described Dapagliflozin  
5mg, 10mg 













International 12 75 Prior Metformin 








International 52 1284 Prior Metformin 






UTI, DKA, BF 
NCT01042977 
Leiter, 2014 81 




Placebo UTI, AKI, BF 
NCT00968812 
Leiter, 2015 82 







Lewin, 2015 83 
International 52 677 Treatment Naive Empagliflozin  
10mg, 25mg 
Linagliptin 5mg UTI 
NCT00263276 
List, 2009 84 
International 12 389 Treatment Naive Dapagliflozin  

























International 12 44 Prior Metformin 











Placebo UTI, DKA 
NCT01340664 
Qiu, 2014 89 


































United States 12 299 Prior metformin Sotagliflozin  
75 mg, 200mg, 
400mg 













International 24 534 Prior metformin Dapagliflozin  
10mg 





















International 48 420 Treatment Naive 




Placebo UTI, BF 
None 
Ross, 2015 99 






Japan 7 days 40 Treatment Naive Luseogliflozin  

















International 16 400 Prior metformin Dapagliflozin  
5mg, 10mg, 20mg 
Placebo UTI, BF 
None 
Seino, 2014 103 
Japan 12 239 Treatment Naive Luseogliflozin  
0.5mg, 2.5mg, 5mg 
Placebo UTI 
None 
Seino, 2014 104 
Japan 12 282 Treatment Naive Luseogliflozin  
1mg, 2.5mg, 5mg, 
10mg 
Placebo UTI, DKA 
None 
Seino, 2014 105 










Placebo UTI, BF 




2.5mg, 5mg, 10mg 
NCT00500331 
Sykes, 2015 108 











International 12 825 Treatment Naive Empagliflozin  
10mg, 25mg 

































































10mg   
Placebo UTI, BF 
NCT01064414 
Yale, 2014 118 
International  52 269 Treatment Naive 
or 1 or 2 
Canagliflozin  
100mg, 300mg 
Placebo UTI, BF 
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NCT01316341 
Zhao, 2015 119 
China 9 days 24 Treatment Naive 







International 206 7028 Treatment Naive Empagliflozin  
10mg, 25mg 
Placebo UTI, AKI, DKA, BF 
None 
Goto, 2012 120 
 



























Neal, 2015 124 












UTI, AKI, BF 
NCT00495469 
Sykes, 2015 126 










Japan 52 194 Treatment Naive Tofogliflozin  
20mg, 40mg 








No comparator UTI 
NCT01095666 
Yang, 2014 128 
 
24 444 Prior metformin Dapagliflozin  
5mg, 10mg 















Japan 24 138 Prior Teneligliptin Canagliflozin  
100mg 




International 24 333 Prior metformin Empagliflozin  
10mg, 25mg 
Placebo UTI, AKI, DKA, BF 
NCT01958671 
Terra, 2017 132 


































International 52 1326 Prior metformin Ertugliflozin  
5mg, 15mg 
Glimepiride AKI, UTI, DKA, BF 
Ito, 2017 137 Japan 24 66 Treatment Naive 
or prior therapy 


















International 26 621 Prior metformin Ertugliflozin  
5mg, 15mg 
Placebo UTI, DKA, F 




Yang, 2017 141 






























3.3.2 Primary Analysis 
Acute Kidney Injury 
 Acute kidney injury was reported in 11 RCTs (8 placebo comparison, and 3 active 
comparison trials): meta-analysis was only possible with placebo-controlled trials. Overall 
SGLT2 inhibitors were found to have a protective effect (RR 0.59; 95% CI 0.39-0.89, I2 = 
0.0%), however this is estimate is heavily weighted by one study using empagliflozin, the 
EMPA-REG trial (Figure 3-2).5 Pooled estimate after removing the EMPA-REG trial was non-
significant (RR 0.48; 95% CI 0.14-1.64; I2 = 0.0%). 







 Diabetic ketoacidosis was reported in 26 RCTs (18 placebo comparisonc, 8 active 
comparisons, and 1 within class comparison trial). Neither placebo (RR 0.66; 95% CI 0.30- 
1.45, I2 = 0.0%) (Figure 3-3) nor incretin (RR 0.43; 95% CI 0.069-2.75; I2 = 0.0%; 3 Studies) 
(Forest plot, Section 4 of Appendix A) comparisons showed a significant difference in risk of 
DKA. Additional analysis using only placebo-controlled trials that had at least one event also 
yielded no significant difference (RR 0.73; 95% CI 0.25-2.16; I2 = 0.0%; 7 studies) (Forest plot, 
Section 4 of Appendix A).  
 




Urinary tract infections 
Urinary tract infection was the most frequently reported outcome examined (110 of 
112 studies reported). When compared to placebo, SGLT2 inhibitors as a class did not 
demonstrate a significant increased risk (RR 1.02; 95% CI 0.95-1.09), however subgroup 
analysis of the individual agents did show a significantly increased risk of UTIs in users of 
dapagliflozin (RR 1.21; 1.02-1.43), but not empagliflozin, canagliflozin, ipragliflozin or non-
marketed SGLT2 inhibitors (grouped) (Figure 3-4). When compared to active treatments, 
SGLT2 inhibitors grouped together did not demonstrate an increased risk of UTIs over 
metformin, sulfonylureas, incretins or glitazones, though the confidence interval was very 
close to significant (RR 1.12; 95% CI 1.00-1.26) (Figure 3-5). When broken down by individual 
SGLT2 inhibitor, it was dapagliflozin that showed an increased risk of UTI over active 
comparators grouped together (RR 1.42; 95% CI 1.07-1.87) (Forest plot, Section 4 of  
Appendix A).   
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Figure 3-4. Risk of urinary tract infections with SGLT2 inhibitors compared to placebo 
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 Bone fracture was reported in 63 RCTs (47 placebo comparisons, 14 active 
comparison, and 2 within class comparisons). SGLT2 inhibitors were not found to have an 
increased risk of fractures over placebo (RR 0.87; 95% CI 0.69-1.09) (Figure 3-6), metformin 
(RR 0.69; 95% CI 0.19-2.51; I2 = 0.0%; 6 studies), sulfonylureas (RR 1.15; 95% CI 0.66-2.00; I2 
= 0.0%; 3 studies) or incretins (RR 1.38; 95% CI 0.31-6.17; I2 = 0.0%; 3 studies). A sub-group 
analysis of canagliflozin compared to placebo alone, the agent identified by the FDA as 
having an increased risk, was also non-significant (RR 1.02; 95% CI 0.63-1.65; I2 = 0.0%; 12 










Lower Limb Amputation  
 Data was identified on amputation for three studies23,48,136. One case of amputation 
was found in the clinicaltrials.gov data for trial number NCT01422876 in a user of 
empagliflozin 25mg, no cases were reported for other treatment groups. The second study 
reported data from the CANVAS program, showed a rate of amputation among users of 
canagliflozin (100-300 mg) was 6.3 per 1000 patient-years, compared to 3.4 per 1000 
patient-years for placebo, this difference was statistically significant (p<0.001). Actual 
number of events were not reported. The third study reported one case in each of the 
treatment groups, ertugliflozin (1/888) and glimepiride (1/437).  
 
3.3.2 Sub-group and Sensitivity Analyses 
 Several sub-group analyses were conducted to examine: the impact of prior and 
concurrent use of other anti-diabetic agents; the influence of risk of bias as per the quality 
appraisal; and the impact of the definition of UTI used as outlined in Table 3-2. Overall these 
additional analyses did not change the findings of the primary analysis. There was a 
decreased risk of AKI in the treatment-naïve group, and the low risk of bias group, but this 
was consistent with the main analysis and driven by the same one large study.144 When the 
analyses were re-run using a fixed-effect models, the risk estimates remained the same or 
had slightly smaller confidence intervals. Forest plots for the fixed effects analysis are in 
Section 5 of Appendix A.  
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Table 3-2. Sub-group Analysis among Placebo Controlled Trials 
Group Relative Risk  
(95% CI, I2) 
# of 
Studies  
Total # of 
outcomes/patients 
Prior use of anti-diabetics 
AKI 
     Prior/Concurrent Diabetes Therapy 
     Treatment Naïve 
 
0.51 (0.14-1.84; 0.72%) 







     Prior/Concurrent Diabetes Therapy 
     Treatment Naïve 
 
0.65 (0.25-1.71; 0.00%) 







     Prior/Concurrent Diabetes Therapy 
     Treatment Naïve 
 
1.04 (0.93-1.16; 8.22%) 







     Prior/Concurrent Diabetes Therapy 
     Treatment Naïve 
 
0.81 (0.57-1.14; 2.61%) 






Risk of Bias 
AKI 
     Low Risk of Bias 
     High Risk of Bias 
 
0.58 (0.38-0.89; 0.0%) 







     Low Risk of Bias 
     High Risk of Bias 
 
0.85 (0.28-2.61; 0.0%) 







     Low Risk of Bias 
     High Risk of Bias 
 
1.00 (0.92-1.08; 0.0%) 







     Low Risk of Bias 
     High Risk of Bias 
 
0.95 (0.76-1.18; 0.0%) 






Definition of UTI 
UTI 
    Predefined list of terms 
    Suggestive of UTI 
    Positive culture 
    As per investigator 
    Not defined 
 
0.99 (0.91-1.07; 0.0%) 
1.13 (0.87-1.47; 0.0%) 
0.91 (0.51-1.62; 24.27%) 
0.82 (0.41-1.61; 0.0%) 










3.3.3 Risk of bias  
 Generally, studies were of good methodological quality, however numerous studies 
were deemed high risk of selective reporting after outcome data was retrieved from 
ClinicalTrials.gov that were not reported in the peer-reviewed publication (28%). Other 
potential sources of bias came from unclear reporting of methodological processes like 
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randomization sequence (32%) or blinded outcome assessment (17%), while most sources 
of bias came from lack of blinding of the researchers and participants (13%) and of the 
outcome assessors (9%). Risk of bias assessment for individual studies are available in 
Section 6 of the Appendix A. Funnel plots do not suggest of the presence of publication bias 
(see Section 7 of Appendix A).  
 
3.4 Discussion 
 This study provides a comprehensive review of the RCT literature with respect to 
key safety outcomes identified through post-marketing surveillance systems and 
communicated to health professionals and the public by drug regulators. We pooled 
outcome data from over 100 RCTs (including unpublished data only available through 
ClinicalTrials.gov) to quantify the association between SGLT2 inhibitors and AKI, DKA, UTI, 
and bone fracture. We found that SGLT2 inhibitors as a class do not appear to increase the 
risk of DKA, UTI, and bone fracture, and may have a protective effect with respect to AKI, 
though this effect was heavily weighted by one large RCT. With respect to UTI, overall 
findings do not hold in subgroup analysis by individual drug, suggesting that increased risk 
of UTI is associated only with dapagliflozin.  
Despite early indication of a protective effect from SGLT2 inhibitors on kidney 
function,15 the FDA published in a safety communication in June 2016 that 101 cases of AKI 
were reported among users of canagliflozin and dapagliflozin.10 SGLT2 inhibitors may 
provide a long-term protective effect on the kidneys via reduced trans-glomerular 
 60 
pressure, similar to the effects of agents that target the renin–angiotensin–aldosterone 
(RAAS) axis.145 Szalat et al. (2017) proposed three possible mechanisms that may explain 
the potential for an increased risk of AKI with SGLT2 inhibitors: 1) excessive diuresis leading 
to volume depletion, a particular concern for those who are hemodynamically unstable 
and volume-depleted; 2) a greater drop in trans-glomerular pressure due to the 
concomitant action of SGLT2 inhibition and RAAS blockade; and 3) renal medullary 
hypoxic injury, likely occurring in patients taking concomitant agents that impair 
medullary oxygenation (e.g. NSAIDS, radio-contract dyes).145 Additional potential 
mechanisms of renal injury include an increase in the urinary uric acid level leading to 
both crystal dependent and crystal independent tubular injury, and activation of aldose 
reductase resulting in fructose generation ultimately leading to increased oxidative stress, 
uric acid, cytokine release and inflammation.146 This systematic review highlights a lack of 
reporting of AKI with only 11 of 111 randomized comparisons having published data on this 
outcome.  Though an overall protective effect was found, this finding was driven by one 
large RCT that compared empagliflozin to placebo. Evidence to support or refute the 
potential risk of AKI with use of canagliflozin or dapagliflozin was insufficient. Case reports 
filed with the FDA suggest that this adverse outcome frequently occurs early in therapy 
(within one month of initiation) and therefore this lack or reporting should not be due to 
the duration of clinical trials. Recent observational data also supports clinical trial data on 
AKI. Nadkarni et al. (2017) reported on the incidence of AKI among two cohorts comparing 
patients with type 2 diabetes using SGLT2 inhibitors to non-users.147 After an average 
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follow-up time of 14 months, adjusted hazard ratios showed SGLT2 inhibitors to be 
protective in one cohort (aHR 0.4 [95% CI 0.2–0.7]; P= 0.004) and favoring SGLT2 inhibitors, 
though not statistically significant, in the second cohort (aHR 0.6 [95% CI 0.4–1.1]; P= 0.09). 
These findings were not driven by users of empagliflozin, rather 91.2% and 71.4% of SGLT2 
inhibitor users in these cohorts were taking either canagliflozin or dapagliflozin respectively. 
Reports of euglycemic DKA among patients with type 2 diabetes is concerning, as a 
diagnosis can easily be missed. Though rare, the SGLT2 inhibitors are thought to increase 
the risk by two potential mechanisms: 1) they increase urinary glucose excretion which 
leads to a reduction in insulin secretion and stimulates free fatty acid production which are 
later converted to ketone bodies; and 2) they stimulate glucagon secretion which may lead 
to an overproduction of ketone bodies.148 An accurate assessment of the potential 
increased risk of DKA among users of SGLT2 inhibitors was difficult with the data reported 
within RCTs. Baseline incidence rates of DKA in patients with type 2 diabetes was found to 
be 1.34 per 1,000 person-years in a 20 year retrospective Danish cohort study, with 
declining incidence each year.149  Therefore, most RCTs had insufficient sample size to 
detect any cases. Of the 16 RCTs that reported DKA, only 7 (representing 11,004 patients) 
had one or more cases. Our findings are consistent with published observational literature, 
which indicates no increased risk, however confidence intervals were wide. A case-control 
study using Truven MarketScan data (a large US claims database),150  and a cross-sectional 
using the FDA Adverse Event Reporting System (FAERS) database151 examining this issue 
have recently been published. Both studies used DPP-4 inhibitors as the active comparator 
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given they have no known risk for DKA and are used in a similar fashion as second line 
therapy in type 2 diabetes, and both showed significant increased risk with SGLT2 inhibiters 
(Case-Control: 7-fold increased risk among 140,352 patients; cross-sectional: HR 2.2; 95% 
CI 1.4-3.6, among 416,670). In contrast, the Danish cohort study did not find an increased 
risk of DKA in individuals taking SGLT2 inhibitors compared to other diabetes therapies (HR 
1.6; 95% CI 0.6-3.5), although the upper bound of the 95% confidence interval does not rule 
out significant harm.149 No meta-analyses assessing this outcome were found. 
Given the mechanism of action of the SGLT2 inhibitors, which work by inhibiting 
glucose reabsorption in the kidney leading to increase glucose excretion in the urine, an 
increased risk of UTI is plausible. In May 2015 the FDA reported in a safety update that 19 
cases of life-threatening kidney or blood infections that originated as a UTI had been 
identified in patients taking a SGLT2 inhibitor. However, a meta-analysis published in 2017, 
which is the largest to date, included 77 RCTs representing 50,820 patients and found no 
increased risk of UTIs in SGLT2 inhibitor users (RR 1.05; 95% CI 0.98-1.12).17 The previous 
meta-analysis limited inclusion to studies of at least 24 weeks and having a full text 
publication. Our study findings are consistent and add to the literature via the inclusion of 
35 more studies, resulting in a more precise effect estimate. Importantly, subgroup analysis 
of individual SGLT2 inhibitors suggest variation of UTI risk within class whereby dapagliflozin 
may increase UTI risk when compared to both placebo and active controls. A reasonable 
biologic mechanism for an increased risk of UTIs among dapagliflozin users is unclear, 
however some early pathophysiological studies suggest that the dose response relationship 
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with urinary glucose excretion seems to plateau at the beginning of the normal 
recommended doses for most SGLT2 inhibits152–157, though continues through the normal 
dosing range for dapagliflozin158.  
In January 2016, the FDA issued an expanded warning regarding a potential 
increased risk for fracture with canagliflozin.12 A disruption in calcium-phosphate 
homeostasis is one potentially contributing mechanism.20 SGLT2 inhibitors increase serum 
phosphate levels via increased tubular reabsorption of phosphate. Increased phosphate 
levels then stimulate parathyroid hormone release which may enhance bone resorption 
leading to an increased fracture risk in patients using SGLT2 inhibitors.159 In an RCT 
conducted by Bode et al. (2015), additional investigation into the change in bone mineral 
density in canagliflozin versus placebo users was conducted.44 Their results showed a 
decreased placebo-corrected bone mineral density in the canagliflozin users at 2 years of 
0.9-1.2% at the hip, 0.3-0.7% at the lumbar spine, 0.5% at the femoral neck, and 0.4% at the 
distal forearm. To date, two meta-analyses have been published examining the risk of 
fracture when comparing SGLT2 inhibitors to placebo.20,21 Ruanpeng et al. (2017) included 
20 RCTs, and Tang et al. (2016) included 38 RCTs. Neither meta-analysis in pooled or 
subgroup analysis of individual SGLT2 inhibitors demonstrated a significant increased risk 
of fracture. A pooled analysis of eight canagliflozin RCTs also found no increased risk.22 The 
results of this current study support the existing literature, demonstrating risk neutrality, 




To date research evidence on the risk of amputations among users of SGLT2 
inhibitors is limited to results from the combined CANVAS and CANVAS-R trials. Only two 
other studies reported amputations, with one event per trial. Further data is needed to 
establish the true risk as well as to identify if this may be a class effect or agent specific.    
 
3.4.1 Limitations 
 Although we conducted a comprehensive systematic review of RCTs of SGLT2 
inhibitors, there are still limitations to be considered when interpreting our findings. First, 
our review focused on select adverse events and excluded any benefits. Though this 
narrows the focus and requires the consideration of additional literature to make clinical 
decisions on appropriate use of SGLT2 inhibitors, it also provides a succinct and in-depth 
assessment of the unexpected adverse effects that have been reported post-market. 
Secondly, several of the outcomes (e.g., AKI, DKA, limb amputations) we evaluated occur 
infrequently. This also resulted in these individual outcomes to be at a higher risk of 
selective reporting bias than the more common adverse effects. We did our best to account 
for this risk by supplementing unreported outcomes with data from clinicaltrials.gov, 
however it is possible the cases of these outcomes were not recorded or reported through 
either of these sources. Thirdly, certain outcomes may have been inadequately 
characterized within study reports. For example, while UTIs were commonly reported 
among RCTs included in this meta-analysis, data on complicated versus uncomplicated 
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infections were not. The FDA highlighted 19 cases of life-threatening infections stemming 
from UTIs. It is possible that SGLT2 inhibitors play a role in the progression of UTI to more 
complicated clinical outcomes. Fourth, the limited duration of included RCTs (36% of studies 
were less than 24 weeks and 63% less than one year) precludes the estimation of long-term 
effects of SGLT2 inhibitors. This may be important in case of declining bone integrity. Finally, 
it was difficult to accurately assess the methodological quality of the outcome assessment 
for the included studies given the fact we were examining secondary and rarely reported 
outcomes. It has been noted that traditional quality appraisal forms are not always well 
suited to systematic reviews of adverse events. This is due to the fact that sometimes data 
on adverse effects may be collected after allocation is known, or through self-assessment 
questionnaires.160   
 
3.5 Conclusion 
Despite the growing body of evidence on the new SGLT2 inhibitors, there remains 
minimal evidence demonstrating the comparative safety with respect to the more serious 
and unexpected outcomes. Current evidence from RCTs does not suggest an increased risk 
of harm with SGLT2 inhibitors, as a class, over placebo or active comparators with respect 
to the AKI, DKA, UTI or fracture. There appears to be treatment effect heterogeneity for the 
risk of UTI among specific SGLT2 inhibitors. Larger sample sizes and more long-term 
evidence is needed to refine our estimates of the risk of AKI, DKA, fracture and amputation 
among SGLT2 inhibitor users.  In particular, the addition of observational studies to future 
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analyses would allow for larger samples and long term outcomes through the use of real 
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4. Dose Response of Sodium Glucose Co-Transporter-2 Inhibitors 
in Relation to Urinary Tract Infections: A Systematic Review and 
Network Meta-Analysis of Randomized Controlled Trials2 
 
4.1 Background 
The sodium glucose co-transporter-2 (SGLT2) inhibitors are a novel group of drugs 
for the treatment of type 2 diabetes mellitus. These products have several benefits 
including a moderate glycemic lowering effect, low risk of hypoglycemia, reductions in 
weight and blood pressure, and reduction in major adverse cardiovascular events.1,2 The 
SGLT2 inhibitors are recommended as one of several options for second-line therapy, with 
empagliflozin and canagliflozin specifically recommended in clinical guidelines as the 
preferred second-line therapies for patients with pre-existing cardiovascular disease.3 Their 
unique mechanism of action – inhibition of the reabsorption of glucose at the proximal renal 
tubule – results in increased urinary glucose excretion4 and has led to speculation about an 
increased risk of urinary tract infections (UTIs).5   According to a public safety advisory in 
the United States, there were 19 reported cases of life-threatening kidney or blood 
infections between March 2013 and October 2014 that originated as a UTI in individuals 
taking SGLT2 inhibitors.6     
                                                     
2 A version of this manuscript has been published. Citation: Jennifer R Donnan, Catherine A Grandy, Eugene 
Chibrikov, Carlo Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, 
Hai Nguyen, John-Michael Gamble. Dose Response of Sodium Glucose Co-Transporter-2 Inhibitors on 
Urinary Tract Infections: A Systematic Review and Network Meta-Analysis . CMAJ Open. 2018. vol. 6 no. 
4. E594-E602. Reproduced with permission through the Creative Commons Licence.  
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Although product monographs for SGLT2 inhibitors identify an increased risk of UTI 
as a potential adverse effect, clinical trial evidence to date does not support this notion. 
Two published meta-analyses of randomized control trials (RCTs) found no increased risk of 
UTIs,7,8 except within a sub-group of dapagliflozin users receiving a 10mg dose,8 which 
indicated a potential dose-response relation. Such a dose-response relation is plausible 
given variation in the rate of urinary glucose excretion with individual agents (Table 4-1). 
Some of these agents have shown a clear dose-response relation, whereas others seem to 
reach a maximum for urinary glucose excretion with certain dosages. Moreover, prior meta-
analyses were limited to studies with at least 24 weeks of follow-up. It is unlikely that 
development of a UTI would require months of treatment, and therefore data from short-
term studies should also be considered. The specific question that we addressed in this 
systematic review and network meta-analysis was whether there is a dose-response 
relation between SGLT2 inhibitors and UTI in individuals with type 2 diabetes, relative to 
other diabetes therapies or placebo.  
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Table 4-1. Comparison of Urinary Glucose Excretion with SGLT2 Inhibitors 





Zhao, 20159 Day 1: 10mg (88g); 25 mg (83g)   
Day 9: 10mg (96g); 25 mg (83g)  
No difference between 
10 and 25 mg doses 
Kanada, 201310 Day 1: 1mg(40g); 5mg (80g); 10mg 
(85g); 25mg (90g) 
Day 27: 1mg (41g); 5mg (77g); 10mg 
(81g); 25mg (93g) (Estimated from 
chart) 
Dose response 
Scheen, 201411 Day 1: 0.5mg (5g), 2.5mg (30g), 10mg 
(50g), 25mg (58g), 50mg (64g), 100mg 
(80g), 200mg (69g), 400 mg (90.8g), 
800 mg (62g) (Estimated from chart) 
Dose response up to 
about 100mg dose 
Product Monograph 10mg (64g); 25mg (78g)  Dose response 
Heise, 201312 Day 1: 10mg (74 g); 25mg (90g); 100mg 
(81g)  




Parkinson, 201613 2.5mg (37.9 g), 5mg (45.2g), 10mg 
(86.4g) 
Dose response 
Yang, 201414 Day 10: 5mg (28g); 10 mg (41g)  Dose response 
Product Monograph 10mg: (~70 g); UGE approached a 
maximum at 20mg 




Iijima, 201515 Ranged from 80g to 110g. Smallest at 
25mg, no great difference at 100–
400mg 
Dose response to 100mg 
dose 
Devineni, 201516 100–300mg: Ranged from 80–120g Not clear 
Product Monograph 100-300mg: Ranged from 77-119g Not clear 





Kapur, 201318 20mg (67mmol), 50mg (97mmol), 
150mg (168mmol), 500mg (223mmol), 
1000mg (304mmol) 
Dose response 
Dobbins, 201219 200mg (509mmol); 1000mg 
(918mmol); 2000mg (574mmol) 




Veltkamp, 201120 A dose response is noted up to the 
50/100mg dose. Actual change in UGE 
depended on study, 50g in one study 
and 80-90g in another.  
Dose response to 50mg 
dose 
Kadokura, 201421 50 mg (80.6g +/- 22.2g); 100mg (89.7 
+/- 12.3g) 
No difference between 
50mg and 100 mg 
Ertugliflozin Amin, 201522 1mg (46.33 g); 5mg (64.54g); 25mg 
(74.49g) 
Dose response 
Tofogliflozin Ikeda, 201523 2.5mg (217.9mmol), 5mg(272.3mmol), 
10mg (346.2mmol), 20mg 




Zambrowicz, 201524 400mg (29.7) Not clear 
Rosenstock, 201525 75mg (~18g), 200mg (~66g), 400mg 
(55-60 g) (Estimated from chart) 




4.2 Methods and Analysis 
4.2.1 Study Design 
This study was designed and reported in accordance with the PRISMA statement on 
systematic reviews and network meta-anlayses26 (PRISMA Checklist Section on of Appendix 
B) and was registered with PROSPERO (www.crd.york.ac.uk/prospero/; no. 
CRD42016038715).27  
 
4.2.2 Eligibility Criteria  
 For this review we sought to identify RCTs that compared an SGLT2 inhibitor with 
placebo, with no treatment, or with an active antidiabetic control. The SGLT2 inhibitor could 
be any one of the currently marketed or investigational agents, but excluded combined 
SGLT1/SGLT2 inhibitors. An active control could be any of the available oral antidiabetic 
agents with the exception of first generation sulphonylureas, because they are rarely used 
in practice. Patients had to be adults (≥ 18 yr) with type 2 diabetes. The studies had to report 
on the outcome of UTI, but were not limited by duration of follow-up, year of publication, 
or publication status. Inclusion was limited to studies published in English.   
 
4.2.3 Search Strategy 
A health science librarian (M.S.) conducted a comprehensive literature search. The 
search strategy was developed in the PubMed database (from inception to May 2018) and 
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was then translated for the Cochrane Library via Wiley (from inception to May 2018), 
Embase via Embase.com (from inception to May 2018) and International Pharmaceutical 
Abstracts databases via Ebsco (from inception to May 2018). Medical Subject Headings and 
keyword terms used to capture type 2 diabetes (e.g., "Diabetes Mellitus, Type 2"[Mesh] OR 
NIDDM[tw] OR t2dm[tw]) were combined with terms relating to SGLT2 inhibitors, including 
generic names, brand names, chemical names and compound codes as applicable. RCTs 
were identified with a methodological search filter.28 The librarian also conducted multiple 
test searches to optimize the sensitivity and specificity of the search parameters. Reference 
lists of key articles were also screened (by J.R.D.). We identified unpublished (grey 
literature) RCT data by searching the ProQuest Dissertations & Theses Global and 
ClinicalTrials.gov databases. For the various search strategies, see Section 2 of Appendix B. 
 
4.2.4 Study Selection and Data Extraction 
DistillerSR software29 was used to facilitate a 2-level screening process. First with 
titles and abstracts and then full text (performed by J.R.D., C.A.G., J.H., and D.C.). We used 
the “liberal accelerated” method of duplicate screening,30 whereby a second reviewer 
screens only citations that have been rejected by the first reviewer.  
For articles included in the review, one reviewer completed the data extraction, and 
another performed verification (performed by J.R.D., C.A.G. and J.H.) (for data extraction 
variables, see Section 3 of Appendix B). Where gaps existed, the extracted data were 
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supplemented with data from ClinicalTrials.gov. Where data from multiple sources 
conflicted, information from the published paper was used. Where multiple publications for 
the same study population existed (e.g., interim analyses or extension studies), the most 
recent publication was used. The exception to this rule was where the most recent 
publication involved a change in the drug dose, then the original publication was used.  
 
4.2.5 Assessment of Risk of Bias 
We used the Cochrane Collaboration domain-based risk assessment tool to identify 
sources of bias in each study.31 This assessment was completed independently by one 
reviewer, with verification by a second reviewer (performed by J.R.D., C.A.G., J.H.).    Each 
domain was identified as being “low”, “high”, or “unclear” risk of bias. In addition, the 
following rules were applied to assign an overall risk of bias: where all domains were 
considered to have low risk, the overall risk was low; where at least 1 domain was 
considered to have high risk, the overall risk was high; and where at least 1 domain was 
considered to have unclear risk (and no domain was considered to have high risk), the 
overall risk was considered to be unclear. We assessed publication bias using a funnel plot 
of placebo controlled trials.31  
 
 91 
4.2.6 Data Synthesis 
We conducted a Bayesian network meta-analysis of RCTs. The doses of SGLT2 
inhibitors were categorized into 2 groups: “high dose” and “low dose”. These categories 
were defined on the basis of available marketed doses and urinary glucose excretion rates. 
Where 2 marketed doses were available for a given drug, the lower dose was categorized 
as “low” and the higher dose as “high”. All other studied doses to the extremes of the 2 
marketed doses were categorized in the most proximal dose category. For example, a dose 
lower than the marketed dose would be considered “low dose”. Where 3 marketed doses 
were available, the middle dose was categorized with the group having the closest urinary 
glucose excretion rate. For experimental products, categories were defined by looking at 
the most commonly studied doses, and setting a threshold, as was done for the marketed 
products. We took this approach to avoid placing too much emphasis on ineffective or 
unsafe doses used in dose-finding studies (for threshold doses, see Section 4 of Appendix 
B). 
We used a random-effects generalized linear model for binary data, with non-
informative priors, to estimate the relative effects, credible intervals and rank probabilities 
of each of the comparators. We tested convergence of the Markov Chain Monte Carlo 
simulation (100,000 iterations) with the Gelman-Rubin diagnostic test and used the 
deviance information criterion to assess model fit. We examined rank probabilities by 
calculating the surface under the cumulative rank curve values. We tested heterogeneity 
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with the I2 statistic for pairwise comparisons and assessed inconsistency by visually 
comparing the direct and indirect pooled estimates.  
We conducted 3 sensitivity analyses. We altered the threshold between low and 
high doses to reflect uncertainty in the dose-response relation with urinary glucose 
excretion. We also restricted the analysis to studies of at least 24 weeks’ duration. Finally, 
we restricted analysis to studies with a “low” overall risk of bias. All of the outcome data 
were analyzed using the gemtc package of R statistical software (version 3.4.1).  
 
4.2.7 Ethics Approval 
 This study was a retrospective analysis of previously published data, and ethics 
approval was not required. 
 
4.3 Results 
4.3.1 Included Studies 
In total, 2,418 titles and abstracts were screened, and 140 citations met our 
inclusion criteria. Of these, 35 were excluded because they represented duplicate data 
(extension studies, post-hoc analyses) or because mixed-doses or unstable doses were 
used. A final list of 105 publications were included (Figure 4-1), representing 108 
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randomized populations, 60,082 individuals, and 4,348 UTIs (Table 4-2). Three of the 




Figure 4-1. Flow Diagram for Included Studies 
 
 
 Most studies examined either dapagliflozin (33 studies), empagliflozin (25 studies), 
canagliflozin (19 studies) or ipragliflozin (11 studies); 20 studies investigated 1 of 4 other 
agents (luseogliflozin, remogliflozin, tofogliflozin, and ertugliflozin). With respect to 
comparisons, 4 studies conducted only within class comparisons, 89 compared the study 
drug with placebo, 26 used an active comparator, and 9 included more than 1 unique 
comparator. Studies ranged from 1 to 208 weeks in duration. 
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Table 4-2. Characteristics of Included Studies 
NCT# 







Background Therapies Intervention(s) Comparator(s) 
NCT01059825 
Amin, 2015 22 
International 12 328 Prior therapy stabilized to 
metformin 
Ertugliflozin  




Amin, 2015 37 
International 4 194 Uncontrolled on 2 agents Ertugliflozin  
1mg, 5mg, 25mg 
Placebo 
NCT02157298 
Araki, 2016 38 






Araki, 2015 39 





Bailey, 2013 40 
International 102 546 Prior metformin Dapagliflozin  
2.5mg, 5mg, 10mg 
Placebo 
None 
Bailey, 2012 41 
International 24 282 Treatment Naive Dapagliflozin  
1mg, 2.5mg, 5mg 
Placebo 
NCT01164501 
Barnett, 2014 42 




Bode, 2015 43 






Bolinder, 2014 44 




Cefalu, 2015 45 




Lu, 2016 46 




DeFronzo, 2015 47 




Del Prato, 2015 48 





Ferrannini, 2013 36 





Ferrannini, 2013 36 




Ferrannini, 2010 49 
International 24 485 Treatment naive Dapagliflozin  








12 412 Treatment naive Ipragliflozin  





Frias, 2016 51 




Hadjadj, 2016 52 





Haering, 2015 53 




Heise, 2013 12 
Germany 4 78 Not described Empagliflozin  
10mg, 25mg, 100mg 
Placebo 
None 
Heise, 2013 54 
Germany 9 days 48 Prior naive mono or combo 
therapy 
Empagliflozin  
2.5mg, 10mg, 25mg, 100mg 
Placebo 
NCT00643851 
Henry, 2012 34 




Henry, 2012 34 





Henry, 2012 34 




Henry, 2012 34 





Ikeda; 2015 23 
International 12 398 Naive or metformin Tofogliflozin  




Inagaki, 2016 55 




Inagaki, 2015 56 






Inagaki, 2013 57 
Japan 12 383 Any prior therapies 
washed-out 
Canagliflozin  




Inagaki, 2014 58 






Ishihara, 2016 59 




Jabbour, 2014 60 
International 48 451 Prior DPP4 maybe 





Ji, 2015 61 







Ji, 2014 62 




Kadokura, 2014 21 
Japan 2 30 Treatment naive or 
monotherapy 
Ipragliflozin  
50mg , 100mg 
Placebo 
NCT01193218 
Kadowaki, 2015 63 








Japan 12 279 Treatment naive or 1 or 2 
agents at low dose 
Dapagliflozin  
1mg, 2.5mg, 5mg, 10mg 
Placebo 
None 
Kaku, 2014 65 






Kaku, 2014 66 
Japan 24 235 Treatment naive or 
washout 
Tofogliflozin  
10mg, 20mg, 40mg 
Placebo 
NCT01242215 
Kashiwagi, 2015 67 




Kashiwagi, 2015 68 
Japan 26 131 Treatment naive or 1 or 2 





Kashiwagi, 2014 69 
Japan 12 361 Treatment naive or 
washout 
Ipragliflozin  





Japan 52 165 Treatment naive or 1 or 2 





Kohan, 2014 71 




Kovacs, 2015 72 






Heerspink, 2013 73 








International 52 1284 Prior metformin and maybe 





Leiter, 2014 75 




Leiter, 2015 76 




Lewin, 2015 77 




List, 2009 78 
International 12 389 Treatment naive Dapagliflozin  Placebo, Metformin 
1500mg max 
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2.5mg, 5mg, 10mg, 20mg, 
50mg 
NCT01646320 
Mathieu, 2015 79 




Matthaei, 2015 80 




Mudaliar, 2014 81 






Nishimura, 2015 82 




Qiu, 2014 83 




Rodbard, 2016 84 




Roden, 2015 85 





Rosenstock, 2012 86 
International 12 451 Prior metformin Canagliflozin  





Rosenstock, 2016 87 




Rosenstock, 2015 88 




Rosenstock, 2014 89 




Rosenstock, 2015 90 
International 78 494 Prior insulin maybe 





Rosenstock, 2012 91 
International 48 420 Treatment naive or 





Ross, 2015 92 




Sasaki, 2015 93 
Japan 7 days 40 Treatment naive Luseogliflozin  





International 52 756 Prior metformin and SU Canagliflozin  
300mg 
Sitagliptin 100mg 
NCT01217892 International 16 400 Prior metformin Dapagliflozin  






Seino, 2014 96 
Japan 12 239 Treatment naive Luseogliflozin  
0.5mg, 2.5mg, 5mg 
Placebo 
None 
Seino, 2014 97 
Japan 12 282 Treatment naive Luseogliflozin  
1mg, 2.5mg, 5mg, 10mg 
Placebo 
None 
Seino, 2014 98 




Stenlof, 2013 99 






Strojek, 2014 100 
International 48 597 Prior SU  Dapagliflozin  
2.5mg, 5mg, 10mg 
Placebo  
NCT00500331 
Sykes, 2015 101 
International 12 336 Treatment naive Remogliflozin  





Tikkanen, 2015 102 




Townsend, 2016 103 




Wan Seman, 2016 
104 





Weber, 2016 105 




Weber, 2016 106 




Wilding; 2013 107 




Wilding, 2013 108 
International 12 343 Prior metformin Ipragliflozin  




Wilding, 2009 109 




Wilding, 2014 110 
international 104 808 Prior insulin others allowed Dapagliflozin  
2.5mg, 5/10mg, 10mg   
Placebo 
NCT01064414 
Yale, 2014 111 




Zhao, 2015 9 





Zinman, 2015 1 




Goto, 2012 112 

















Merker, 2015 115 




Neal, 2015 116 










Sykes, 2015 118 
UK 12 252 Treatment naive Remogliflozin  





Tanizawa, 2014 35 




Tanizawa, 2014 35 




Yang, 2014 14 




Gupta, 2017 119 





Kadowaki, 2017 120 




Softeland, 2017 121 




Terra, 2017 122 




Terauchi, 2017 123 














Hollander, 2018 125 
International 52 1326 Prior metformin Ertugliflozin  
5mg, 15mg 
Glimepiride 
Ito, 2017 126 Japan 24 66 Treatment naive or prior 







Pratley, 2018 127 
International 52 1233 Prior metformin Ertugliflozin  
5mg, 15mg 




International 26 621 Prior metformin Ertugliflozin  
5mg, 15mg 
Placebo 




Yang, 2017 130 




Henry, 2018 131 




We included all of the studies in the first run of the analysis. However, despite 
200,000 iterations of the Markov Chain Monte Carlo simulation, assessment of the 
Gelman-Rubin statistic showed that many nodes did not approach convergence. There 
were also unexpected protective effects in comparisons that included luseogliflozin. On 
examination of study results, we found only 2 cases of UTI were reported across the 4 
luseogliflozin studies, each of which was of short duration (7 days-24 weeks). After 
removal of these studies all nodes approached convergence.  The deviance information 
criterion was also lower, indicating a better model fit. Figure 4-2 shows the network of 
available direct evidence without luseogliflozin.  
 
Figure 4-2. Network Diagram 
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 Most comparisons showed a non-significant difference in the risk of UTI (Table 4-
3). Exceptions included comparisons of high dose dapagliflozin (≥10 mg) with placebo 
(odds ratio [OR] 1.30; 95% credible interval 1.09 – 1.57), with active comparators (OR 
1.44; 95% credible interval 1.15 – 1.79), with empagliflozin at both high (OR 1.39; 95% 
credible interval 1.12 – 1.72) and low doses (OR 1.30; 95% credible interval 1.04 – 1.60) 
and with ertugliflozin at low doses (OR 1.43; 95% credible interval 1.01 – 2.01). Low-dose 
canagliflozin compared with active comparators also had significantly greater risk (OR 
1.29; 95% credible interval 1.03 – 1.64). Examination of rank probabilities using surface 
under the cumulative rank curve values showed results that were consistent with the 
primary analysis. Specifically, high-dose dapagliflozin was the least favorable and high-
dose remogliflozin and active comparators (grouped) were the most favorable with 
respect to risk of UTI (for the forest plot of placebo treatment comparisons and the list 
of surface under the cumulative rank curve values, see Section 5 of Appendix B) 
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Table 4-3. Risk of Urinary Tract Infections from SGLT2 Inhibitors: Odds Ratios and 95% Credible Intervals for Network Meta-Analysis Comparisons 








































































































































































































































































































































































































































































































Examination of the I2 value for each of the comparisons showed homogeneity, with 
most values of I2 at 0% (and all < 45%). When we back-calculated indirect risk estimates and 
compared them with direct evidence to assess for consistency, we found no major 
discrepancies between the estimates, which suggested that the consistency assumption 
was met (for the complete list of pairwise, indirect and pooled estimates, see Section 6 of 
Appendix B). 
 
4.3.2 Risk of bias 
 Generally, the studies were of high methodologic quality. The overall quality 
assessment indicated that more than half of the studies (54 or 51%) were at low risk of bias. 
About one-third (31 or 30%) had unclear reporting of randomization sequence, and one-
quarter (26 or 25%) had unclear or high risk of bias for blinded outcome assessment (Figure 








4.3.3 Sensitivity Analysis 
 The results of the sensitivity analyses were consistent with those of the primary 
analysis. When the threshold between high and low doses was altered, high-dose 
dapagliflozin still showed an increased risk of UTI compared with placebo, active 
comparators and high-dose empagliflozin, but also showed an increased risk relative to low 
doses of ipragliflozin and ertugliflozin. The thresholds for dapagliflozin doses were not 
adjusted in this sensitivity analysis, because an alternate definition was not suitable. 
Ipragliflozin at low doses showed a significantly lower risk of UTI than high doses of 
canagliflozin, ertugliflozin, ipragliflozin, and dapagliflozin.  










In the analysis of studies lasting 24 weeks or longer, fewer comparisons among 
experimental agents were possible. However, the findings were consistent with those of 
the primary analysis, whereby high-dose dapagliflozin had a high risk compared with 
placebo, active comparator and empagliflozin. Restriction of the analysis to studies with an 
overall low risk of bias (n=57) resulted in no significant differences among the drug 
regimens. In each of the sensitivity analyses, there were treatment arms with insufficient 
data to accurately estimate risk (for complete results of the sensitivity analyses, see Section 
8 of Appendix B).  
 
4.4 Discussion 
 The main findings of this study suggest no dose-response association between 
SGLT2 inhibitors and UTI risk; however, dapagliflozin (at doses ≥ 10 mg) appears to be an 
exception to this general finding. Specifically, high dose dapagliflozin compared with 
placebo, active comparators and empagliflozin was associated with a small increase in the 
risk of UTI.  
Several other meta-analyses have reported on the association between SGLT2 
inhibitors and UTIs7,8,132–138 with inconsistent results, including increased risk with 
dapagliflozin7,8,133, increased risk for SGLT2 inhibitors,134,135         and no difference in risk.136–
138 However, given the continuing postmarketing surveillance of these new agents, new 
RCTs are being published rapidly, and these previous meta-analyses are quickly becoming 
outdated.134,137 In addition, several studies have applied additional eligibility criteria, such 
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as including only marketed agents133, placebo comparison trials133 , or studies of a certain 
duration (e.g. > 24 wk).7,8,133 The largest meta-analysis to date, which pooled results from 
86 RCTs representing 50,880 patients, found no increased risk of UTIs (relative risk  1.03, 
95% confidence interval 0.96 – 1.11).138 Subgroup analysis by dose in this previous study 
also showed an increased risk only among users of dapagliflozin at a 10-mg dose.               
A mechanism for the increased risk of UTI with dapagliflozin is not clear; however, 
there is variation in the pharmacokinetic and pharmacodynamic profiles of individual SGLT2 
inhibitors. The SGLT2 inhibitors have shown a positive dose-effect relation with urinary 
glucose excretion, but this appears to have a ceiling effect with several agents. Maximum 
effects have been documented at about the starting doses for empagliflozin (10 mg)9,12 and 
canagliflozin (100 mg)15–17,139, but continued through the dosing range with dapagliflozin13. 
This may explain why the current study showed a dose-dependent relation for UTIs with 
dapagliflozin. It is unclear why an increased risk of UTI was observed with low-dose 
canagliflozin. Our sensitivity analysis showed a potential decreased risk of UTI among users 
of low-dose ipragliflozin ( 50mg) relative to those using high doses of canagliflozin, 
empagliflozin, ertugliflozin or ipragliflozin; high and low doses of dapagliflozin; or placebo. 
Pharmacodynamic evidence for ipragliflozin has been variable, with inconsistent estimates 
of the degree of urinary glucose excretion and the dose-response relation. However, there 
is also no indication that ipragliflozin is unique in any way that would support a physiological 
mechanism for the decreased risk of UTI. Further work is needed to examine this finding.    
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Our findings are consistent with previous findings supporting the lack of compelling 
data that would suggest a class effect in terms of UTI risk. Our study also extends the 
evidence by including additional studies, which has resulted in a more precise effect 
estimate. This study included as many studies as we could fine to investigate dose response 
encompassing both marketed and non-marketed agents, and active and inactive 
comparators in studies of any duration.  
 
4.4.1 Limitations 
 This systematic review of the association between SGLT2 inhibitors and UTIs had 
some limitations. The outcome of UTI is very well reported, but we did not identify data on 
the progression of UTI to more serious infections. This gap in reporting makes it impossible 
to support or refute the concern that SGLT2 inhibitors may lead to serious infections. It is 
already known that, as a population, patients with diabetes have an increased risk of 
infections of all origins.140 The 19 serious cases of UTI associated with SGLT2 inhibitors 
reported in the United States may be a result of increased vigilance for newly marketed 
drugs. The role of urinary glucose excretion in the pathogenesis of urinary tract infections 
is not well characterized. It has been postulated that increased urinary glucose excretion 
may not directly cause infections but rather may create a rich environment for bacterial 
growth and affect bacterial adherence to uroepithelial cells.141–143 Because of the volume 
of studies included, it was not feasible to contact authors regarding these data. Other 
limitations included restriction to studies published in English, and verification of data 
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abstraction and bias assessment by a second reviewer, rather than independent duplication 
of abstraction and assessment. Finally, we found no study that compared 2 different SGLT2 
inhibitors in a single trial; therefore the strength of evidence for comparisons between 
SGLT2 inhibitors is weak.     
 
4.5 Conclusions 
Current evidence does not support a dose-response risk profile for UTIs with SGLT2 
inhibitors as a class. Although high doses of dapagliflozin (≥ 10 mg) did appear to be 
associated with increased risk, this risk was attenuated in an analysis restricted to RCTs at 
low risk of bias. Further studies are needed to quantify the association between SGLT2 
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5. Capturing Patient Preferences towards Benefits and Risks of 
Second-line Diabetes Therapies: A Discrete Choice Experiment  
 
5.1 Background 
Guidelines recommend that metformin be initiated in all patients with type 2 
diabetes without a contraindication. However, given the progressive nature of the disease, 
within three years of receiving monotherapy, 50% of patients are inadequately controlled 
and require add-on therapy.1 In selecting a second-line agent, clinicians must make trade-
offs between the potential benefits and harms in light of patient specific characteristics 
(e.g., level of hyperglycemia, comorbidities, cardiovascular risk, and preferences). More 
recent updates of the Canadian and American diabetes clinical practice guidelines2,3 have 
also highlighted the importance of taking patient preferences into consideration. Individual 
patients may place different levels of importance on the various aspects of drug therapy. 
For instance, some may place an emphasis on the risk of weight gain, while others may 
place more of an emphasis on the risk of cardiovascular events.  Given the choice, they 
would have to make trade-offs on the performance of various risks, benefits, and 
convenience factors. Clinicians may implicitly consider these trade-offs on behalf of their 
patients; however, they may not always be reflective of their patients’ wishes.4 It has been 
demonstrated in fact that preferences of clinicians and patients can differ substantially, 
whereby physicians underestimate the degree to which medication characteristics 
influenced their decisions.5 
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Consideration for patient preferences has become vitally important as it is 
recognized that the values of informed patients influence both treatment adherence and 
patient satisfaction.6 As such, increasing attention has been placed on incorporating patient 
preferences into policy decisions, guideline development, and front-line patient care. 
Regulatory agencies including the European Medicines Agency7 and the United States Food 
and Drug Administration8 have recommended that preference data be included in 
regulatory approval applications. It is recognized that incorporating patient preferences 
helps to capture a perspective that cannot be gathered through clinical trial data. 9 
Such preferences can be determined quantitatively through choice modelling techniques, 
such as discrete choice experiments (DCE).   
A DCE is a survey method used get a quantitative estimate of the trade-offs 
individuals take into consideration when they make a decision. The approach has a long 
history in market research and transport economics, but has in the last couple of decades 
has been increasingly applied to health care decision analysis.10 This survey method is built 
upon multi-attribute utility theory which refers to the idea that when people make choices 
between alternatives, they take into consideration the characteristics of those alternatives. 
They then make trade-offs based on these characteristics to settle on a final selection. For 
example, a drug may have the characteristics of efficacy, time to onset of effect, side effects, 
and cost. A DCE presents survey respondents with a series of choice tasks which outlines 
two or more alternatives with the attributes (characteristics) that are deemed to be 
important to consider to make a choice. Respondents are asked to choose their preferred 
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alternative by making trade-offs on the performance of the attributes. The descriptors used 
to describe performance (e.g. for an attribute “cost”, the descriptor may be “$30”, “$60” or 
“$90”) are referred to as the levels and they come from a pre-specified list.  
There have been several DCEs conducted in the diabetes population, however 
surveys have tended to focus on specific attributes such as adherence or weight gain, or 
have excluded insulin therapy.11,1213 Importantly, Canadian patient preferences have not 
been elicited. The objective of this study was to measure the strength of preferences, 
relative importance, and trade-offs that patients with type 2 diabetes make between 
attributes of glucose-lowering medications.  
 
5.2 Methods 
5.2.1 Study Design 
This DCE followed the general framework for good research practices as suggested 
by the International Society for Pharmacoeconomics and Outcomes Research.14 The study 
was carried out in two phases. We first identified the attributes and levels of diabetes 
therapies that were shown to influence choice using qualitative methods.  Second, we 
designed and implemented a survey that contained choice tasks to measure patients’ 
preferences for the attributes of glucose-lowering therapies.  
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5.2.2 Identification of Attributes and Levels 
 A search of the medical literature was conducted using PubMed, to identify any 
choice modelling studies that had been previously published in the area of type 2 diabetes 
and more generally in medication therapy. This review helped to generate an initial list of 
attributes. To further refine the list of attributes and identify gaps, we supplemented our 
literature search with stakeholder (patients and clinicians) focus groups and interviews.  
For the focus groups, individuals with type 2 diabetes were recruited through the 
family practice unit at Memorial University of Newfoundland using letters that were mailed 
by family physicians on behalf of the study team. Individuals were considered eligible if they 
were at least 18 years of age and had been diagnosed with type 2 diabetes by a health 
professional. They could have been at any stage of disease progression and did not have to 
be currently receiving medication therapy. Individuals also had to be able to communicate 
in English and must not have had any cognitive impairment that would prevent them from 
fully participating in a group discussion. Participants were offered a $10 gift card to a local 
grocery store as a thank-you for their time. Family physicians were also recruited through 
the family practice unit to participate in key informant interviews.  Focus group participants 
answered a series of open-ended questions aimed at understanding the factors/attributes 
that they consider when starting a new diabetes medication. Once focus groups were 
complete, a preliminary list of attributes and levels was prepared and used as a starting 
point for discussion with clinicians participating in key informant interviews. Clinicians 
helped to refine the list and establish realistic and relevant levels for attributes. A formal 
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qualitative analysis of the focus groups and interviews was not conducted due to a low 
response rate of seven patients and three physicians. The information we heard was used 
to inform research team discussion and consensus on the attributes to be included. In 
general, patients were vague regarding their preferences and concerns when starting a new 
medication. They did not want other parts of their body impacted, but very rarely 
highlighted a specific concern. One issue they were passionate about was their preference 
against injectable therapy. They also were very confident in their physician’s 
recommendations and trusted they were selecting the best therapy for them. As a result of 
these discussions, the study team decided to group attributes into reasonable categories 
(e.g. minor side effects) to enable a broader inclusion of potential risks and benefits of 
diabetes therapies. A final list of eight attributes, each containing three levels were 
identified as described above (Table 5-1).  
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Table 5-1. Attributes and Levels 
Attribute Description Levels 
Efficacy Expected decrease in hemoglobin 
A1C (HbA1C) 
0% reduction in HbA1C 
1% reduction in HbA1C 
2% reduction in HbA1C 
Macrovascular events Reduction in heart attack, stroke, or 
death from cardiovascular diseases 
No reduction in risk 
20% reduction in risk 
40% reduction in risk 
Microvascular events Reduction in eye, kidney and nerve 
damage 
No reduction in risk 
20% reduction in risk 
40% reduction in risk 
Minor side effects Risk of minor side effects (e.g. weight 
gain, stomach upset, skin rash, low 
energy) 
0 out of 100 people 
20 out of 100 people 
40 out of 100 people 
Severe hypoglycemia Risk of severe hypoglycemic (low 
blood sugar) episodes over 10 years 
0 out of 100 people 
20 out of 100 people 
40 out of 100 people 
Serious side effects Risk of a serious but rare side effect 
over a 10-year period 
0 out of 100 people 
2 out of 100 people 
4 out of 100 people 
Cost Cost for one month supply $30, $90, $150 
Life Expectancy Reduction in life expectancy No change in life expectancy 
Increase in life expectancy by 1.5 years 
Increase in life expectancy by 3 years 
 
5.2.3 Experimental Design 
An unlabelled survey design was used,15 meaning that alternatives were described 
as “Option A” and “Option B” without a descriptor that holds any meaning (e.g. new and 
old treatment) as we did not want participants to have any pre-conceived opinions about 
the alternatives. Two active alternatives were presented with each choice task, as well as 
an option to select neither.  
A fractional factorial design was used with a total of 12 choice tasks generated by 
software package Sawtooth (Orem, UT; Version 9).16 Two additional choice tasks made up 
of dominant questions were also included for quality assurance. In these dominant choice 
tasks, one of the alternatives was designed to be superior or equivalent to the other 
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alternative on all attributes. If participants choose the non-dominant alternative for either 
question, this indicates a lack of understanding of the survey question, and all choice data 
for that participant are eliminated from analyses. A total of 250 different survey designs 
were generated, making a balanced and D-efficient design. Efficiency aims to optimize the 
ability of the survey to characterize the widest range of choice sets, given that it is not 
feasible to include every possible combination of attributes and levels. Each attribute level 
appeared with the same frequency, however overlap was allowed, meaning that some 
choice tasks presented the same level for a given attribute. Efficiency was tested using 
simulated data.   
At the beginning of the DCE portion of the survey, participants were asked to 
imagine that they were 55 years old and had diabetes that was not being well controlled 
with metformin (standard first line therapy), and required another medication. Then they 
were asked to choose one of the options in the choice task. When making their choice, 
participants had to make trade-offs between the descriptions. Choosing the neither option 
meant that they accepted natural progression of their disease without treatment (to view 
a sample choice task, refer Appendix C).   
Additional questions including sociodemographic (e.g. age, sex, income, education), 
duration of diabetes, comorbidities, and current medication use were also collected. The 
survey tool was pilot tested among the study team as well as with a patient advisory council 
through the Newfoundland and Labrador Support for People and Patient-Oriented 
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Research and Trials (SUPPORT) group. Pilot respondents provided feedback on survey 
comprehension, technical ease and length. A sample of the final full survey is available in 
the supplementary appendix. 
5.2.4 Study Sample and Elicitation Method 
Participants were eligible to complete the survey if they were Canadian, 18 years of 
age or older, reported to have been diagnosed with type 2 diabetes by a health care 
professional and were able to complete a survey in the English language. Individuals were 
asked to participate regardless of their diabetes medication history. We recruited 
individuals to complete the survey through an online research company (Research Now) 
who used email solicitation of a sample of individuals with type 2 diabetes from across 
Canada.  Screening questions on age and chronic health conditions were asked at the 
beginning of the survey to address eligibility criteria. To help ensure comprehension of the 
concepts explored in the survey, as well as the process for making choices, a 4-minute video 
was embedded in the survey to walk participants though the procedures and explain 
concepts that may not be easily understood (e.g., risk, percent and specific clinical 
outcomes). Participants could not proceed until the video concluded. Only data from 
respondents who completed the full survey were included. To maximize data quality, data 
from respondents who completed the survey in less than 7 minutes were excluded.  
Traditionally, sample size estimation for DCEs have been done using one of several 
rules of thumb.17–19 For example, one such rule of thumb is including a minimum of 10 
observations for each independent variable.20 For this study we wanted to estimate 15 
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parameters from the included attributes (one for cost, and 2 for each of the 7 other 
attributes) plus 3 stratification variables, for a total of 18 parameters and minimum sample 
of 180. Though other methods for estimating sample size for DCE in health care studies have 
been described,21 they may overestimate required sample size when there are several 
parameters to estimate. Instead of limiting to the number estimated by the above rule of 
thumb, we chose to maximize sample size based on our available budget to ensure 
sufficient power and allow for more in-depth analysis. As such, our aim was to recruit 500 
Canadians with type 2 diabetes. 
 
5.2.5 Statistical analysis  
 Descriptive statistics were collected and qualitatively compared to national 
averages. Dominance of options, that is the consistent selection of either A or B within the 
choice tasks, was also examined. Preference weights for each of the attributes in the survey 
were quantified using generalized linear models whereby the beta-coefficients for each 
attribute represent the relative preference for that attribute, and the dependent variable is 
the stated preference for a hypothetical drug profile. Classic diagnostic assumption tests 
were used to examine linearity of the effect estimates for levels within each attribute. 
Marginal rate of substitution (MRS) was determined by taking the ratio of two coefficients. 
When cost is used in the MRS, it represents the willingness to pay (WTP) for the comparison 
attribute.    
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 Each choice made within the DCE represents an observation in the dataset. The 
choice data was effects coded for all attributes, except cost which had continuous coding 
allowing for more interpretable WTP values. Though each attribute contained levels on a 
continuous scale, using the effects coding allowed for relaxation of the linearity assumption 
and to test for any non-linearity that exists within the preference weights.  
All data were analysed using both Sawtooth (Lighthouse Studio) and R (version 3.4.1) 
statistical software packages (mlogit, mclogit). A counts analysis was conducted to assess 
the significance of each attribute on choice. Counts analysis examines the proportion of 
times a particular attribute level is chosen to the number of times it appears in the survey. 
We used a multinomial logit (MNL) model for the base analysis and then a mixed MNL to 
test the robustness of the analysis, to account for intra-respondent variation, and allow for 
the independence of irrelevant alternatives assumption (IIA) to be relaxed.22 Interactions 
between attributes were assessed using a likelihood ratio test, where interactions with 
baseline characteristics (presence of cardiovascular disease, age (<65, >=65) and sex) were 
considered significant with a p-value<0.05. Exploratory post-hoc sub-group analyses were 
conducted to examine the impact of income, education and geographic location on overall 
findings. 
5.2.6 Assessment of Validity and Reliability 
 We conducted several assessments to examine the validity and reliability of our 
findings using approaches outlined by Janssen et al. (2017).23 Measurement validity was 
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assessed by comparing results with expectations for the weight and direction of estimates. 
Choice validity was assessed by looking for attribute dominance (always selecting a profile 
with a particular attribute level) through counts analyses, and task non-attendance (always 
selecting a profile in a certain position in the choice task). Finally, measurement reliability 
was assessed through the dominant choice task. 
5.2.7 Ethical Considerations 
This study was carried out in accordance with the Tri-Council Policy Statement and 
approved by the Memorial University Research Ethics Board (#20171424). 
 
5.3 Results 
There were 1268 people sampled, and 550 respondents who completed the full 
survey. Of these, 37 were excluded due to choosing a non-dominant alternative among one 
of the dominant choice tasks (36[6.5%] chose one non-dominant and 1[0.2%] chose two 
non-dominant alternatives), and 11 (2.0%) were excluded due to completion in less than 7 
minutes.  Of the 502 included in the analysis, respondents took an average of 22.8 minutes 
(median = 14.0, interquartile range = 11.1 to 17.7 minutes) to answer the survey. None of 
the respondents exclusively selected option A, while 1(0.2%) exclusively selected option B, 
and 11(2.2%) exclusively chose to opt out, which reflected a preference for no therapy at 
all. Of the 718 individuals who did not complete the full survey, 404 were disqualified (due 
to not meeting the inclusion criteria or because sample quota was already met), 134 did not 
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provide consent, 188 did not complete the required informational video, and 36 quit while 
answering qualifying and choice task questions (Figure 5-1). 
Figure 5-1. Flowchart of survey respondent recruitment 
 
 
The average age of respondents was 59 years (SD=12), 59% were male, 55% had 
tried two or more oral medications, and 63% had diabetes for at least 6 years (Table 5-2). 
This is comparable to the Canadian population of individuals with Type 2 Diabetes, with 
slightly more males (56.3%, 2017).24 However, our population tended to have a higher 
income and education levels, while we know that the prevalence of diabetes is higher 







550  - Complete 
quality responses
404 - Did not meet 
inclusion criteria OR 
sample quota was met
134 - Did not provide 
consent
188 - Did not complete 
required instructional 
video
36 - Stopped after 
starting the choice 
tasks
37 - Selected a 
dominant choice task
11 - Completed the 
survey in < 7 minutes
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Table 5-2. Respondent Characteristics 
Characteristic Number (%) 
N=502 
Sex 
    Female 
    Male 
 
208 (41.4%)  
294 (58.6%) 
Marital Status 
    Divorced / Separated 
    Married / Common Law 
    Single 







    Employed 
    Retired 
    Student 






Level of Education 
    Did not complete high school 
    Graduated high school   
    Some college/university        
    Trade/technical/vocational training    
    Bachelor’s degree  
    Graduate degree  










    Less than $25,000 
    $25,000 to $49,999 
    $50,000 to $74,999 
    $75,000 to $99,999 







Length of time with diabetes 
    Less than a year 
    1-2 years 
    3-5 years 
    6-10 years 







Number of different oral diabetes 
medications tried (present or past) 
    None 
    1 oral medication 
    2 oral medications 
    3 oral medications 
    More than 3 oral medications 









Use of injectable diabetes medications 
   Yes 




Cardiovascular Health Conditions  
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    No heart or stroke related conditions 
    High blood pressure 




Other Health Conditions 
    None 
    Asthma or COPD 
    Osteoarthritis 
    Anxiety or depression 








All attributes were found to significantly influence choice with p-values all less than 
0.01 for the within attribute chi-squared test, and followed the expected direction of 
preference (i.e. negative preference for worse outcomes or higher cost). Counts analysis 
showed that no particular attribute level dominated choice selection, with level selection 
ranging from 31.5% to 59.7%. Results of the mixed MNL model were used for interpretation 
of results, as these estimates take within respondent correlations into account (Table 5-3). 
Overall the mixed MNL model showed greater preferences weights for all attributes.  
The effect estimates show that cost and life expectancy carried the most weight 
during decision making, with the greatest absolute value, while minor and serious side 
effects carried the least weight (Figure 5-2). Using the least desirable level for each attribute 
as the reference, odds ratios and marginal WTP were calculated. When all other attributes 
are held constant, the odds of an individual selecting the drug that increases life expectancy 
by 3 years is 6.2 times that of selecting a drug with no impact on life expectancy. The odds 
of selecting a drug with no chance of minor side effects is only 1.7 times that of selecting a 
drug with a 40% chance of a minor side effect (Table 5-3). All attributes meet the linearity 
assumption, showing a linear relationship between levels.  On average, people were willing 
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to pay $134 per month for a medication that improved life expectancy by 3 years, compared 
to no change, but only $31 per month for a medication that would have no increased risk 
of serious side effects, instead of 4% risk of serious side effects (over 10 years). 
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Table 5-3. Weighted Estimates (Effect Coded) from Mixed Effects Models for Attributes of Diabetes Medications from the Discrete Choice Experiment 
Attribute Variable Estimate Std. Error Lower CI Upper CI OR WTP 
Cost (per month) Cost [per $CAD] -0.818 0.045 -0.906 -0.731 NA NA 
% Drop in HbA1C 0% reduction -0.446 0.028 -0.359 -0.251 Ref Ref 
1.0% reduction 0.023 0.037 -0.050 0.096 1.6 $34.38 
2.0% reduction 0.422 0.040 0.344 0.500 2.4 $63.61 
Macrovascular events No reduction in risk -0.579 0.028 -0.462 -0.347 Ref Ref 
A 20% reduction in risk 0.088 0.037 0.016 0.159 1.9 $48.91 
A 40% reduction in risk 0.491 0.041 0.411 0.571 2.9 $78.48 
Microvascular events No reduction in risk -0.467 0.026 -0.368 -0.266 Ref Ref 
A 20% reduction in risk 0.019 0.037 -0.053 0.092 1.6 $35.66 
A 40% reduction in risk 0.447 0.040 0.369 0.526 2.5 $67.03 
Minor side effects 0 out of 100 people 0.231 0.028 0.120 0.227 1.7 $39.72 
20 out of 100 people 0.080 0.037 0.007 0.153 1.5 $28.64 
40 out of 100 people -0.311 0.038 -0.386 -0.235 Ref Ref 
Severe hypoglycemia 
(over 10 years) 
0 out of 100 people 0.428 0.028 0.251 0.356 2.3 $61.33 
20 out of 100 people -0.019 0.037 -0.092 0.053 1.5 $28.55 
40 out of 100 people -0.409 0.041 -0.488 -0.329 Ref Ref 
Serious side effects 
(over 10 years) 
0 out of 100 people 0.205 0.028 0.076 0.182 1.5 $31.10 
2 out of 100 people 0.013 0.037 -0.060 0.086 1.3 $17.00 
4 out of 100 people -0.219 0.038 -0.293 -0.144 Ref Ref 
Life expectancy No change -0.897 0.029 -0.657 -0.544 Ref Ref 
Increase by 1.5 years -0.033 0.037 -0.104 0.039 2.4 $63.36 
Increase by 3 years 0.930 0.050 0.832 1.027 6.2 $133.95 
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Figure 5-2. Effect-coded estimates for attribute levels of diabetes therapies (n=502) 
 
 
An examination of potential interactions between attributes using the likelihood 
ratio test showed that no combination of attribute levels resulted in a significant change in 
the main effects. Interactions between attributes and baseline characteristics using a CL 
model and likelihood ratio test were significant  (p-value < 0.05 for all tests) between: 1) 
40% reduction in macrovascular risk and the presence of existing cardiovascular disease, 
indicating those with cardiovascular disease placed a higher preference weight to this 
reduction; 2) cost and gender, indicating that females had a greater negative preference 
towards cost; and 3) life expectancy increased by 3 years and gender, indicating that males 
had a greater preference towards medications that increased life expectancy. Despite 
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significant interactions, the interpretation of the findings were not impacted, with odds 
ratios remaining consistent across models and therefore the most parsimonious model was 
selected. 
Our respondent population was of a slightly higher income and education than the 
general population, and therefore a post-hoc sub-group analysis was done to examine the 
impact of these variables. This analysis demonstrated that while WTP was much higher for 
the higher income subgroup (e.g. $197 vs. $88 per month for a medication that improved 
life expectancy by three years) and high education subgroup (e.g. $194 vs. $102 per month 
for a medication that improved life expectancy by three years), overall ranking of attributes 
did not change substantially. The top two attributes of importance remained cost and life 
expectancy. However the for the lower income and lower education sub-groups “cost” 
ranked as the most important and for the  higher income and higher education subgroups, 
“life expectancy” ranked most important. The least two important attributes also remained 
consistent. Rankings only changed where preference weights were already very close in the 
base case analysis.     
A final subgroup analysis examined geographic variation across Canada. The sample 
was divided into Eastern (including Newfoundland and Labrador, Nova Scotia, New 
Brunswick and Prince Edward Island, n=65), Central (including Quebec and Ontario, n=232), 
and Western (including Manitoba, Saskatchewan, Alberta and British Columbia, n=169). 
Results demonstrated mostly consistent results across sub groups, with the exception of 
some preference weights for Eastern Canada (Table 5-4). Eastern Canadians showed a 
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higher WTP for efficacy, severe hypoglycemia, serious but rare side effects and life 
expectancy. This may be due to the small number of respondents in Eastern Canada or may 
be due to differences in preferences across attributes, further research is needed to 
understand if true differences exist.  
 
Table 5-4. Sub-Group Analysis Examining Willingness to Pay by Geographic Region 
Attribute Variable Eastern Central Western Full 
% Drop in HbA1C 0% reduction Ref Ref Ref Ref 
1.0% reduction $68.19 $26.46 $33.73 $34.38 
2.0% reduction $101.95 $59.24 $65.56 $63.61 
Macrovascular events No reduction in risk  Ref Ref Ref Ref  
A 20% reduction in risk $83.44 $49.68 $48.26 $48.91 
A 40% reduction in risk $96.57 $90.48 $83.99 $78.48 
Microvascular events No reduction in risk  Ref Ref Ref  Ref 
A 20% reduction in risk $38.51 $38.25 $39.06 $35.66 
A 40% reduction in risk $78.58 $65.34 $73.80 $67.03 
Minor side effects 0 out of 100 people $40.95 $34.54 $55.45 $39.72 
20 out of 100 people $18.99 $31.81 $26.41 $28.64 
40 out of 100 people  Ref Ref Ref  Ref 
Severe hypoglycemia 
(over 10 years) 
0 out of 100 people $43.29 $29.11 $36.01 $31.37 
20 out of 100 people $34.87 $26.18 $23.78 $28.55 
40 out of 100 people  Ref Ref Ref  Ref 
Serious side effects 
(over 10 years) 
0 out of 100 people $58.17 $26.65 $34.02 $31.10 
2 out of 100 people $40.80 $11.82 $15.61 $17.00 
4 out of 100 people  Ref Ref Ref  Ref 
Life expectancy No change  Ref Ref Ref  Ref 
Increase by 1.5 years $54.67 $61.19 $62.54 $63.36 





 There has been increasing interest into taking patient preferences into 
consideration for policy making, guideline development and patient-clinician interactions. 
Using choice modelling, we estimated relative preference weights for various attributes of 
diabetes therapies, and all eight attributes were shown to influence choice significantly. On 
average, patients weighted the potential for improved life expectancy and lower cost as 
more important than other risks and benefits measured, though improved cardiovascular 
outcomes, reduction in hemoglobin A1C and reduction in the risk of severe hypoglycemia 
also ranked as important.    
Three prior studies have examined patient preferences for attributes of medications 
used in the management of type 2 diabetes using a DCE design.11,14,26. In the first, Hauber 
et al. surveyed patients in the United Kingdom and the United States. They found similar 
preferences between the two nations, and found that glucose control, risk of heart attack 
and potential for weight gain to be the biggest drivers of patient preferences. Mansfield et 
al. (2017) examined preferences from patients in both Spain and Germany, finding unique 
differences between populations. German respondents tended to most strongly oppose a 
higher risk of gastrointestinal symptoms, while Spanish respondents were most strongly 
opposed to the injectable route of administration.  Finally, Janssen et al. (2018) examined a 
US population and found that patients tended to place the greatest weight on the duration 
of nausea each day and the choice between “pill” versus “pill with an injection”. It is difficult 
to draw direct comparisons between these previous studies and our current study as the 
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attributes selection and descriptions differed across studies. Previous studies tended to 
capture more specific attributes (e.g gastrointestinal symptoms, weight gain) and therefore 
were not able to measure patient preferences for some of the more serious outcomes like 
severe hypoglycemia, nephrotoxicity or retinopathy, or the very practical consideration of 
cost. Additionally, those studies that examined cardiovascular disease varied greatly, with 
one suggesting a cardiovascular harm11 and the other a small cardiovascular benefit (5% 
reduction).26 Though patients with diabetes inherently have an increased risk of 
cardiovascular events, the use of diabetes medications are generally not associated with an 
increased risk. Rather, newer medication classes have demonstrated significant reduction 
in the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or 
nonfatal stroke (34% with empagliflozin in the EMPA-REG trial,27 13% with liraglutide in the 
LEADER trial,28 and 26% with semaglutide in the SUSTAIN-6 trial29). Therefore, 
cardiovascular risk may play a bigger role in decision making for anti-diabetic medications 
than captured in previous studies. One additional important take away message from these 
previous studies is that preferences can vary between cultures and if patient preferences 
are to be considered in prescribing decisions, they need to be specific to the cultural 
context. 
A limitation of these previous studies is the limited number of attributes captured. 
We chose to group attributes into relevant categories. This meant that we were able to 
capture a wide range of benefits and risks, without overburdening the survey respondents 
with too many attributes. Accurately modelling choices for medication selection is difficult 
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given the array of potential benefits and harms that could play a role in patient decisions. 
Pre-survey discussions with patients revealed that they were less concerned about specific 
side effects or benefits when they made their choices, but rather the impact on overall 
health. As a result of these discussions, we grouped outcomes into strategic categories 
(macrovascular, microvascular, minor side effects, and rare but severe side effects). While 
macrovascular events such as heart attack and stroke are often considered together in 
clinical trials and DCEs,27–29 other outcomes are typically measured independently. With 
respect to patient preferences however, it is reasonable to think that patients would weight 
such groups similarly. Though outcomes are grouped together in this survey, when 
assessing the overall preference for one drug over another, the weights can be applied to 
unique outcomes (e.g. cancer and amputation) within a category, taking the specific 
probability of occurrence into account.  
 
5.4.1 Limitations 
We found it challenging to recruit and engage patients in the pre-survey stage of 
this study. Though we feel that we have captured the most important attributes in the 
survey based on patient and clinician input, a larger sample for our focus groups would have 
been beneficial. As with any DCE, we were faced with several limitations including ordering 
effect, hypothetical bias and framing effect which are inherent to these types of survey 
designs.14 We did however use strategies to attempt to mitigate against each of these. 
Ordering effect, refers to the impact that the order of choice tasks has on choice outcomes. 
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The order of choice tasks were randomly varied across all versions to minimize the ordering 
effect. Hypothetical bias refers to the bias that is introduced due to the fact that participants 
are not making real choices, but rather putting themselves in hypothetical situations. While 
we only surveyed individuals with type 2 diabetes and presented them with realistic 
scenarios and realistic descriptors of the medications, not all individuals surveyed would 
have experienced each of the attributes presented. This could leave the potential for 
hypothetical bias. For example, not all patients would have experienced a severe 
hypoglycemic event and therefore may not be able to evaluate the relative weight of such 
an event compared to patients that have experienced a severe hypoglycemic event (or 
multiple events). Framing effect refers to the manner in which attributes or choices are 
described and the influence this has on choice. We attempted to minimize this by providing 
additional information and visual aid to improve respondents understanding of the 
attributes. For example, we included a mandatory 4-minute video before they completed 
choice tasks to ensure they have an understanding of the attributes and their impact on 
disease, however concepts of risk may still have been difficult for some respondents to fully 
understand. Finally, our sample was not fully representative of the general population with 
respect to income, education and language, a challenge that comes with using online survey 
companies. As such, these findings may not be fully generalizable to lower income segments 
of the population or those in predominantly French speaking parts of Canada. While we 
anticipate the rank order of attributes to remain fairly consistent, the preference weights 
may differ.   
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5.5 Conclusion 
This study contributes to the growing literature base focused on quantitatively 
measuring patient preferences for various health care interventions. Using a DCE we found 
that all eight examined attributes for diabetes, including cost, risk of macrovascular and 
microvascular events, risk of minor side effects, severe hypoglycemia, serious long term 
consequences, and life expectancy were each shown to significantly influence choice. While 
cost and life expectancy carried the most weight, serious and minor side effects carried the 
least weight. These study findings can help guide and inform patient and clinician 
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6. Incorporating Patient Preferences into a Quantitative Risk 
Benefit Analysis Comparing Sodium Glucose Co-Transporter-2 
Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in 
Type 2 Diabetes. 
 
6.1 Background 
Type 2 diabetes affects approximately 8% of Canadian adults and substantially 
increases the risk of microvascular (e.g. retinopathy, neuropathy) and macrovascular (e.g. 
coronary heart disease, vascular disease) complications.1,2 These complications lead to 
significant patient burden and contribute to management costs that are 1.5 to 2.5 times 
higher in people with diabetes compared to those without.3,4 Metformin has been the long-
standing first-line agent for the management of diabetes, with any other diabetes 
medication being considered acceptable second-line or add on options. However clinical 
practice guidelines are shifting due to the promising cardiovascular benefits seen in 
randomized controlled trials of the Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors and 
the Glucagon-Like Peptide-1 (GLP1) receptor agonists in patients with pre-existing 
cardiovascular disease.5–11 As a result are now the preferred second-line therapies for 
individuals with cardiovascular disease.12,13  
Despite the cardiovascular benefits, these drugs also come with several potential 
harms. Drug regulators including the US Food and Drug Administration (FDA), Health 
Canada, and the European Medicines Agency have released advisories regarding several 
side effects identified in post market surveillance. For the SGLT2 inhibitors these include 
acute kidney injury (AKI)14, diabetic ketoacidosis (DKA),15 urinary tract infections (UTI),16 
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bone fractures17 and lower limb amputations,18,19 based primarily on case report data. For 
the GLP1 receptor agonists these include pancreatitis20 and pre-cancerous findings in the 
pancreas.21 As such, it is not clear if either the SGLT2 inhibitors or the GLP1 receptor agonists 
outperforms the other, and no head-to-head trials have been conducted. Risk benefit 
assessment (BRA) is one way to quantify differences in the benefit-risk balance of these 
agents. A BRA provides a summary measure of the trade-offs that exist between potential 
benefits and harms of medications. There are more than a dozen approaches to BRA found 
in the medical literature,22 however most use unweighted metrics (e.g. number need to 
treat). This means that only probabilities of benefits and risks are considered and not the 
associated duration of, or preferences for, these outcomes. More modern methods for 
conducting BRA account for patient preferences or values and duration of impact.23–26 Such 
preferences can be collected through conjoint analyses, such as discrete choice 
experiments (DCE). Though this is still an emerging approach, regulatory agencies including 
the European Medicines Agency (EMA)27 and the Food and Drug Administration (FDA)28 
have recommended that preference data be included in regulatory approval applications.  
Despite increased interest in measuring patient preferences for drug therapies, 
utilization of such data for conducting quantitative BRA in the type 2 diabetes population is 
lacking. In the context of the SGLT2 inhibitors and the GLP1 receptor agonists, this is 
especially interesting given the equal placement in clinical practice guidelines. This study 
will bring together Canadian patient preferences for attributes of diabetes therapies as well 
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as probabilities of efficacy and safety retrieved from the literature using the incremental 
net benefit (INB).  
 
6.2 Methods 
6.2.1 Study Design 
We performed a quantitative benefit risk analysis that combined efficacy and safety 
probabilities with preference weights, captured as maximal acceptable risk (MAR), to 
measure the INB as described in the Unified Framework for Benefit Risk Assessment.23 While 
other preference weight metrics can be used in the INB model, the MAR implicitly includes 
the duration of impact of the outcomes when preference weights are captured choice 
surveys. Quality adjusted life year (QALY) could also be used, but these utility weights are 
often gathered from multiple sources and not reflective of the trade-offs that patients make 
between alternatives.  
The INB quantifies the difference between the sum of the benefits from the sum of 
the harms between two interventions, as shown in equation 1. In this equation the pi 
represents the risk difference for a beneficial outcome i, and qj is the risk difference for a 
harmful outcome j, each weighted by MAR. MAR represents the trade-offs people are 
willing to make between trade-offs. The  variable then represents the importance a 
decision maker places on harms over benefits. A =1 means importance is equal and a >1 
indicates a higher importance on avoidance of harms.     
𝐼𝑁𝐵𝑀𝐴𝑅 =  ∑ 𝑀𝐴𝑅𝑖∆𝑝𝑖
𝐼
𝑖=1 −  𝜇 ∑ 𝑀𝐴𝑅𝑗∆𝑞𝑗
𝐽
𝑗=1                 (1) 
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6.2.2 Population and Interventions 
 The population of interest includes adults, 18 years or older, living with type 2 
diabetes and established cardiovascular disease. Interventions included the SGLT2 
inhibitors as a class (empagliflozin, dapagliflozin, and canagliflozin) and the GLP1 receptor 
agonists as a class (semaglutide, liraglutide, lixisenatide, exenatide, and albiglutide).  
 
6.2.3 Benefit and Harm Outcomes 
 To identify the outcomes important in the comparison of SGLT2 inhibitors to GLP1 
receptor agonists, we conducted a literature review and consulted with clinicians. The focus 
was to address benefits and harms with demonstrated differences compared to placebo. A 
Value Tree is presented in Figure 6-1 and outlines all of the included outcomes. Beneficial 
outcomes included non-fatal myocardial infarction, non-fatal stroke, hospitalization for 
heart failure, a composite of microvascular outcomes (new or worsening nephropathy, or 
retinopathy), and all-cause mortality. These were considered benefits as SGLT2 inhibitors 
and GLP1 receptors have been shown to decrease the risk of occurrence. Though change in 
hemoglobin A1C values is typically used to measure efficacy of antihyperglycemic agents, it 
was not included in this BRA. As hemoglobin A1C is a surrogate marker for reduction in risk 
of micro and macrovascular disease complications, those harder endpoint were thought to 
be more appropriate. Likewise, a reduction in body weight has been demonstrated with 
both SGLT2 inhibitors and GLP1 agonists, however this is also a surrogate outcome for 
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reduction of disease complications and measured on a continuous scale, and so was 
excluded from this analysis.  
Harmful outcomes included non-severe and severe hypoglycemia, typical and 
complicated urinary tract infection, genital infection, nausea and vomiting, bone fracture 
and amputation. These outcomes have each been demonstrated or speculated to be 
elevated in one or both the SGLT2 inhibitors and GLP1 receptor agonists. Cancer, including 
but not limited to pancreatic cancer, was intended to be part of the model however this 
outcome was inconsistently captured. Additionally, the duration of follow-up within studies 
was also too short to capture true difference that may exist. Pancreatitis and diabetic 
ketoacidosis was also examined, and while speculated to be associated with GLP1 receptor 
agonists and SGLT2 inhibitors respectively, no meta-analyses have demonstrated this 
difference and therefore they were excluded from the model. To collect outcome 
probabilities we looked to the following sources in the following order: 1) network and 
pairwise meta-analyses; 2) randomized controlled trials; and 3) observational studies. 
 Network meta-analyses reported dichotomous outcomes in odds ratios and hazard 
ratios. Since the incidence of each of the outcomes was low (less than 10%), odds ratios and 
hazard ratios were considered equivalent estimates of risk.29 Baseline rates for outcomes 
were estimated from the placebo arms of randomized controlled trials for SGLT2 inhibitors 
and GLP1 receptor agonists that examined populations with existing cardiovascular risk. 
Given some differences noted in baseline risk, two baseline probability rates were 
estimated, one for the SGLT2 inhibitors and one for the GLP1 receptor agonists, by using 
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median annual probability rates from respective groups of trials. The minimum and 
maximum probabilities were used as the range. Probability estimates for the SGLT2 
inhibitors and GLP1 receptor agonists were estimated by multiplying the respective baseline 
probability rate by the corresponding risk estimate for each outcome.    
 
Figure 6-1. Value Tree of Outcomes Captured in this Benefit Risk Assessment 
  
6.2.3.1 Outcomes Preferences 
 The Maximal Acceptable Risk (MAR) was used as the preference weight, which were 
estimated from a previously conducted discrete choice experiment designed to inform the 



























of preferences and trade-offs that Canadian adults living with type 2 diabetes make 
between characteristics of glucose-lowering medications. To do this the survey was 
distributed across Canada through a survey company. Eligible and interested individuals 
completed 14 choice tasks where they were ask to select between two hypothetical 
diabetes medications. Drug were described with using eight attributes. We made the 
assumption that the preference weights for similar attributes would be close to the same. 
For example, we assumed that a cardiovascular event, whether it be a myocardial infarction 
or stroke, would carry a similar preference weight. The eight attributes included in the 
survey, along with associated descriptions, levels and resulting preference weights are 
provided in Table 6-1. Levels within the attributes behaved in a linear fashion and therefore 




Table 6-1. Attributes and Levels used in Discrete Choice Experiment to Solicit Preference Weights 
Attribute Description Levels Preference Weight 
(Standard Deviation) 
Efficacy Expected decrease in A1C 0% reduction in HbA1C 
1% reduction in HbA1C 
2% reduction in HbA1C 
-0.525 (0.025) 
Macrovascular events Reduction in heart attack, stroke, or death 
from cardiovascular diseases 
No reduction in risk 
20% reduction in risk 
40% reduction in risk 
0.286 (0.024) 
Microvascular events Reduction in eye, kidney and nerve 
damage 
No reduction in risk 
20% reduction in risk 
40% reduction in risk 
0.373 (0.025) 
Minor side effects Probability of minor side effects (e.g. 
weight gain, stomach upset, skin rash, low 
energy) 
0 out of 100 people 
20 out of 100 people 
40 out of 100 people 
0.308 (0.024) 
Severe hypoglycemia Probability of severe hypoglycemic (low 
blood sugar) episodes over 10 years 
0 out of 100 people 
20 out of 100 people 
40 out of 100 people 
-0.193 (0.024) 
Serious side effects Probability of a serious but rare side effect 
over a 10-year period 
0 out of 100 people 
2 out of 100 people 
4 out of 100 people 
-0.296 (0.024) 
Cost Cost for one month supply $30, $90, $150 -0.143 (0.024) 
Life Expectancy Change in life expectancy No change in life expectancy 
Increase in life expectancy by 
1.5 years 




 Table 6-2 presents the preference weights from the DCE that were assigned to each 
outcome along with estimated annual baseline probabilities and risk measures for both 
SGLT2 inhibitors and GLP1 receptor agonists.  
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Table 6-2. Preference Weights and Risk Estimates for SGLT2 Inhibitors and GLP1 Receptor Agonists used in the 








































































































































OR 0.71  








































































































OR 1.16  
(1.0-1.34) 32 
1.439 0.297  
(0.2-1.3) 









OR 1.49  
(1.17-1.90) 32 
0.539 0.268  
(0.0-0.6) 





 The MAR for each outcome was first calculated using equation (2), using life 
expectancy as the reference outcome. Patients would have inherently considered the 
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duration of impact for each of the attributes they considered in the discrete choice 
experiment and therefore the duration of impact is captured within the MAR value. The 
base case analysis also assumed that =1. The ∆𝑝𝑖 and ∆𝑞𝑗in the MAR calculation (equation 
2) refer to the difference between each level used to describe an attribute within the 
discrete choice experiment. For example, for macrovascular events the three levels used no 
reduction in risk, a 20% reduction in risk and a 40% reduction in risk. Therefore the ∆𝑝𝑖 
would be equal to 20%. The ∆𝑝𝑖 and ∆𝑞𝑗 then used within the INB calculation (equation 3) 
represent the actual difference in outcomes between the intervention and no intervention 
as identified in the literature.      
𝑀𝐴𝑅𝑖𝑗 =  
𝑣𝑖/∆𝑝𝑖
𝑣𝑗/∆𝑞𝑗
                                          (2) 
𝐼𝑁𝐵𝑀𝐴𝑅 =  ∑ 𝑀𝐴𝑅𝑖∆𝑝𝑖
𝐼
𝑖=1 −  𝜇 ∑ 𝑀𝐴𝑅𝑗∆𝑞𝑗
𝐽
𝑗=1                 (3) 
 
Several sensitivity analyses were conducted to test the robustness of the 
comparison. These included, where possible: 1) altering MAR between the lower and upper 
95% confidence intervals; 2) altering baseline probabilities of outcomes within the 95% 
confidence intervals; and 3) altering intervention probabilities of outcomes between within 
the 95% confidence intervals. Each of these simulations, were conducted using Monte Carlo 
simulation with 10,000 iterations and a normal distribution was assumed. Further sensitivity 
tested: 1) various combinations of outcomes included in the mode (e.g. removing outcomes 
with data from observational studies, limiting to only cardiovascular outcomes, adding 
outcomes that were excluded from the base case due to statistically insignificant 
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differences (diabetic ketoacidosis); 2) excluding MAR; and 3) altered values of  from 0.5 
and 3, the value representing importance placed on harms over benefits.   
 
6.3 Results  
 The primary analysis for the base case scenario favored the SGLT2 inhibitors by 
demonstrating an incremental net benefit over the GLP1 receptor agonists. The model 
showed that there was a 0.24% annual net probability of benefit over harm for the SGLT2 
inhibitors compared to the GLP1 receptor agonists. This is to say, that if a cohort of 10,000 
people were prescribed and SGLT2 inhibitor instead of a GLP1 receptor agonist, 24 
additional people would experience a positive net benefit. This absolute difference is quite 
small and therefore it is not clear if this difference is of clinical importance. The greatest 
contributor to the difference in INB between drug classes was the impact of the composite 
in microvascular outcomes and nausea and vomiting.  
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Table 6-3. Calculation of Incremental Net Benefit for SGLT2 Inhibitors and GLP1 Receptor Agonists  
  SGLT2 Inhibitors GLP1 Agonists 
  MAR 
Change in % 
Probability 
over Baseline 
(p or q ) 
𝑀𝐴𝑅𝑖∆𝑝𝑖 𝑀𝐴𝑅𝑗∆𝑞𝑗 
Change in % 
Probability 
over Baseline 









Non-Fatal Stroke 0.046 -0.025 0.001  0.13 0.006  
Non-Fatal Myocardial 
Infarction 
0.046 0.156 0.008  0.14 0.006  
Hospitalization for Heart 
Failure 
0.046 0.227 0.014  0.12 0.005  
Composite Microvascular 
Outcome 
0.038 2.097 0.096  0.34 0.014  





Severe Hypoglycemia -0.028 -0.160  -0.006 0.23  -0.008 
Non-Severe Hypoglycemia -0.017 0.000  0.006 2.53  0.000 
Nausea and Vomiting -0.017 0.357  0.009 -2.19  0.052 
Urinary Tract Infection -0.017 0.111  0.003 0.10  -0.002 
Complicated UTI -0.109 0.053  0.009 -0.32  0.057 
Genital Infection -0.017 0.816  0.019 0.00  0.000 
Bone Fracture -0.109 0.198  0.035 -0.10  0.017 
Amputation -0.109 0.177  0.031 0.00  0.000 
 𝐼𝑁𝐵𝑀𝐴𝑅 =  ∑ 𝑀𝐴𝑅𝑖∆𝑝𝑖
𝐼
𝑖=1
−  𝜇 ∑ 𝑀𝐴𝑅𝑗∆𝑞𝑗
𝐽
𝑗=1
  0.562 0.107  0.334 0.115 
 Net Benefit 0.456 0.219 
 INB 0.237 
 
6.3.1 Sensitivity Analyses 
 The series of sensitivity analysis demonstrated that in almost all of model inputs 
leads to an INB that favors SGLT2 Inhibitors (Table 6-4). When estimates for baseline 
probability rates of outcomes were altered to reflect 95% confidence intervals, only 0.87% 
of iterations resulted in a negative INB, indicating a greater overall benefit for GLP1 
agonists. When the intervention probability rates were altered to reflect 95% confidence 
intervals, results remained consistent with base case analysis with only 0.11% of iterations 
resulting in a favor for GLP1 receptor agonists. When the MAR was altered to reflect the 
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95% confidence interval, all iterations resulted in an INB favoring SGLT2 inhibitors (Table 6-
4).  
 
Table 6-4. Sensitivity Analyses for Monte Carlo Simulations 











Baseline Outcome Probabilities 0.07 0.03 -0.05 0.37 0.87% 
Intervention Outcome Probabilities  0.25 0.08 -0.12 0.54 0.11% 
Maximal Acceptable Risk 0.24 0.00 0.23 0.24 0.0% 
 
 
Further sensitivity analyses removed select outcomes from the model to assess 
impact. In the first analysis complicated UTI was removed as it was the only outcome 
gathered from observational studies, as well as gastrointestinal upset, as this outcome may 
have inconsistent reporting (INB = 0.145). The second analysis removed all outcomes, 
except for cardiovascular outcomes and all-cause mortality (INB = 0.147). A third analysis 
removed composite microvascular complications as this was the biggest contributor to INB, 
yet the baseline risks from RCTs varied dramatically (INB = 0.155). The final analysis added 
in ketoacidosis with estimates from an observational study35 demonstrating an increased 
risk (INB = 0.229).  Though some analyses narrowed the INB, all analyses favored the SGLT2 
inhibitors. 
When the MAR was excluded from the INB and only probabilities of outcomes were 
included, the INB equaled 2.8 in favor of SGLT2 inhibitors. The INB was heavily driven by 
microvascular benefit in the SGLT2 inhibitors and the high probability of nausea and 
vomiting in the GLP1 receptor agonists. In the final sensitivity analysis where  was altered, 
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the INB did not change substantially. When =0.5 indicating a higher tolerance for harms, 
the INB=0.232; at =2, indicating a lower tolerance for harm, the INB=0.244; and when =3 
INB=0.252. 
 





 Based on the best available data on outcome probabilities for SGLT2 inhibitors and 
GLP1 receptor agonists, and preference weights from a Canadian DCE, SGLT2 inhibitors 
outperformed GLP1 receptor agonists with higher INB in diabetes patients with 
cardiovascular disease. Sensitivity analysis demonstrated that uncertainty within the 





















Baseline Probabilities Intervention Probabilities Maximal Acceptable Risk
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within sensitivity analyses, we must acknowledge that this model is very sensitive to some 
key inputs. Though clinical trial data demonstrated a microvascular benefit for the 
composite microvascular outcome for both SGLT2 inhibitors and GLP1 receptor agonists, it 
was the greatest contributor to difference in INB between classes. It must be noted that 
this outcome was not well reported among trials and therefore there is greater uncertainty. 
Composite microvascular, using the same definition, was only captured in one SGLT2 
inhibitor trial and one GLP1 receptor agonist trial and therefore it is unknown if the effects 
seen can be generalized to the whole class.  Also, it would be ideal to capture each 
microvascular outcome independently as it is unlikely that each system would respond to a 
drug in the same manner. However, definitions for outcomes differ dramatically across 
trials making this difficult to achieve. When looking to the literature on the impact of SGLT2 
inhibitors and GLP1 receptor agonists on microvascular outcomes, it appears that both 
SGLT2 inhibitors and GLP1 receptor agonists have consistent renal benefits,37 with much 
less data or certainty regarding neuropathy or retinopathy.   
Generally, examples of quantitative BRA in the literature are limited and have 
typically limited model inputs to data from a single trial. While this greatly increases the 
internal validity, it is not practical for study questions like the one addressed in this paper 
for several reasons: 1) there may not be head-to-head trials comparing interventions of 
interest; 2) when available, data from meta-analyses of multiple well conducted trials is 
stronger than data from individual trials; and 3) outcomes of interest for a BRA may not all 
be reflected in a single trial.  
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 Using data from multiple sources allowed us to capture the most recent and relevant 
estimates, however it also posed challenges with maintaining internal validity. Though most 
of our data came from placebo-controlled randomized controlled trials with very similar 
inclusion criteria of adults with type 2 diabetes and cardiovascular disease, rates of 
outcomes in the placebo arms differed across studies. This could be an indication of 
different baseline characteristics or differences in processes for capturing outcomes. For 
example, urinary tract infections were well documented in trials of SGLT2 inhibitors, but 
less commonly in GLP1 receptor agonists, perhaps due to no known increased risk for these 
agents. The GLP1 receptor agonists that did report on urinary tract infection tended to have 
lower rates, which may be a reflection on less diligent identification or different definitions 
used. Unfortunately, in many cases definitions for all secondary outcomes were not clearly 
presented. This difference in placebo group rates make it challenging to establish baseline 
rates for the BRA model. Another issue is that risk measures are not consistent across 
studies (e.g. odds ratio, hazard ratio, relative risk) and may not include number of events 
and population size, requiring some assumptions to be made. The INB model is also not able 
to accommodate outcomes that are captured on a continuous scale, like hemoglobin A1C 
or body weight. In this particular model we could justify the elimination of these outcomes, 
however other BRAs may provide an appropriate balance of risk and benefits with the 
exclusion of continuous outcomes.    
There is also limited guidance and best practices for using preference weights 
derived from a DCE for BRA. While there is literature recommending best practices for DCE 
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survey style, generating efficient experimental designs, testing data quality and approaches 
to handling heterogeneity, there nothing recommending best practices for generating 
preference weights suitable for BRA.38 For instance, guidance on: 1) ensuring risk is 
effectively communicated to participants; 2) the role of survey training materials (e.g. 
descriptions of attributes and levels); 3) whose preferences are most appropriate (e.g. 
patients, general public, clinicians); and 4) how to capture the necessary breadth of 
outcomes in a DCE. This last issue in particular is problematic for BRA of medications, as 
there are typically many benefits and harms that could be of interest and it is recommended 
that a DCE include no more than eight attributes to reduce responder burden. But it could 
be argued that even eight attributes is difficult to interpret when they are complex (e.g. 
measures of risk). In the DCE we conducted to support this BRA, it was decided to group like 
outcomes to be able to accommodate more of them. For instance, we presented 
cardiovascular outcomes together, assuming they would have similar preference weights. 
Given that this BRA demonstrated that it was the benefits (myocardial infarction, stroke, 
hospitalization for heart failure, composite microvascular outcome and all-cause mortality) 
that played the biggest role in INB, a DCE that examined these outcomes individually might 
give more insight into the preference-weighted differences in INB between SGLT2 inhibitors 
and GLP1 receptor agonists.            
 With respect to limitations specific to data used in this model, there were some 
outcomes that were only reported in a limited number of studies. Genital infections are a 
known risk for users of SGLT2 inhibitors due to its unique mechanism of action of increasing 
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urinary glucose excretion, however no evidence of risk among GLP1 receptor agonist users 
is known. Therefore we had to assume a risk equivalent to placebo arms for this outcome. 
Complicated urinary tract infections were also very poorly reported decreasing reliability of 
the estimates used. Though given the impact of complicated urinary tract infection on the 
overall model, more reliable estimates would likely not have changed interpretation.  The 
best estimates for microvascular outcomes was a composite microvascular outcomes. This 
outcomes however encompassed renal deaths, meaning that renal deaths were captured 
in two outcomes used in our model (all-cause mortality and composite microvascular 
outcome). Given that the risk of all-cause mortality was similar between groups (Hazard 
Ratio=0.8 for SGLT2 inhibitors, and Hazard Ratio = 0.88 for GLP1 receptor agonists) this 
double counting should not have made an impact on the interpretation of the results.           
Finally, while preference weights for the route of administration were not captured 
in the Canadian DCE, there is certainty evidence that  patients place a higher preference on 
oral over injectable route when given the choice.39–44 Had we been able to capture this in 
our model, it can be assumed that overall INB would be even greater for SGLT2 inhibitors.  
 
6.5 Conclusions 
 While this BRA demonstrated a greater INB for the SGLT2 inhibitors over GLP1 
receptor agonists, the actual benefit is quite small with 24 out of 10,000 treated 
experiencing a positive net benefit. Additionally, the challenges and limitations in using the 
INB model to capture the balance between preference-weighted benefits and risks in this 
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context are many. This study demonstrates the need for more guidance on conducting 
preference-weighted BRA for informing clinical decisions.  Currently there is insufficient 
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7.1 General Discussion 
 This program of research set out to examine the balance between benefits and risks 
of the sodium-glucose co-transporter-2 (SGLT2) inhibitors. This was in response to recent 
changes to Canadian, American and European Clinical Practice Guidelines for type 2 
diabetes which have indicated that agents in these classes should be the preferred second-
line agents in patients with type 2 diabetes and cardiovascular disease. Aside from the 
glucose lowering and cardiovascular benefits, which have been the impetus for pushing 
SGLT2 inhibitors in this population, these agents have been associated with several other 
beneficial outcomes including weight loss (between 1.8 to 2.7 kg),1 reduction of blood 
pressure (systolic: 3.4–5.4 mmHg and diastolic: 1.5–2.2 mmHg),2–4 and renoprotection, 
including slower progression of kidney disease, and fewer clinically relevant renal events5. 
Chapters 2 and 3 of this thesis examined some of the unanticipated signals for adverse 
effects of the SGLT2 inhibitors, including acute kidney injury (AKI), diabetic ketoacidosis 
(DKA), urinary tract infections (UTI), bone fractures and amputations.6 Other more well 
established side effects include genitourinary tract infections (Odds Ratio 5.06; 95% 
Confidence Interval 3.44, 7.45),7 and volume depletion that could lead to postural dizziness, 
orthostatic hypotension or dehydration.8 Knowledge of the estimated probabilities of each 
of these outcomes occurring can be found in the literature, however examination of the 
balance between risk and benefit while also accounting for the duration of impact or patient 
preferences for each of these outcomes has not been previously done.  
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 To examine in balance of benefit and risks of the SGLT2 inhibitors we conducted four 
unique studies: 1) A systematic review and meta-analysis of the unanticipated adverse 
effects of the newest classes of antihyperglycemic agents, the SGLT2 inhibitors, captured in 
post-market surveillance; 2) A network meta-analysis of the dose response relationship 
with SGLT2 inhibitors and urinary tract infections (UTI); 3) A discrete choice experiment 
(DCE) to quantify patient preferences for attributes of diabetes therapies; and 4) a 
quantitative risk-benefit assessment using the INB model, as described in the “Unified 
Framework for the Classification of Methods for Benefit-Risk Assessment”.9    
The analysis of the unanticipated adverse outcomes of the SGLT2 inhibitors, as 
identified by regulatory agencies, suggested no significant increase in the risk of acute 
kidney injury (AKI), diabetic ketoacidosis (DKA), UTI, and bone fractures.6 Amputation was 
poorly reported, however analysis of the CANVAS trials10,11 does show an increased risk and 
warrants further review as new data are available. A sub-group analysis looking at risk of 
UTI, showed only dapagliflozin at doses 10mg or more were associated with an increased 
risk. Finding of the network meta-analysis of the dose response relationship of SGLT2 
inhibitors and UTI were consistent with the previous meta-analysis showing dapagliflozin 
high dose to be the only category to be associated with an increased risk.12  
The DCE estimated preferences weights that were consistent with what would be 
expected. All eight examined attributes for diabetes, including cost, risk of macrovascular 
and microvascular events, risk of minor side effects, severe hypoglycemia, serious long term 
consequences, and life expectancy were each shown to significantly influence choice. As 
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expected life expectancy and cost were more important in the decision making process. 
Minor and serious but rare side effects carried the least weight.    
Finally, the BRA demonstrated that there was a minimal difference in INB between 
the SGLT2 inhibitors and the GLP1 receptor agonists. The SGLT2 inhibitors demonstrated a 
greater INB and these results were fairly consistent in sensitivity analysis. However given 
the overall benefit, a 0.2% probability of benefit for SGLT2 inhibitors over GLP1 receptor 
agonists, strong conclusions are not warranted. Additionally, some outcome probability 
estimates were not well reported, specifically consistent measures of microvascular 
outcomes, and changes in these estimates could lead to GLP1 agonists demonstrating 
greater benefit.   
 
7.2 Patient Preferences and Benefit Risk assessment 
The integration of patient preferences into BRA has been gaining much support over 
the last decade, both within the regulatory and clinical decision making contexts.13–16 This 
is due in part to: 1) the development in evidence that the trade-offs that are made by 
patients differ from those made by clinicians and policy makers,17 and 2) the move to 
include patients across the spectrum of health care research and development.    
Research has shown that, when compared, the preferences for treatments differ 
between patients and clinicians. This has been demonstrated in various clinical areas, 
including obstetrics, cardiovascular disease, cancer gynecology and respiratory illness.18–23 
For example, one study showed that patients preferred a drug to exhibit a higher minimum 
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clinically important difference (MCID) compared to physicians when deciding to take an 
antihypertensive therapy.18 This demonstrated that patients had a lower risk threshold 
compared to physicians in this clinical scenario. Interestingly, in another study, the opposite 
risk tolerance was shown for cancer therapy. While preferences differed in this scenario 
too, patients were far more likely to accept an intensive therapy with severe side effects 
and low chance of cure compared to physicians, nurses and even the general public.19      
 We are seeing patients actively engaged now throughout all areas of health 
research. From identifying research priorities to supporting study design, data collection 
and interpretation. In Canada, as of 2015, the Canadian Institutes for Health Research had 
committed $357 Million in funding to SPOR (Strategy for Patient Oriented Research)  
SUPPORT units across the country, with the expectation that that funding be matched one 
to one, translating into $700 Million from Canadian stakeholders.24 The United States have 
seeing similar initiatives, with the Patient-Centered Outcomes Research Institute (PCORI) 
established to fund research that enables patients to be more engaged in their health care 
decisions.    
 
7.2.1 Regulatory Context 
In the regulatory arena, the European Medicines Agency (EMA), is currently re-
evaluating the PrOACT-URL BRA Framework that they adopted in 2012, based on a more 
generic decision making framework25 involving 12 steps (Figure 7-1). The PrOACT-URL 
Framework does not require a quantitative assessment to be carried out, though it does 
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recommend a quantitative approach when the decisions are complex and more ambiguous. 
In such cases the Multi-Criteria Decision Analysis (MCDA) was the preferred method.26 
MCDA fits within the PrOACT-URL Framework as many of the steps overlap. It involves 
group consensus among clinical experts and decision makers to define the problem, 
treatment options and criteria for assessing the treatment decision. Within MCDA these 
inputs are then used to generate a decision tree and quantify the different between 
treatment alternatives.9 This process is valuable, as it incorporates the perspectives of 
clinicians and decision makers, it does not allow for the inclusion of patient preferences.16   
In the EMA’s Roadmap to 2015, the need for a more systematic approach to integrate 
patient preferences into benefit-risk assessment are recommended, however official 




Figure 7-1. European Medicines Agency 12-Step PrOACT-URL Framework 
PROBLEM 
1. Determine the nature of the problem and its context 
2. Frame the problem 
OBJECTIVES 
3. Establish objectives that indicate the overall purposes to be 
achieved 
4. Identify criteria for a) favorable effects; b) unfavorable effects 
ALTERNATIVES 
5. Identify the options to be evaluated against the criteria 
CONSEQUENCES 
6. Describe how the alternatives perform for each of the criteria 
TRADE-OFFS 
7. Assess the balance between the favorable and unfavorable effects 
UNCERTAINITY 
8. Report the uncertainty associated with the favorable and 
unfavorable effects 
9. Consider how the balance between favorable and unfavorable 
effects is affected by        uncertainty 
RISK TOLERENCE 
10. Judge the relative importance of the decision maker’s risk attitude 
for this product 
11. Report how this affected the balance reported in Step 9 
LINKED DECISIONS 
12. Consider the consistency of this decision with similar past decisions, 
and assess whether taking this decision could impact future 
decisions.   
 
The United States Food and Drug Administration (FDA) updated their Benefit-Risk 
Assessment in Drug Regulatory Decision Making guidance document in 2018.27 Within this 
framework there is an emphasis on being more patient-focused. In 2013, the FDA started 
to hold public meetings, webcasts and public dockets, to gather patient input on a variety 
of health conditions and treatments. Each meeting resulted in the preparation of a Voice of 
the Patient report which are then used to help to inform regulatory decisions. Additionally 
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the FDA released guidance on best practices for collecting and voluntary submitting patient 
preference data from industry.28 This guidance document recommends that for 
straightforward decisions a qualitative assessment of patient preferences may suffice. 
These would include examples where there is a clear benefit for one product over another, 
or when there are few alternatives with very different risk benefit profiles. In more complex 
scenarios, like when there are many alternatives or cases with similar risk-benefit profiles, 
quantification of patient preferences with such approaches as stated preference surveys 
(e.g. discrete choice experiments) are warranted.28 This document also provides guidance 
on best practices for: communication of risk; minimization of cognitive bias; ensuring logical 
soundness; relevance of choices to patients; data collection; analysis or data; and reporting 
standards. 
In Canada, Australia and New Zealand, there are no formal guidelines or 
recommendations. Canada has initiated some pilot work to see how patient preferences, 
along with other stakeholder input, might be included in decision making. This work 
collected qualitative data only and had a limited scope of orphan drugs.13 Canada is looking 
to other existing models, like those described above, and assessing suitability and feasibility 
within the Canadian context and build on lessons already learned.29 In Australia the 
Therapeutics Goods Administration indicates that consideration for patient preferences is 
seen to be most relevant at the individual patient-clinician decision making stage.30 There 
does not appear to be any active push towards capturing patient preferences at early stages 
of regulatory approval processes.     
 184 
7.2.2 Clinical Context 
 Once drug products are approved for sale within a country, there is still much debate 
among clinicians, patients and patient advocates regarding the most appropriate place for 
that product in therapy. This is especially complex when there are already many products 
in a therapeutic area, as is the case with type 2 diabetes. As we have learned with the SGLT2 
inhibitors and the GLP1 agonists, it is post market trials and surveillance where many of the 
most important safety concerns, and sometimes benefits, are identified. The need to 
update BRAs as new evidence is available is important for supporting regulatory and clinical 
decisions throughout the product’s life cycle.  
 The guidance on the integration of patient preferences into BRA for informing 
clinical decisions is less well established. As described in the “Unified Framework for the 
Classification of Methods for Benefit-Risk Assessment”9, there are several approaches to 
capture preference-weighted BRA measures, including but not limited to, relative value-
adjusted, number needed to treat/harm, benefit-harm balance,31 maximal acceptable risk 
(MAR), and incremental net benefit (INB) based on either relative value-adjusted life year 
(RVALY), quality adjusted life year (QALY) or MAR.9  While each of these methods are 
promising, and have the added strength of capturing the benefit-risk balance through a 
more patient-centered approach, there are many challenges to implementation.  
 Very few published studies have attempted to quantify a preference-weighted BRA 
to compare available therapeutic alternatives for clinical decisions, and those that have also 
faced similar challenges.32–34 In one recent example, Yebyo, et al. (2018) conducted a BRA 
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of statins for primary prevention of cardiovascular disease. They too were faced with many 
of the same challenges that we encountered. They based much of their outcome data on a 
network meta-analysis, but found that some outcomes were not well reported. When 
supplementing with data from large observational studies, due to a higher variance, data 
from these studies did not contribute much to the pooled benefit-risk balance estimate. 
They attempted to use population-based baseline estimates of risk, as they are thought to 
better reflect a real world population, however estimates were not available for all 
outcomes leading to data coming from multiple sources. Additionally, assumptions had to 
be made to extend the time horizon beyond the period studied in clinical trials used to 
estimate outcome probability.  
 
7.2.3 Readiness for Using Discrete Choice Data to Support Benefit-Risk Assessment 
The use of the stated preference method, discrete choice experiment (DCE), has 
probably become the most commonly used method for capturing patient preferences as it 
has gained considerable popularity across all areas of modelling health care decisions. As a 
method traditionally used in transport economics and marketing, publications providing 
best practices for use in health care are becoming more plentiful.35–39 However publications 
providing guidance on some practical considerations for appropriately integrating 
preference weights into BRA are still lacking. Vass and Payne (2017) have highlighted some 
concerns with using DCEs to inform BRA, which are applicable in both the regulatory and 
clinical contexts.40 These include: 
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1. Communication of Risk: It is well known that patients and general public have a 
difficult time interpreting information about risk, and the relative magnitude of 
risk.41,42 This is true across various patient demographics and is amplified when 
investigators fail to effectively communicate such risks within the design of a DCE. 
A lack of understanding ultimately leads to compromised responses and 
subsequent analyses of results. While many researchers take the interpretation 
of risk into consideration in their design, there exists no gold standard for 
communicating risk which may result in inconsistent findings.      
2. Role of Training Materials: The International Society of Pharmacoeconomics and 
Outcomes Research (ISPOR) has indicated in their best practice documents that 
every DCE should include an introduction explaining the role of the survey, 
descriptions of the attributes and levels used, and instructions on responding to 
questions.37 It is recognized however, that this component of surveys is generally 
under-developed and these introductions are of mixed quality. With the use of 
online survey platforms, the use of interactive training materials is being 
introduced. It is speculated, but not proven, that interactive tools would increase 
engagement and therefore improve data quality.43  
3. Need to Take Account of Attitudes: DCEs only account for preferences, but not 
attitudes. Attitudes represent a person’s inherent feelings and thoughts, and may 
actually be a factor that influences choices. Some researchers advocate for a 
hybrid model that captures both attitudes and preferences.44 
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4. Whose Risk Preferences: There seems to be some consistency with the 
recommendation for the use of patient preferences to inform BRA, however this 
is different that the approach that has been used in health economic models, 
where it has been argued that the public’s preferences are the most informative 
for policy makers. Therefore this shift from public to the patient perspective has 
led to some disagreement and inconsistency in the literature.40   
5. Analysis of Benefit-Risk Preference Data: Results of DCE are often presented as 
average preferences as estimated from conditional logit models. It is likely 
however that not all patients would share the same preference distribution, and 
therefore mixed logit and latent class analysis may provide more insight into how 
segments of the population behave differently. There is however no guidance on 
how to use heterogenous DCE findings to inform regulatory decisions. 
Additionally, some other experts question whether the random utility framework 
(which a DCE is analysed under) is the most appropriate for BRA, and suggest 
perhaps a random regret minimization framework45 would be a better fit. The 
random utility theory suggests that people attempt to maximize utility when they 
are choosing between alternatives, while the random regret minimization theory 
suggests that individuals aim to minimize the regret they experience when they 
forgo an option performs well.  Random utility theory has been the mainstay of 
frameworks used in DCE anlaysis, regret minimization is a model that is still being 
explored.46 
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6. Understanding the Generalizability of the Results: The degree of uncertainty for 
preference weights is not consistently presented in published findings of DCEs. 
This is problematic for predicting generalizability. Just as in health economic 
model parameter reporting, best practices for reporting on DCE studies should 
also include a measure of uncertainty.  
 
In addition to these concerns as already identified in the literature, our experiences 
in attempting to integrate patient preferences from a DCE into a quantitative BRA identified 
further unanswered questions and concerns. First, there is little consensus on the best 
approach to defining attributes and levels for DCE in healthcare. There is some push 
towards including a qualitative component to identify drivers of decisions, with some 
suggestions on specific techniques (e.g. nominal group technique),47 however there is no 
official recommendations for best practices. When results of DCEs are meant to inform 
quantitative BRA, the guidance on the selection of the most appropriate outcomes 
(attributes) is non-existent. This is particularly important because medications have many 
potential side effects, and not all can be uniquely captured in a DCE. The selection and 
presentation of the most appropriate attributes is critical for survey integrity. In the DCE we 
conducted and described in Chapter 4, we decided, after consulting patients and clinicians 
and finally through team consensus, to group like outcomes together. This required the 
assumption that outcomes within the same group would be equally as desirable (or 
undesirable) to the respondent. For example, we grouped cardiovascular outcomes as a 
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single attribute, likewise minor but common side effects were grouped together. DCE 
methodology literature recommend limiting the number of attributes to six-eight for a 
single survey, however we were able to estimated preferences weights for more outcomes 
by grouping them into eight groups, rather than eight specific outcomes. While this 
approach holds promise, it is not clear if our assumptions hold true and thus requires further 
investigation.     
Secondly, the DCE generates preference weights that cannot be compared to 
preference weights from other studies. This means that DCE have to be uniquely designed 
to meet the criteria for a specific BRA. It is unlikely that an existing DCE with the needed 
attributes and geographical perspective will already be available, leading to added 
resources and time to build the survey alongside a BRA. Finding ways to translate 
preference weights from DCE to more commonly used metrics, like QALY, would not only 
allow for comparison across studies but data from DCEs would be more generalizable and 
subsequently used more widely. Bansback et al (2012)48  demonstrated how DCE could be 
used to estimate health state utility values, however more research needs to be done to 
see how preference weights from other DCEs could be anchored to health state utility 
values.   
   
7.3 Implications for Clinical Practice 
 Globally we are seeing a push towards more patient-centered care. From including 
the patient voice in regulatory decisions, defining the health care research agenda, and 
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ensuring that patients are active participants in their own health care journey. Results from 
patient preference weighted BRA, like the one presented in this thesis, can be important 
for supporting shared decision making. While our DCE showed that life expectancy and cost 
were the most important drivers of decisions, when multiplied by the probability of specific 
outcomes, it was in fact the microvascular complications that were the greatest contributor 
to the difference in INB between SGLT2 inhibitors and GLP1 agonists. This knowledge can 
allow clinicians to tailor their patient interactions to focus on the key points for decision 
making.  
Though not demonstrated in the present study, other types of analyses of discrete 
choice data would allow for capturing preferences of subgroups of the population.  For 
example, it is also possible preferences could differ by gender or stage of disease and other 
patient characteristics. Knowledge of how patient preferences differ among various 
segments of the population could support the creation of sophisticated decision support 
tools. For example is it conceivable that electronic applications could be built to allow 
patients to provide data on key patient and preference characteristics, then the application 
could offer alternatives that best suit the individual and allow for a targeted physician 
interaction.  
 
7.4 Areas for Future Research 
As discussed, the integration of patient preferences into quantitative BRA is still an 
emerging field of research. Experts in the field continue to identify areas in need of more 
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research, clarification or guidance. My research program, as described in this dissertation, 
has further identified several questions. These are grouped according to the study in which 
they were identified, and broader questions are listed at the end.  
 
7.4.1 Systematic Review and Meta-analyses of Safety Outcomes for SGLT2 Inhibitors 
 This meta-analysis of unanticipated safety outcomes, identified by regulatory 
agencies, did not support the notion of increased risk of urinary tract infections, diabetic 
ketoacidosis, acute kidney injury or bone fractures based on data from randomized 
controlled trials (RCT). However, data on acute kidney injury, diabetic ketoacidosis and 
complicated urinary tract infections was not well reported. There does seem to be an 
increase in the risk of amputation in users of canagliflozin, however this was demonstrated 
in only one set of studies (CANVAS and CANVAS-R)49 and not reported in most other 
included trials. Generally, the lack of reporting for several of these outcomes highlights the 
need for: 1) better reporting in RCTs moving forward; and 2) greater attention placed on 
these outcomes in observational research.  
 
7.4.2 Discrete Choice Experiment to Capture Patient Preferences Towards Characteristics 
of Diabetes Medications  
 As highlighted above, more research needs to be established to support the use of 
DCE data for BRA. This includes: 1) establishing best practices for communicating risk; 2) 
comparing training materials used to describe the considerations for DCE to respondents; 
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3) an exploration of statistical models, like latent class analysis, that allow for estimating 
preferences for various subgroups, and not limiting analysis to overall average preferences; 
4) a study designed to determine the reliability of preference data when attributes are 
grouped (e.g. cardiovascular events); and methodological research to identify reliable 
methods to anchor DCE preference weights to more commonly used metrics like QALY.  
 
7.4.3 Quantitative BRA Comparing SGLT2 Inhibitors and GLP1 Agonists  
 Many of the challenges and limitations identified within this BRA were resulting 
from questions and assumptions surrounding the inputs used in the model. With this in 
mind, the final results were not conclusive as the model was sensitive to potential changes 
in outcome estimates. One element that we were not able to capture in this BRA were 
things like progression of disease, time of onset, and frequency of outcomes. More 
sophisticated BRA models like discrete event simulation or Marcov modelling would allow 
these factors to be considered. While these models would be more reflective of the real 
world, it requires more inputs and therefore assumptions. Depending on the assumptions 
made, validity may be compromised.  
 
7.4.4 General Areas for Future Research 
Though not discussed in much detail within Chapter 4, we engaged patient who live 
with diabetes in focus groups to help identify important attributes of diabetes therapies for 
decision making. While patients were very keen to discuss their experiences with diabetes 
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and diabetes therapies, they did not have very specific comments about common outcomes 
of importance. When probed, their responses remained vague with comments like “I don’t 
want it to affect my other organs.” The only attribute that garnered any enthusiastic 
responses was regarding injection therapy. Patients were very opposed to injection 
therapy, however it is not clear if this was due to their understanding that injections (which 
to them was interpreted as insulin), meant that their disease was getting worse, or, if it was 
the route of administration itself causing opposition. It was also clear from discussions that 
patients placed a high degree of trust in their physicians, and did not tend to question their 
recommendations. These discussions with patients, and subsequently with colleagues, 
made me question if there are perhaps cultural differences within Canada with respect to 
patient readiness to engage in shared decision making, or, if perhaps this is a Canada wide 
phenomenon. We are constantly being encouraged to practice in a patient centered 
manner, and patient advocacy groups are certainly speaking up on behalf of patients, 
however there is no real evidence to show that the general patient population is prepared 
to take on this important role.  
Finally, while I have discussed above how preference weighted BRA can support 
clinical practice and inform shared-decision making interactions, it is not clear what the 
most appropriate tools would be for doing this. More comparative effectiveness research 
on how benefit-risk data can be presented in decision support tools would bring some 
clarity to this issue. Important comparisons to consider would be: 1) physician support 
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versus patient support tools; 2) paper-based versus interactive electronic application; and 
3) different approaches to presenting risk.  
   
7.5 Conclusion     
 
This program of research used emerging methods, including a network meta-
analysis, a DCE, and preference-weighted BRA to examine the balance between risks and 
benefits of the SGLT2 inhibitors and GLP1 agonists. These studies resulted in a final INB that 
favored SGLT2 inhibitors, though as discussed, these findings were small in magnitude and 
may not be of clinical importance. More importantly, this research identifies several 
challenges and limitations, including gaps in methodological guidance that still exist to 
successfully integrate patient preferences into BRA. This is a developing field of research 
and a promising one for understanding how patient preferences influence benefit-risk 
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Section/topic  # Checklist item  
Reported in 
Section 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   3.0 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 




INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3.1 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
3.1 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
3.2.1 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
3.2.3 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
3.2.2 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Appendix 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
3.2.4 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
3.2.4 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
Appendix 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
3.2.5 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  3.2.6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
3.2.6 
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Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
3.2.5 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
3.2.6 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
3.3.1 
figure 3-1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
Appendix 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Appendix 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table 3-1, Figure 
3-2 – 3-6, 
Appendix 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Figure 3-2 – 3-6 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  Appendix 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Table 3-2 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy makers).  
3.4 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
3.4.1 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  3.5 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
See Donnan 
(2019) BMJ Open 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Section 2: Search Strategies 
 
Table A-1. Pubmed Search Strategy 
 
Search String Results 
1 Population "Diabetes Mellitus, Type 2"[Mesh] OR NIDDM[tw] OR t2dm[tw] 
OR ((“type 2"[tw] OR "type ii"[tw] OR "adult onset"[tw] OR 
“mature onset”[tw] OR “late onset”[tw] OR “noninsulin-





"Sodium-Glucose Transport Proteins/antagonists and 
inhibitors"[Mesh] OR "Sodium-Glucose Transporter 2"[Mesh] OR 
"sodium-glucose co-transporter 2"[tw] OR SGL2[tw] OR 
SGLT2[tw] OR gliflozin*[tw] OR "Canagliflozin"[Mesh] OR 
canagliflozin*[tw] OR invokana[tw] OR sulisent[tw] OR "TA 
7284"[tw] OR TA7284[tw] OR "JNJ 28431754"[tw] OR 
JNJ28431754[tw] OR "2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-
hydroxymethyltetrahydro-2H-pyran-3,4,5-triol"[Supplementary 
Concept] OR dapagliflozin*[tw] OR farxiga[tw] OR forxiga[tw] OR 
“BMS 512148”[tw] OR BMS512148[tw] OR 
"empagliflozin"[Supplementary Concept] OR empagliflozin*[tw] 
OR jardiance[tw] OR "BI 10773"[tw] OR BI10773[tw] OR 
ipragliflozin[Supplementary Concept] OR ipragliflozin*[tw] OR 
suglat[tw] OR "ASP 1941"[tw] OR ASP1941[tw] OR "1,5-anhydro-
1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-
thioglucitol"[Supplementary Concept] OR luseogliflozin*[tw] OR 
lusefi[tw] OR “TS 071”[tw] OR TS071[tw] OR "remogliflozin 
etabonate"[Supplementary Concept] OR remogliflozin*[tw] OR 
"KGT 1681"[tw] OR KGT1681[tw]  OR "(2S,3R,4R,5S,6R)-2-(4-
chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-
pyran-3,4,5-triol" [Supplementary Concept] OR sotagliflozin*[tw] 
OR  "LX 4221"[tw] OR LX4221[tw] OR "6-((4-ethylphenyl)methyl)-
3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-
1(3H),2'-(2H)pyran)-3',4',5'-triol" [Supplementary Concept] OR 
tofogliflozin*[tw] OR apleway[tw] OR deberza[tw] OR "CSG 
452"[tw] OR CSG452[tw] OR "5-(4-chloro-3-(4-
ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-
dioxabicyclo(3.2.1)octane-2,3,4-triol" [Supplementary Concept] 
OR ertugliflozin*[tw] OR "PF 04971729"[tw] OR PF04971729[tw] 
2936 
3 #1 AND #2 
 
2080 










("randomized controlled trial"[pt] OR "controlled clinical 
trial"[pt] OR randomized[tiab] OR placebo[tiab] OR "clinical trials 
as topic"[Mesh:NoExp]  OR randomly[tiab] OR trial[ti]) NOT 


























Table A-2: Cochrane Library Search Strategy 
#1 ([mh "Diabetes Mellitus, Type 2"] or NIDDM or t2dm or (("type 2" or 
"type ii" or "adult onset" or "mature onset" or "late onset" or 
"noninsulin-dependent" or "non insulin dependent") and (diabetes)))  
25,454 
#2 ([mh "Sodium-Glucose Transport Proteins"/ai] or [mh "Sodium-Glucose 
Transporter 2"] or "sodium-glucose co-transporter 2" or SGL2 or SGLT2 or 
gliflozin* or [mh canigliflozin] or canagliflozin* or invokana or sulisent or 
"TA 7284" or TA7284 or "JNJ 28431754" or JNJ28431754 or dapagliflozin* 
or farxiga or forxiga or "BMS 512148" or BMS512148 or empagliflozin* or 
jardiance or "BI 10773" or BI10773 or ipragliflozin or suglat or "ASP 1941" 
or ASP1941 or luseogliflozin* or lusefi or "TS 071" or TS071 or 
remogliflozin* or "KGT 1681" or KGT1681 or sotagliflozin* or "LX 4221" or 
LX4221 or tofogliflozin* or apleway or deberza or "CSG 452" or CSG452 or 
ertugliflozin* or "PF 04971729" or PF04971729) 
1,082 




Table A-3: Embase Search Strategy 
No. Query Results 
#5 #3 AND #4 2,016 
#4 - EMBASE 
RCT filter from 










#3 #1 AND #2 4,869 
#2 
 
'sodium glucose cotransporter 2'/de OR 'sodium 
glucose cotransporter 2 inhibitor'/exp OR 'sodium-
glucose co-transporter 2':ab,ti OR sgl2:ab,ti OR 
sglt2:ab,ti OR gliflozin*:ab,ti OR canagliflozin*:ab,ti OR 
invokana:ab,ti OR sulisent:ab,ti OR 'ta 7284':ab,ti OR 
ta7284:ab,ti OR 'jnj 28431754':ab,ti OR 
jnj28431754:ab,ti OR dapagliflozin*:ab,ti OR 
farxiga:ab,ti OR forxiga:ab,ti OR 'bms 512148':ab,ti OR 
bms512148:ab,ti OR empagliflozin*:ab,ti OR 
jardiance:ab,ti OR 'bi 10773':ab,ti OR bi10773:ab,ti OR 
ipragliflozin*:ab,ti OR suglat:ab,ti OR 'asp 1941':ab,ti 
OR asp1941:ab,ti OR luseogliflozin*:ab,ti OR lusefi:ab,ti 
OR 'ts 071':ab,ti OR ts071:ab,ti OR remogliflozin*:ab,ti 
OR 'kgt 1681':ab,ti OR kgt1681:ab,ti OR 
sotagliflozin*:ab,ti or 'LX 4221':ab,ti or LX4221:ab,ti or 
tofogliflozin*:ab,ti or apleway:ab,ti or deberza:ab,ti or 
'CSG 452':ab,ti or CSG452:ab,ti or ertugliflozin*:ab,ti or 





'non insulin dependent diabetes mellitus'/de OR 
niddm:ab,ti OR t2dm:ab,ti OR ('type 2':ab,ti OR 'type 
ii':ab,ti OR 'adult onset':ab,ti OR 'mature onset':ab,ti 
OR 'late onset':ab,ti OR 'noninsulin dependent':ab,ti OR 









Table A-4: IPA Search Strategy 
#  Query  Limiters/ 
Expanders  
Results  
S1  TX NIDDM OR t2dm OR (("type 2" OR "type ii" OR 
"adult onset" OR "mature onset" OR "late onset" 
OR "noninsulin dependent" OR "non insulin 






S2  TX "sodium-glucose co-transporter 2" OR sgl2 OR 
sglt2 OR gliflozin OR canagliflozin OR invokana OR 
sulisent OR "ta 7284" OR ta7284 OR "jnj 
28431754" OR jnj28431754 OR dapagliflozin* OR 
farxiga OR forxiga OR "bms 512148" OR 
bms512148 OR empagliflozin* OR jardiance OR 
"bi 10773" OR bi10773 OR ipragliflozin* OR suglat 
OR "asp 1941" OR asp1941 OR luseogliflozin* OR 
lusefi OR "ts 071" OR ts071 OR remogliflozin* OR 
"kgt 1681" OR kgt1681 OR sotagliflozin* OR "LX 
4221" OR LX4221 OR tofogliflozin* OR apleway 
OR deberza OR "CSG452" OR CSG452 OR 











S4  TI randomized OR AB randomized OR TI 
randomised OR AB randomised OR TI placebo OR 

















Table A-5: ProQuest Search Strategy 
all(NIDDM OR t2dm OR (("type 2" OR "type ii" OR "adult onset" OR "mature 
onset" OR "late onset" OR "noninsulin-dependent" OR "non insulin 
dependent") AND (diabetes))) AND all("sodium-glucose co-transporter 2" OR 
SGL2 OR SGLT2 OR gliflozin* OR canagliflozin* OR invokana OR sulisent OR 
"TA 7284" OR TA7284 OR "JNJ 28431754" OR JNJ28431754 OR dapagliflozin* 
OR farxiga OR forxiga OR "BMS 512148" OR BMS512148 OR empagliflozin* 
OR jardiance OR "BI 10773" OR BI10773 OR ipragliflozin OR suglat OR "ASP 
1941" OR ASP1941 OR luseogliflozin* OR lusefi OR "TS 071" OR TS071 OR 
remogliflozin* OR "KGT 1681" OR KGT1681 OR sotagliflozin* OR "LX 4221" OR 
LX4221 OR tofogliflozin* OR apleway OR deberza OR "CSG 452" OR CSG452 




Section 3: List of Extracted Variables 
 
Table A-6. List of Extracted Variables 
Variable Extraction Notes 
NCT Number, Author and Year  
Country in which the study was conducted International if applicable 
Start and End years  
Observation Period (# of weeks)  
Total number of participants randomized  
Number of Males  
Number of Females  
Background diabetes therapy  
Intervention 1: SGLT2 Agent This was captured for as many 
interventions that were used.  Intervention 1: Dose 
Intervention 1: Number of Persons 
Intervention 1: Mean Age 
Intervention 1: Age SD 
Intervention 1: Mean baseline HbA1C 
Intervention 1: A1C SD 
Comparison 1: SGLT2 Agent This was captured for as many 
comparison groups that were used. Comparison 1: Dose 
Comparison 1: Number of Persons 
Comparison 1: Mean Age 
Comparison 1: Age SD 
 9 
Comparison 1: Mean baseline HbA1C 
Comparison 1: A1C SD 
Acute Kidney Injury Reported (yes/no)  
Urinary Tract Infection Reported (yes/no)  
Definition of UTI  
Ketoacidosis Reported (yes/no)  
Bone Fracture Reported (yes/no)  
Amputation Reported (yes/no)  
AKI: Outcomes in Intervention 1(n/N) This was captured for each individual 
intervention and control group AKI: Outcomes in Comparison 1 (n/N) 
UTI: Outcomes in Intervention 1(n/N) 
UTI: Outcomes in Comparison 1 (n/N) 
DKA: Outcomes in Intervention 1(n/N) 
DKA: Outcomes in Comparison 1 (n/N) 
BF: Outcomes in Intervention 1(n/N) 
BF: Outcomes in Comparison 1 (n/N) 
Amp: Outcomes in Intervention 1(n/N) 
Amp: Outcomes in Comparison 1 (n/N) 
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Section 4: Additional Forest Plots 
 













Figure A3: Risk of Acute Kidney Injury with SGLT2 Inhibitors compared to Active Comparators 
 
 




Figure A5. Risk of Ketoacidosis among users of an SGLT2 Inhibitor compared to an Incretin 
 
 

















Figure A10: Risk of Fracture with SGLT2 Inhibitors compared to Incretins 
 
 














Section 5: Forest Plots for Fixed Effects Analysis 
 




















Section 6: Risk of Bias Assessment  
 


















Amin, 2015 NCT01059825 Low  Low  Low  Low  Low  Low  Low  low 
Amin, 2015 NCT01059825 Unclear  Unclear  Low  Unclear  Low  Unclear  Unclear  high 
Araki, 2016 NCT02157298 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Araki NCT01368081 Low  Low  Medium  Unclear  Low  High  Unclear  high 
Bailey, 2013 NCT00528879 Low  Low  Low  Low  Medium  Unclear  Unclear  high 
Bailey, 2012 None Low  Low  Low  Low  Low  Low  Low  low 
Barnett, 2014 NCT01164501 Low  Low  Low  Low  Low  High  Unclear  high 
Bode, 2015 NCT01106651 Low  Low  Low  Low  Low  High  Unclear  high 
Bolinder, 2014 NCT00855166 Low  Low  Low  Low  low  Low  Unclear  low 
Cefalu, 2015 NCT01031680 Low  Low  Medium  Low  Low  High  Low  high 
Chuang, 2016 NCT01505426 Low  Low  Low  Low  Low  Low  Unclear  low 
DeFronzo, 
2015 
NCT01422876 Low  Low  Low  Unclear  Low  Low  Unclear  low 
Prato, 2015 NCT00660907 Low  Low  Low  Low  Low  High  Unclear  high 
Ferrannini, 
2013 
NCT00881530 High  High  High  High  Low  High  Unclear  high 
Ferrannini, 
2010 
NCT00528372 Unclear  Unclear  Low  Unclear  Unclear  Unclear  Unclear  high 
Fonseca, 2013 NCT01071850 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Frias, 2016 NCT02229396 Low  Low  Low  Low  Low  Low  Unclear  low 
Hadjadj, 2016 NCT01719003 Low  Low  Low  Low  Low  High  Unclear  high 
Haering, 2015 NCT01289990 Low  Low  Low  Unclear  Low  Low  Unclear  low 
Heise, 2013 None Low  Low  Unclear  Unclear  Low  Unclear  Unclear  high 
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Heise, 2013 None Unclear  Low  Low  Low  Low  Low  Unclear  low 
Henry, 2012 NCT00643851 Low  Low  Low  Low  Low  High  Unclear  high 
Henry, 2012 NCT00859898 Low  Low  Low  Low  Low  High  Unclear  high 
Ikeda; 2015 NCT00800176 Unclear  Low  Low  Unclear  Low  Low  Unclear  high 
Inagaki, 2016 NCT02220920 Low  Low  Low  low  Low  Low  Unclear  low 
Inagaki, 2015 NCT01387737 Unclear  Low  High  High  Medium  Unclear  Unclear  high 
Inagaki, 2013 NCT01022112 Low  Low  Low  Low  Low  High  Unclear  high 
Inagaki, 2014 NCT01413204 Low  Low  Low  Low  Low  High  Unclear  high 
Ishihara, 2016 NCT02175784 Unclear  Low  Medium  Low  Low  Low  Low  high 
Jabbour, 2013 NCT00984867 Unclear  Low  Medium  Low  Low  High  Unclear  high 
Ji, 2015 NCT01381900 Low  Low  Low  Low  Low  High  Unclear  high 
Ji, 2014 NCT01095653 Low  Low  Low  Low  Low  High  Unclear  high 
Kadokura, 
2014 
NCT01023945 Low  Low  Low  Low  Low  Low  Unclear  low 
Kadowaki, 
2015 
NCT01193218 Low  Low  Low  Medium  Low  High  Unclear  high 
Kaku, 2013 NCT00972244 Low  Low  Low  Unclear  Low  High  Unclear  high 
Kaku, 2014 none Unclear  low  Low  Unclear  Medium  Unclear  Unclear  high 
Kaku, 2014 None Low  Low  Low  Low  Low  Low  Unclear  low 
Kashiwagi, 
2015 
NCT01242215 Low  Low  Low  Unclear  Low  Low  Unclear  low 
Kashiwagi, 
2015 
NCT01057628. Low   Low  Low  Low  Low  Low  Unclear  low 
Kashiwagi, 
2014 
NCT00621868 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Kashiwagi,201
5 
NCT01316094 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Kohan, 2014 NCT00663260 Unclear  Low  Low  Unclear  Low  Low  Unclear  high 
Kovacs, 2015 NCT01210001 Low  Low  Low  Medium  Low  High  Unclear  high 
Heerspink, 
2013 





NCT01106677 Low  Low  Low  Low  Low  High  Unclear  high 
Leiter, 2014 NCT01042977 Low  Low  Low  Low  Unclear  Low  Unclear  low 
Leiter, 2015 NCT00968812 Low  Low  Low  Low  Low  High  Unclear  high 
Lewin, 2015 NCT01422876 Unclear  Low  Low  Low  Low  Low  Low  low 
List, 2008 NCT00263276 Unclear  Low  Low  Low  Unclear  Low  Unclear  high 
Mathieu, 2015 NCT01646320 Low  Low  Low  Low  Low  Low  Unclear  low 
Matthaei, 
2015 
NCT01392677 Low  Low  Low  Low  Low  Low  Unclear  low 
Mudaliar, 
2013 
None Unclear  Low  Low  Low  Unclear  Low  Unclear  high 
Nishimura, 
2015 
NCT01947855 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Qiu, 2014 NCT01340664 Low  Low  Low  Low  Low  Low  Unclear  low 
Rodbard, 2016 NCT01989754 Low  Low  Low  Low  Low  Low  Unclear  low 
Roden, 2015 NCT01289990 Low  Low  Low  Low  Low  High  Unclear  high 
Rosenstock, 
2012 
NCT00642278 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Rosenstock, 
2015 
NCT01376557 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Rosenstock, 
2016 
NCT01809327 Low  Low  Low  Low  Low  High  Unclear  high 
Rosenstock, 
2015 
NCT01606007 Low  Low  Low  Low   Low  Low  Unclear  low 
Rosenstock, 
2014 
NCT01306214 Low  Low  Low  Low  Low  High  Unclear  high 
Rosenstock, 
2015 
NCT01011868 Low  Low  Low  Low  Low  High  Unclear  high 
Rosenstock, 
2012 
NCT00683878 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Ross, 2015 None Unclear  Low  Low  Low  Low  Low  Unclear  low 
Sasaki, 2015 None Low  Low  Medium  High  Unclear  Unclear  High  high 
Schernthaner, 
2013 
NCT01137812 Low  Low  Low  Low  Low  Low  Unclear  low 
Schumm-
Draeger, 2014 
NCT01217892 Low  Low  Low  Low  Low  Low  Unclear  low 
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Seino, 2014 None Low  Low  Low  Low  Low  Low  Unclear  low 
Seino, 2014 None Low  Low  Low  Low  Low  Low  Unclear  low 
Seino, 2014 None Low  Low  Low  Low  Low  Low  Unclear  low 
Stenlof, 2013 NCT01081834 Unclear  Low  Low  Unclear  Low  Low  Unclear  high 
Strojek, 2014 NCT00680745 Low  Low  Low  Low  Low  High  Unclear  high 
Sykes, 2015 NCT00500331 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Tikkanen, 
2015 
NCT01370005 Medium  Low  Low  Low  Low  Low  Unclear  high 
Townsend, 
2016 
None Unclear  Low  Low  Low  Low  Low  Unclear  low 
Seman, 2016 None Unclear  Low  High  High  Unclear  Unclear  Unclear  high 
Weber, 2016 NCT01137474 Low  Low  Low  Low  Medium  High  Unclear  high 
Weber, 2016 NCT01195662 Low  Low  Low  Low  Low  High  Unclear  high 
Wilding; 2013 NCT01106625 Low  Low  Low  Low  Low  High  Unclear  high 
Wilding, 2013 NCT01117584 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Wilding, 2009 NCT00357370 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Wilding, 2014 NCT00673231 Low  Low  Low  Low  Low  High  Unclear  high 
Yale, 2014 NCT01064414 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Zhao, 2015 NCT01316341 Medium  Low  Low  Low  Low  Low  Unclear  high 
Zinman, 2015 NCT01131676 Low  Low  Low  Low  Low  Low  Low  low 
Goto, 2012 None Unclear  Low  Low  Unclear  Low  Low  Unclear  high 
Dagogo-Jack, 
2017 




NCT01734785 Unclear  Low  Low  Unclear  Low  Low  Unclear  high 
Merker, 2015 NCT01289990 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Neal, 2015 NCT01032629 Low  Low  Low  Low  Low  Low  Unclear  low 
Ridderstrale, 
2014 
NCT01167881 Low  Low  Low  Low  Low  Low  Unclear  low 




None Low  Low  High  High  Low  Low  Unclear  high 
Yang, 2014 NCT01095666 Unclear  Low  Low  Low  Low  Low  Unclear  low 
Gupta, 2017 None Low  Low  Low  Low  Low  Low  Unclear  low 
Kadowaki, 
2017 
NCT02354235 Low  Low  Low  Low  Low  Low  Unclear  low 
Softeland, 
2017 
NCT01734785 Low  Low  Low  Low  Low  Low  Unclear  low 




Low  Low  Low  Low  Low  Low  Unclear  low 
Terauchi, 2017 NCT02201004 Low  Low  Low  Low  Low  Low  Unclear  low 
Grunberger, 
2018 NCT01986855 Low  Low  High  High  High  Low  Unclear  
high 
Hollander, 
2018 NCT01999218 Low  Low  Low  Low  Low  Low  Unclear  
Low 
Ito, 2017  Low  Low  High  High  Low  Low  Unclear  
High 
Pratley, 2017 NCT02099110 Low  Low  Low  Low  Low  Low  Unclear  
Low 
Rosenstock, 
2017 NCT02033889 Low  Low  Low  Low  Low  Low  Unclear  
Low 
Seino, 2018  Low  Low  Low  Low  Low  Low  Unclear  
Low 
Yang, 2018 NCT02096705 Low  Low  Low  Low  Low  Low  Unclear  
Low 
Mansfeild, 
2017 NCT02429258 Low  Low  Low  Low  Low  Low   Unclear  
Low 












Section 7: Assessment of Publication Bias 
 









Blinded Participant and Researcher
Allocation Concealment
Randomization Sequence
Low Medium High Unclear
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Figure A18. Funnel Plot for Placebo Controlled Trials: Urinary Tract Infection 
 
 




Figure A20. Funnel Plot for Sulfonylurea Controlled Trials: Urinary Tract Infection 
 










































−1 −0.5 0 0.5 1
 29 







Supporting documentation for the systematic review and network meta-analysis of the 
dose response relationship between SGLT2 inhibitors and urinary tract infections 
 
 




Section/topic  # Checklist item  
Reported in 
Section 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   4.0 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 




INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4.1 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
4.1 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
4.2.1 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
4.2.2 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4.2.3 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Appendix 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
4.2.4 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
4.2.4 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
Appendix 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
4.2.5 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  4.2.6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
4.2.6 
 
Page 1 of 2  
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Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
4.2.5 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
4.2.6 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
4.3.1 
figure 4-1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
Appendix 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Appendix 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table 4-2 – 4-3 
Appendix 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Table 4-2 – 4-3 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  Figure 4-3 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  4.3.3 
Appendix 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy makers).  
4.4 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
4.4.1 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  4.5 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 





From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  




Section 2: Search Strategies 
 
Table B1. Pubmed Search Strategy 
 
Search String Results 
1 Population "Diabetes Mellitus, Type 2"[Mesh] OR NIDDM[tw] OR 
t2dm[tw] OR ((“type 2"[tw] OR "type ii"[tw] OR "adult 
onset"[tw] OR “mature onset”[tw] OR “late onset”[tw] OR 
“noninsulin-dependent”[tw] OR “non insulin 




"Sodium-Glucose Transport Proteins/antagonists and 
inhibitors"[Mesh] OR "Sodium-Glucose Transporter 
2"[Mesh] OR "sodium-glucose co-transporter 2"[tw] OR 
SGL2[tw] OR SGLT2[tw] OR gliflozin*[tw] OR 
"Canagliflozin"[Mesh] OR canagliflozin*[tw] OR 
invokana[tw] OR sulisent[tw] OR "TA 7284"[tw] OR 
TA7284[tw] OR "JNJ 28431754"[tw] OR JNJ28431754[tw] 
OR "2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-
hydroxymethyltetrahydro-2H-pyran-3,4,5-
triol"[Supplementary Concept] OR dapagliflozin*[tw] OR 
farxiga[tw] OR forxiga[tw] OR “BMS 512148”[tw] OR 
BMS512148[tw] OR "empagliflozin"[Supplementary 
Concept] OR empagliflozin*[tw] OR jardiance[tw] OR "BI 
10773"[tw] OR BI10773[tw] OR 
ipragliflozin[Supplementary Concept] OR ipragliflozin*[tw] 
OR suglat[tw] OR "ASP 1941"[tw] OR ASP1941[tw] OR 
"1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-
methylphenyl)-1-thioglucitol"[Supplementary Concept] 
OR luseogliflozin*[tw] OR lusefi[tw] OR “TS 071”[tw] OR 
TS071[tw] OR "remogliflozin etabonate"[Supplementary 
Concept] OR remogliflozin*[tw] OR "KGT 1681"[tw] OR 
KGT1681[tw]  OR "(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-
ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-
3,4,5-triol" [Supplementary Concept] OR sotagliflozin*[tw] 
OR  "LX 4221"[tw] OR LX4221[tw] OR "6-((4-
ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-
(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-
3',4',5'-triol" [Supplementary Concept] OR 
tofogliflozin*[tw] OR apleway[tw] OR deberza[tw] OR 
"CSG 452"[tw] OR CSG452[tw] OR "5-(4-chloro-3-(4-
ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-
dioxabicyclo(3.2.1)octane-2,3,4-triol" [Supplementary 
Concept] OR ertugliflozin*[tw] OR "PF 04971729"[tw] OR 
PF04971729[tw] 
2936 
3 #1 AND #2 
 
2080 





("randomized controlled trial"[pt] OR "controlled clinical 
trial"[pt] OR randomized[tiab] OR placebo[tiab] OR 
"clinical trials as topic"[Mesh:NoExp]  OR randomly[tiab] 






























Table B2: Cochrane Library Search Strategy 
 
#1 ([mh "Diabetes Mellitus, Type 2"] or NIDDM or t2dm or 
(("type 2" or "type ii" or "adult onset" or "mature onset" or 
"late onset" or "noninsulin-dependent" or "non insulin 
dependent") and (diabetes)))  
25,454 
#2 ([mh "Sodium-Glucose Transport Proteins"/ai] or [mh 
"Sodium-Glucose Transporter 2"] or "sodium-glucose co-
transporter 2" or SGL2 or SGLT2 or gliflozin* or [mh 
canigliflozin] or canagliflozin* or invokana or sulisent or "TA 
7284" or TA7284 or "JNJ 28431754" or JNJ28431754 or 
dapagliflozin* or farxiga or forxiga or "BMS 512148" or 
BMS512148 or empagliflozin* or jardiance or "BI 10773" or 
BI10773 or ipragliflozin or suglat or "ASP 1941" or ASP1941 
or luseogliflozin* or lusefi or "TS 071" or TS071 or 
remogliflozin* or "KGT 1681" or KGT1681 or sotagliflozin* 
or "LX 4221" or LX4221 or tofogliflozin* or apleway or 
deberza or "CSG 452" or CSG452 or ertugliflozin* or "PF 
04971729" or PF04971729) 
1,082 





Table B3: Embase Search Strategy 
No. Query Results 
#5 #3 AND #4 2,016 
#4 - EMBASE 










#3 #1 AND #2 4,869 
#2 
 
'sodium glucose cotransporter 2'/de OR 'sodium 
glucose cotransporter 2 inhibitor'/exp OR 
'sodium-glucose co-transporter 2':ab,ti OR 
sgl2:ab,ti OR sglt2:ab,ti OR gliflozin*:ab,ti OR 
canagliflozin*:ab,ti OR invokana:ab,ti OR 
sulisent:ab,ti OR 'ta 7284':ab,ti OR ta7284:ab,ti 
OR 'jnj 28431754':ab,ti OR jnj28431754:ab,ti OR 
dapagliflozin*:ab,ti OR farxiga:ab,ti OR 
forxiga:ab,ti OR 'bms 512148':ab,ti OR 
bms512148:ab,ti OR empagliflozin*:ab,ti OR 
jardiance:ab,ti OR 'bi 10773':ab,ti OR 
bi10773:ab,ti OR ipragliflozin*:ab,ti OR 
suglat:ab,ti OR 'asp 1941':ab,ti OR asp1941:ab,ti 
OR luseogliflozin*:ab,ti OR lusefi:ab,ti OR 'ts 
071':ab,ti OR ts071:ab,ti OR remogliflozin*:ab,ti 
OR 'kgt 1681':ab,ti OR kgt1681:ab,ti OR 
sotagliflozin*:ab,ti or 'LX 4221':ab,ti or 
LX4221:ab,ti or tofogliflozin*:ab,ti or 
apleway:ab,ti or deberza:ab,ti or 'CSG 452':ab,ti 
or CSG452:ab,ti or ertugliflozin*:ab,ti or 'PF 





'non insulin dependent diabetes mellitus'/de OR 
niddm:ab,ti OR t2dm:ab,ti OR ('type 2':ab,ti OR 
'type ii':ab,ti OR 'adult onset':ab,ti OR 'mature 
onset':ab,ti OR 'late onset':ab,ti OR 'noninsulin 








Table B4: IPA Search Strategy 
#  Query  Limiters/ 
Expanders  
Results  
S1  TX NIDDM OR t2dm OR (("type 2" OR "type 
ii" OR "adult onset" OR "mature onset" OR 
"late onset" OR "noninsulin dependent" OR 
"non insulin dependent") AND (diabetes))  
Search modes - 
Boolean/Phrase  
6,110 
S2  TX "sodium-glucose co-transporter 2" OR 
sgl2 OR sglt2 OR gliflozin OR canagliflozin OR 
invokana OR sulisent OR "ta 7284" OR ta7284 
OR "jnj 28431754" OR jnj28431754 OR 
dapagliflozin* OR farxiga OR forxiga OR "bms 
512148" OR bms512148 OR empagliflozin* 
OR jardiance OR "bi 10773" OR bi10773 OR 
ipragliflozin* OR suglat OR "asp 1941" OR 
asp1941 OR luseogliflozin* OR lusefi OR "ts 
071" OR ts071 OR remogliflozin* OR "kgt 
1681" OR kgt1681 OR sotagliflozin* OR "LX 
4221" OR LX4221 OR tofogliflozin* OR 
apleway OR deberza OR "CSG452" OR 
CSG452 OR ertugliflozin* OR "PF 04971729" 
OR PF04971729 
Search modes - 
Boolean/Phrase  
337 
S3  S1 AND S2  Search modes - 
Boolean/Phrase  
267 
S4  TI randomized OR AB randomized OR TI 
randomised OR AB randomised OR TI 
placebo OR AB placebo OR TI randomly OR 
AB randomly OR TI trial  
Search modes - 
Boolean/Phrase  
59,232 








Table B5: ProQuest Search Strategy 
all(NIDDM OR t2dm OR (("type 2" OR "type ii" OR "adult onset" OR 
"mature onset" OR "late onset" OR "noninsulin-dependent" OR "non 
insulin dependent") AND (diabetes))) AND all("sodium-glucose co-
transporter 2" OR SGL2 OR SGLT2 OR gliflozin* OR canagliflozin* OR 
invokana OR sulisent OR "TA 7284" OR TA7284 OR "JNJ 28431754" OR 
JNJ28431754 OR dapagliflozin* OR farxiga OR forxiga OR "BMS 512148" 
OR BMS512148 OR empagliflozin* OR jardiance OR "BI 10773" OR 
BI10773 OR ipragliflozin OR suglat OR "ASP 1941" OR ASP1941 OR 
luseogliflozin* OR lusefi OR "TS 071" OR TS071 OR remogliflozin* OR 
"KGT 1681" OR KGT1681 OR sotagliflozin* OR "LX 4221" OR LX4221 OR 
tofogliflozin* OR apleway OR deberza OR "CSG 452" OR CSG452 OR 




Section 3: List of Extracted Variables 
 
Table B6. Variables extracted from included RCTs 
Variable Extraction Notes 
NCT Number, Author and Year  
Country in which the study was conducted International if applicable 
Start and End years  
Observation Period (# of weeks)  
Total number of participants randomized  
Number of Males  
Number of Females  
Background diabetes therapy  
Intervention 1: SGLT2 Agent This was captured for as many 
interventions that were used.  Intervention 1: Dose 
Intervention 1: Number of Persons 
Intervention 1: Mean Age 
Intervention 1: Age SD 
Intervention 1: Mean baseline HbA1C 
Intervention 1: A1C SD 
Comparison 1: SGLT2 Agent This was captured for as many 
comparison groups that were used. Comparison 1: Dose 
Comparison 1: Number of Persons 
Comparison 1: Mean Age 
Comparison 1: Age SD 
Comparison 1: Mean baseline HbA1C 
Comparison 1: A1C SD 
Acute Kidney Injury Reported (yes/no)  
Urinary Tract Infection Reported (yes/no)  
Definition of UTI  
Ketoacidosis Reported (yes/no)  
Bone Fracture Reported (yes/no)  
Amputation Reported (yes/no)  
AKI: Outcomes in Intervention 1(n/N) This was captured for each individual 
intervention and control group AKI: Outcomes in Comparison 1 (n/N) 
UTI: Outcomes in Intervention 1(n/N) 
UTI: Outcomes in Comparison 1 (n/N) 
DKA: Outcomes in Intervention 1(n/N) 
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DKA: Outcomes in Comparison 1 (n/N) 
BF: Outcomes in Intervention 1(n/N) 
BF: Outcomes in Comparison 1 (n/N) 
Amp: Outcomes in Intervention 1(n/N) 





Section 4: Thresholds for high and low dose SGLT2 inhibitors 
 
Table B7. Dose categories for primary analysis 
Category Definition 
Canagliflozin high dose 200 mg or more 
Canagliflozin low dose 100 mg or less 
Dapagliflozin high dose 10 mg or more 
Dapagliflozin low dose 5 mg or less 
Empagliflozin high dose 25 mg or more 
Empagliflozin low dose 10 mg or less 
Iprgliflozin high dose 100 mg or more 
Ipragliflozin low dose 50 mg or less 
Ertugliflozin high dose 15 mg or more 
Ertugliflozin low dose 10 mg or less 
Remogliflozin high dose 500 mg or more 
Remogliflozin low dose 250 mg or less 
Tofogliflozin high dose 40 mg or more 
Tofogliflozin low dose 20 mg or less 
 
 
Table B8. Dose categories for sensitivity analysis 
Category Definition 
Canagliflozin high dose 100 mg or more 
Canagliflozin low dose 50 mg or less 
Dapagliflozin high dose 10 mg or more 
Dapagliflozin low dose 5 mg or less 
Empagliflozin high dose 10 mg or more 
Empagliflozin low dose 2.5 mg  
Iprgliflozin high dose 50 mg or more 
Ipragliflozin low dose 25 mg or less 
Ertugliflozin high dose 10 mg or more 
Ertugliflozin low dose 5 mg or less 
Remogliflozin high dose 1000 mg or more 
Remogliflozin low dose 500 mg or less 
Tofogliflozin high dose 20 mg or more 






Section 5: Additional Materials for the Primary Analysis  
 
Figure B0-1. Forest plot of results on the primary analysis with placebo as the control 
 
 
Table B9. Rank Probabilities according to the surface under the cumulative rank curve (SUCRA) values 
Category SUCRA 
Active 0.745      
Cana_high 0.427      
Cana_low 0.292      
Dapa_high 0.173     
Dapa_low 0.414       
Empa_high 0.701     
Empa_low 0.543     
Ertu_high 0.393     
Ertu_low 0.677 
Ipra_high 0.537     
Ipra_low 0.503      
Placebo 0.562      
Remo_high 0.694    
Remo_low 0.518 





Section 6:  Breakdown of pairwise, indirect and pooled estimates 
 
Figure B0-2. Breakdown of pairwise, indirect, and pooled estimates 
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Figure B2 Continued. A. Breakdown of pairwise, indirect, and pooled estimates 
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Figure B2 Continued. A. Breakdown of pairwise, indirect, and pooled estimates 
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Figure B2 Continued. A. Breakdown of pairwise, indirect, and pooled estimates 
 
 48 
Figure B2 Continued. A. Breakdown of pairwise, indirect, and pooled estimates 
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Figure B2 Continued. A. Breakdown of pairwise, indirect, and pooled estimates 
 
 52 




Figure B2 Continued. A. Breakdown of pairwise, indirect, and pooled estimates 
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Figure B2 Continued. A. Breakdown of pairwise, indirect, and pooled estimates 
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Figure B2 Continued. A. Breakdown of pairwise, indirect, and pooled estimates 
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Section 7: Risk of Bias Assessment  
 





















Amin, 2015 77 
Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
NCT01059825 
Amin, 2015 78 
Unclear Risk Unclear Risk Low Risk Unclear Risk Low Risk Unclear 
Risk 
Unclear risk Unclear 
NCT02157298 
Araki, 2016 79 
Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Unclear risk Unclear 
NCT01368081 
Araki, 2015 80 
Low Risk Low Risk High Risk Unclear Risk Low Risk High Risk Unclear risk High 
NCT00528879 
Bailey, 2013 81 
Low Risk Low Risk Low Risk Low Risk High Risk Unclear 
Risk 
Unclear risk High 
None 
Bailey, 2012 82 




Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Low 
NCT01106651 
Bode, 2015 84 




Low Risk Low Risk Low Risk Low Risk low Risk Low Risk Low Risk Low 
NCT01031680 
Cefalu, 2015 86 
Low Risk Low Risk High Risk Low Risk Low Risk High Risk Low Risk High 
NCT01505426 
Lu, 2016 87 




Low Risk Low Risk Low Risk Unclear Risk Low Risk Low Risk Low Risk  Unclear 
NCT00660907 Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Low 
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Unclear Risk Unclear Risk Low Risk Unclear Risk Unclear Risk Unclear 
Risk 




Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Unclear 
NCT02229396 
Frias, 2016 93 








Low Risk Low Risk Low Risk Unclear Risk Low Risk Low Risk Low Risk Unclear 
None 
Heise, 2013 96 
Low Risk Low Risk Unclear Risk Unclear Risk Low Risk Unclear 
Risk 
Unclear risk Unclear 
None 
Heise, 2013 97 
Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Unclear 
NCT00643851 
Henry, 2012 98 
Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Low 
NCT00859898 
Henry, 2012 98 
Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Unclear 
NCT00800176 
Ikeda; 2015 99 








Unclear Risk Low Risk High Risk High Risk High Risk Unclear 
Risk 

















Unclear Risk Low Risk High Risk Low Risk Low Risk High Risk Unclear risk Low 
NCT01381900 
Ji, 2015 106 
Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Low 
NCT01095653 
Ji, 2014 107 








Low Risk Low Risk Low Risk High Risk Low Risk High Risk Unclear risk Unclear 
NCT00972244 
Kaku, 2013 110 
Low Risk Low Risk Low Risk Unclear Risk Low Risk High Risk Low Risk High 
None 
Kaku, 2014 111 
Unclear Risk low Risk Low Risk Unclear Risk High Risk Unclear 
Risk 
Unclear risk Low 
None 
Kaku, 2014 112 








Low Risk  Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Unclear 







Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Unclear 
NCT00663260 
Kohan, 2014 117 













Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Unclear 
NCT01042977 
Leiter, 2014 121 
Low Risk Low Risk Low Risk Low Risk Unclear Risk Low Risk Low Risk Low 
NCT00968812 
Leiter, 2015 122 
Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Unclear 
NCT01422876 
Lewin, 2015 123 
Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Unclear 
NCT00263276 
List, 2009 124 












Unclear Risk Low Risk Low Risk Low Risk Unclear Risk Low Risk Unclear risk Unclear 





Qiu, 2014 129 
































Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Unclear 
None 
Ross, 2015 139 
Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk High 
None 
Sasaki, 2015 140 
Low Risk Low Risk High Risk High Risk Unclear Risk Unclear 
Risk 










Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
None 
Seino, 2014 143 
Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
None 
Seino, 2014 144 
Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
None 
Seino, 2014 145 








Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Unclear 
NCT00500331 
Sykes, 2015 148 












Unclear Risk Low Risk High Risk High Risk Unclear Risk Unclear 
Risk 








Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Low 















Low Risk Low Risk Low Risk Low Risk Low Risk High Risk Low Risk Unclear 
NCT01064414 
Yale, 2014 158 
Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk High 
NCT01316341 
Zhao, 2015 159 
High Risk Low Risk Low Risk Low risk Low Risk Low Risk Unclear Risk Low 
NCT01131676 
Zinman, 2015 9 
Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Unclear 
None 
Goto, 2012 160 













Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
NCT01032629 
Neal, 2015 164 




Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
NCT00495469 Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk High 
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Low Risk Low Risk High Risk High Risk Low Risk Low Risk Unclear Risk Unclear 
NCT01095666 
Yang, 2014 168 
Unclear Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
None 
Gupta, 2017 169 








Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
NCT01958671 
Terra, 2017 172 












Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk High 








Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
Seino, 2018 180 Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
NCT02096705, Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk Low 
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Yang, 2017 181 
NCT02429258, 
Henry, 2018 182 
Low Risk Low Risk Low Risk Low Risk Low Risk Low Risk  Low Risk Low 
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Section 8: Results of Sensitivity Analyses 
 
Table B11. Risk of Urinary Tract Infection among users of SGLT2 Inhibitors: Threshold for high and low dose SGLT2 inhibitors changed in sensitivity analysis 
 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table B12. Risk of Urinary Tract Infection among users of SGLT2 Inhibitors: RCTs of 24 weeks or longer 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Capturing Adult Patient Preferences towards Benefits and Risks of Second-line Therapies in Type 
2 Diabetes: A Discrete Choice Experiment 
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Survey on Diabetes Medication Preferences
Dear Participant,
My name is Jennifer Donnan and I am a PhD candidate at Memorial University’s School of Pharmacy. As
part of my research I am interested in finding out about the factors that influence patient’s decisions
when they start new diabetes drugs. This information will be used in further research that will attempt
to measure patient preferences and discern how we can better use these preferences to make drug
therapy decisions.
This survey should take between 20 and 30 minutes and will consist of:
1. Some background questions;
2. A short video that will help you to answer the questions that follow; and
3. A series of 16 questions where you will be asked to compare 2 hypothetical drugs, and choose which
you would prefer.
It is entirely up to you to decide whether or not to take part in this research. You are free to not
answer any question to which you are not comfortable responding, and you can choose to stop the
survey at any time. Your confidentiality is important to us. Research Now will not release your identity
to the research team, only the responses to this survey.
Should you have any further questions about this study, or if you wish to receive information on the
results of this study, you can contact Jennifer Donnan at the contact information provided below. If you
wish to speak with someone who is not involved in the study but can advise you on your rights as a
participant in this study, you can contact the Ethics office at the contact information listed below.
Researcher:
Mrs. Jennifer Donnan, BSc.Pharm, MSc, MBA Phone: 709-739-8798 or by email at
Jennifer.donnan@mun.ca
Ethics Office:
Health Research Ethics Authority Phone: 709-777-6974 or by email at info@hrea.ca
If you indicate your consent below, you do not give up your legal rights and do not release the
researchers from their professional responsibilities.
Before you begin please note: 
- You may encounter difficulties if you attempt to complete this survey using a mobile device; and
- You will not be able to navigate back once you leave each page.
Please indicate if you consent to participate in this survey.
I consent to participate





Survey on Diabetes Medication Preferences
Screening Questions








None of the above












Survey Part 2: Introduction
The main part of this survey will consist of 16 choice tasks like the one you will be introduced
to in the video below. Please take 4 minutes to watch this video, as it will provide important
tips on how to complete the choice tasks.
DCE Video PP V2
DCEBackground1
Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































No reduction in risk
A 40% reduction in risk
0 out of 100 people
40 out of 100 people
0 out of 100 people





A 20% reduction in risk
No reduction in risk
40 out of 100 people
20 out of 100 people
2 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random1 Q7_Random1
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































A 40% reduction in risk
A 20% reduction in risk
20 out of 100 people
0 out of 100 people
0 out of 100 people





No reduction in risk
No reduction in risk
20 out of 100 people
20 out of 100 people
4 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random2 Q7_Random2
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































A 20% reduction in risk
A 20% reduction in risk
0 out of 100 people
40 out of 100 people
4 out of 100 people





A 40% reduction in risk
A 20% reduction in risk
40 out of 100 people
0 out of 100 people
2 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random3 Q7_Random3
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































A 20% reduction in risk
A 40% reduction in risk
20 out of 100 people
40 out of 100 people
2 out of 100 people





No reduction in risk
No reduction in risk
40 out of 100 people
20 out of 100 people
0 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random4 Q7_Random4
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































No reduction in risk
A 20% reduction in risk
20 out of 100 people
40 out of 100 people
2 out of 100 people





A 40% reduction in risk
A 20% reduction in risk
0 out of 100 people
20 out of 100 people
0 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Fixed1 Q7_Fixed1
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































No reduction in risk
A 20% reduction in risk
20 out of 100 people
20 out of 100 people
4 out of 100 people





A 40% reduction in risk
A 40% reduction in risk
0 out of 100 people
0 out of 100 people
4 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random5 Q7_Random5
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































A 20% reduction in risk
No reduction in risk
0 out of 100 people
0 out of 100 people
0 out of 100 people





A 40% reduction in risk
A 40% reduction in risk
40 out of 100 people
40 out of 100 people
2 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random6 Q7_Random6
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































No reduction in risk
A 40% reduction in risk
40 out of 100 people
0 out of 100 people
2 out of 100 people





A 20% reduction in risk
A 20% reduction in risk
20 out of 100 people
20 out of 100 people
0 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random7 Q7_Random7
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































A 40% reduction in risk
No reduction in risk
0 out of 100 people
40 out of 100 people
0 out of 100 people





A 20% reduction in risk
No reduction in risk
20 out of 100 people
0 out of 100 people
4 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random8 Q7_Random8
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































A 20% reduction in risk
A 20% reduction in risk
20 out of 100 people
20 out of 100 people
2 out of 100 people





No reduction in risk
A 20% reduction in risk
40 out of 100 people
40 out of 100 people
4 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Fixed2 Q7_Fixed2
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































No reduction in risk
A 20% reduction in risk
0 out of 100 people
40 out of 100 people
0 out of 100 people





A 40% reduction in risk
A 40% reduction in risk
40 out of 100 people
20 out of 100 people
4 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random9 Q7_Random9
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































No reduction in risk
A 20% reduction in risk
40 out of 100 people
0 out of 100 people
2 out of 100 people





A 40% reduction in risk
No reduction in risk
20 out of 100 people
20 out of 100 people
2 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random10 Q7_Random10
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































A 40% reduction in risk
A 20% reduction in risk
40 out of 100 people
40 out of 100 people
4 out of 100 people





A 20% reduction in risk
A 40% reduction in risk
0 out of 100 people
40 out of 100 people
4 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random11 Q7_Random11
* Risk for a minor or major side effects: 0%




Imagine you are a 55 year old individual with type 2 diabetes. You have tried metformin (an
oral diabetes medication) but you have not been able to get your blood sugar levels under
control. You need to add an additional diabetes therapy. Consider the options below and select
the one you would prefer based on the characteristics presented.






































A 40% reduction in risk
A 40% reduction in risk
0 out of 100 people
20 out of 100 people
0 out of 100 people





No reduction in risk
No reduction in risk
20 out of 100 people
0 out of 100 people
4 out of 100 people




Choosing to not manage blood glucose means: 
* Cost: $0
* Drop in blood glucose: 0%
* Risk of diabetes complications: no reduction in your risk of complications from diabetes
(e.g. heart attack, stroke, kidney failure, loss of eye sight and nerve pain)
Q7_Random12 Q7_Random12
* Risk for a minor or major side effects: 0%




The next few questions of this survey relate to the length of time a medication has been on the market
and used by the general population.
Would you prefer a medication that has been on the market:
5 Years
10 Years
Would you prefer a medication that has been on the market for:
6 Months
5 Years














The final few questions will provide some background information on your diabetes experience.
What is your gender?
Male
Female
What is your current marital status?
Single




What is your current employment status?
Student
Employed
Unemployed and seeking employment
Unemployed
Retired
What is the highest level of education that you have completed?


























How long have you known that you have diabetes?




Greater than 10 years





More than 3 oral medications
I am not sure




Do you have any heart or stroke related conditions? Please select any of the following that apply to you.





























History of heart attack
History of stroke
Other, please specify













































When respondents take the survey in regular mode this page will not
be displayed. Respondents will be redirected to the link below:
http://endlinks.researchnow.com/d/?status=1&rnid=
[Script] &study= [Script]




When respondents take the survey in regular mode this page will not
be displayed. Respondents will be redirected to the link below:
http://endlinks.researchnow.com/d/?status=2&rnid=
[Script] &study= [Script]




When respondents take the survey in regular mode this page will not
be displayed. Respondents will be redirected to the link below:
http://endlinks.researchnow.com/d/?status=3&rnid=
[Script] &study= [Script]
P o w e r e d  b y  S a w t o o t h  S o f t w a r e ,  I n c .
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